<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="generator" content=
"HTML Tidy for HTML5 for Mac OS X version 5.4.0" />
<title></title>
</head>
<body link="blue" lang="EN-US" xml:lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style=
"border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;">
<font size="1" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face=
"Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED
STATES</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face=
"Times New Roman" style=
"font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE
COMMISSION</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Washington, D.C.
20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face=
"Times New Roman" style=
"font-size:18.0pt;font-weight:bold;">Form&nbsp;10-Q</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(Mark&nbsp;one)</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<b><font size="3" face="Wingdings" style=
"font-size:12.0pt;font-weight:bold;">x</font></b><font size="1"
style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b><font size="3" style=
"font-size:12.0pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO
SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT
OF&nbsp;1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">For
the quarterly period ended March&nbsp;31, 2018</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Or</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<b><font size="3" face="Wingdings" style=
"font-size:12.0pt;font-weight:bold;">o</font></b><font size="1"
style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
<b><font size="3" style=
"font-size:12.0pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO
SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT
OF&nbsp;1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt .5in;text-align:center;text-indent:-.5in;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">For the transition period
from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Commission file
number&nbsp;001-37558</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face=
"Times New Roman" style=
"font-size:18.0pt;font-weight:bold;">Nabriva Therapeutics
plc</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(Exact name of
registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Ireland</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Not
applicable</font></b></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(</font></b>State or
jurisdiction of organization)</p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(I.R.S. Employer
Identification No.)</font></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">25-28
North Wall Quay</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">IFSC,
Dublin 1,&nbsp;Ireland</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Not
applicable</font></b></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(Address of principal
executive offices)</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>
</td>
</tr>
</table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">+353 1
649 2000</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(Registrant’s telephone
number, including area code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.55in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by
Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of
1934 during the preceding 12&nbsp;months (or for such shorter
period that the registrant was required to file such reports), and
(2)&nbsp;has been subject to such filing requirements for the past
90&nbsp;days.&nbsp;Yes&nbsp;&nbsp;</font><font face=
"Wingdings">x</font> &nbsp;No&nbsp;&nbsp;<font face=
"Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.55in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site,
if any, every Interactive Data File required to be submitted and
posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (§232.405
of this chapter) during the preceding 12&nbsp;months (or for such
shorter period that the registrant was required to submit and post
such files).&nbsp;Yes&nbsp;&nbsp;</font><font face=
"Wingdings">x</font>&nbsp;&nbsp;No&nbsp;<font face=
"Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.55in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Indicate by check
mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of 
“large accelerated filer,” “accelerated filer,” “smaller reporting
company” and “emerging growth company” in Rule&nbsp;12b-2 of the
Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Large&nbsp;accelerated&nbsp;filer</font>
<font face="Wingdings">o</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accelerated filer</font> <font face=
"Wingdings">x</font></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Non-accelerated filer</font> <font face=
"Wingdings">o</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Smaller reporting company</font> <font face=
"Wingdings">o</font></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(Do not check if a
smaller reporting company)</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="49%" valign="top" style=
"padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Emerging growth company</font> <font face=
"Wingdings">x</font></p>
</td>
</tr>
</table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">If
an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section&nbsp;7(a)(2)(B)&nbsp;of the
Securities Act.&nbsp;</font><font face="Wingdings">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.05in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Indicate by check mark whether the registrant
is a shell company (as defined in Rule12b-2 of the
Act).&nbsp;Yes&nbsp;&nbsp;</font><font face="Wingdings">o</font>
&nbsp;No&nbsp;&nbsp;<font face="Wingdings">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.55in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As of
April&nbsp;30, 2018, the registrant had 40,306,924 ordinary shares
outstanding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style=
"border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;">
<font size="1" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C902551\18-8686-1\task8875459\8686-1-ba.htm',USER='C902551',CD='May  1 06:52 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">NABRIV<a name=
"TableOfContents" id="TableOfContents">A THERAPEUTICS
plc</a></font></b></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">INDEX TO REPORT ON
FORM&nbsp;10-</font></b><b>Q</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="12%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="77%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="10%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Page</font></b></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href="#PARTI_075715" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;"><b>PART&nbsp;I — FINANCIAL
INFORMATION</b></font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM1_FINANCIALSTATEMENTS_070307" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;1:</font></a></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM1_FINANCIALSTATEMENTS_070307" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Financial Statements</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ConsolidatedBalanceSheetsunaudit_070313" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Consolidated balance sheets as of
December&nbsp;31, 2017 and March&nbsp;31, 2018
(unaudited)</font></a></p>
</td>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ConsolidatedStatementsofOperatio_070454" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Consolidated statements of operations and
comprehensive income (loss) for the three months ended
March&nbsp;31, 2017 and 2018 (unaudited)</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">6</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ConsolidatedStatementsofCashFlow_070459" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Consolidated statements of cash flows for the
three months ended March&nbsp;31, 2017 and 2018
(unaudited)</font></a></p>
</td>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">7</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#NotestotheUnauditedConsolidatedF_075753" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Notes to the unaudited consolidated financial
statements</font></a></p>
</td>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">8</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM2_MANAGEMENTSDISCUSSIONANDAN_080447" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;2:</font></a></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM2_MANAGEMENTSDISCUSSIONANDAN_080447" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Management’s Discussion and Analysis of
Financial Condition and Results of Operations</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">16</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM3_QUANTITATIVEANDQUALITATIVE_081327" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;3:</font></a></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM3_QUANTITATIVEANDQUALITATIVE_081327" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Quantitative and Qualitative Disclosures About
Market Risk</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">24</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM4_CONTROLSANDPROCEDURES_081353" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;4:</font></a></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM4_CONTROLSANDPROCEDURES_081353" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Controls and Procedures</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">25</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href="#PARTII_122059" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;"><b>PART&nbsp;II — OTHER
INFORMATION</b></font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM1_LEGALPROCEEDINGS_081550" title="Click to goto "><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;1:</font></a></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM1_LEGALPROCEEDINGS_081550" title="Click to goto "><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Legal
Proceedings</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">26</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM1A_RISKFACTORS_081553"><font size="2" face="Times New Roman"
style="font-size:10.0pt;">Item&nbsp;1A:</font></a></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM1A_RISKFACTORS_081553"><font size="2" face="Times New Roman"
style="font-size:10.0pt;">Risk Factors</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">26</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM2_UNREGISTEREDSALESOFEQUITYS_103515"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Item 2:</font></a></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM2_UNREGISTEREDSALESOFEQUITYS_103515"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Unregistered Sales of
Equity Securities and Use of Proceeds</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">61</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM3_DEFAULTSUPONSENIORSECURITI_103851"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Item 3:</font></a></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM3_DEFAULTSUPONSENIORSECURITI_103851"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Defaults Upon Senior
Securities</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">62</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM4_MINESAFETYDISCLOSURES_103853"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;4:</font></a></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM4_MINESAFETYDISCLOSURES_103853"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Mine Safety
Disclosures</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">62</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM5_OTHERINFORMATION_103855"><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;">Item&nbsp;5:</font></a></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM5_OTHERINFORMATION_103855"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Other
Information</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">62</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM6_EXHIBITS_103857"><font size="2" face="Times New Roman"
style="font-size:10.0pt;">Item&nbsp;6:</font></a></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#ITEM6_EXHIBITS_103857"><font size="2" face="Times New Roman"
style="font-size:10.0pt;">Exhibits</font></a></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">62</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="12%" valign="top" style=
"padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><a href=
"#SIGNATURES_104918"><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">SIGNATURES</font></a></p>
</td>
<td width="77%" valign="top" style=
"padding:0in 0in 0in 0in;width:77.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="10%" valign="top" style=
"padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">64</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
2<a name="PB_2_065708_1582" id="PB_2_065708_1582"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C902519\18-8686-1\task8876881\8686-1-bc.htm',USER='C902519',CD='May  1 16:17 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">FORWARD-LOOKING
STATEMENTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">This Quarterly
Report on Form&nbsp;10-Q contains forward-looking statements that
involve substantial risks and uncertainties. All statements
contained in this Quarterly Report, other than statements of
historical fact, including statements regarding our strategy,
future operations, future financial position, future revenues,
projected costs, prospects, plans and objectives of management, are
forward-looking statements. The words “anticipate, “around” 
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
 “project,” “target,” “potential,” “will,” “would,” “could,” 
“should,” “continue,” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. The
forward-looking statements in this report include, among other
things, statements about:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the
timing and conduct of our clinical trials of our lead product
candidate, lefamulin, including statements regarding the timing and
completion of the trials, and the period during which the results
of the trials will become available;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
expectations regarding how far into the future our cash on hand
will fund our ongoing operations;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the
timing of and our ability to submit applications for, obtain and
maintain marketing approval of lefamulin;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the
potential receipt of revenues from future sales of lefamulin;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .45in;text-indent:-10.1pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
plans to pursue development of lefamulin for additional indications
other than community-acquired bacterial pneumonia, or CABP;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
plans to pursue research and development of other product
candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
ability to establish and maintain arrangements for manufacture of
our product candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
sales, marketing and distribution capabilities and strategy;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
ability to successfully commercialize lefamulin and our other
product candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the
potential advantages of lefamulin and our other product
candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
estimates regarding the market opportunities for lefamulin and our
other product candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the
rate and degree of market acceptance and clinical benefit of
lefamulin and our other product candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
ability to establish and maintain collaborations;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the
future development or commercialization of lefamulin in the greater
China region;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the
potential benefits under our license agreement with Sinovant
Sciences,&nbsp;Ltd.;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
ability to acquire or in-license additional products, product
candidates and technologies;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
future intellectual property position;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
estimates regarding future expense, capital requirements and needs
for additional financing;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
ability to effectively manage our anticipated growth;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 40.5pt;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
ability to maintain the level of our expenses consistent with our
internal budgets and forecasts;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .45in;text-indent:-10.1pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> the demand
for securities of pharmaceutical and biotechnology companies in
general and our ordinary shares in particular;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
competitive factors;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 40.5pt;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> compliance
with current or prospective governmental regulation;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 40.5pt;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> general
economic and market conditions;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font> our
ability to attract and retain qualified employees and key
personnel; and,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
3<a name="PB_3_065935_6117" id="PB_3_065935_6117"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\C902551\18-8686-1\task8875459\8686-1-be.htm',USER='C902551',CD='May  1 07:00 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 32.5pt;text-indent:-10.0pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
other risks and uncertainties, including those described in the ‘
‘Risk Factors’’ section of this Form&nbsp;10-Q.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We may not
actually achieve the plans, intentions or expectations disclosed in
our forward-looking statements, and you should not place undue
reliance on our forward-looking statements. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements we
make.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">You should
refer to the “Risk Factors” section of this Form&nbsp;10-Q for a
discussion of important factors that we believe could cause actual
results or events to differ materially from the forward-looking
statements that we make. Our forward-looking statements do not
reflect the potential impact of any future acquisitions, mergers,
dispositions, joint ventures or investments we may make. We do not
assume any obligation to update any forward-looking statements,
except as required by applicable law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">SPECIAL NOTE REGARDING THE
REDOMICILIATION</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.35in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">On June&nbsp;23,
2017, Nabriva Therapeutics plc, a public limited company organized
under the laws of Ireland, or Nabriva Ireland, became the successor
issuer to Nabriva Therapeutics AG, a stock corporation
(<i>Aktiengesellschaft</i>) organized under the laws of Austria, or
Nabriva Austria, for certain purposes under both the Securities Act
of 1933, as amended, and the Securities Exchange Act of 1934, as
amended, or the Exchange Act.&nbsp; Such succession occurred
following the conclusion of a tender offer related to the exchange
of American Depositary Shares and common shares of Nabriva Austria
for ordinary shares of Nabriva Ireland, which resulted in Nabriva
Ireland, a new Irish holding company, becoming the ultimate holding
company of Nabriva Austria (the predecessor registrant and former
ultimate holding company) and its subsidiaries, which we refer to
as the Redomiciliation Transaction.&nbsp; On October&nbsp;19, 2017,
Nabriva Austria was converted into a limited liability company
under Austrian law and renamed Nabriva Therapeutics
GmbH.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Throughout this
Quarterly Report on Form&nbsp;10-Q, unless the context requires
otherwise, all references to “Nabriva,” “the Nabriva Group,” “the
Company,” “we,” “ours,” “us,” or similar terms on or prior to
June&nbsp;23, 2017 (the effective date of the Redomiciliation
Transaction), refer to our predecessor, Nabriva Therapeutics AG,
together with its subsidiaries.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
4<a name="PB_4_065951_5335" id="PB_4_065951_5335"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\C902551\18-8686-1\task8875459\8686-1-be.htm',USER='C902551',CD='May  1 07:00 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">PART&nbsp;I</font></b><a name=
"PARTI_075715" id="PARTI_075715"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM
1.&nbsp; FINANCIAL STATEMENTS</font></b><a name=
"ITEM1_FINANCIALSTATEMENTS_070307" id=
"ITEM1_FINANCIALSTATEMENTS_070307"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">NABRIVA THERAPEUTICS
plc</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Consolidated Balance Sheets
(unaudited)</font></b><a name=
"ConsolidatedBalanceSheetsunaudit_070313" id=
"ConsolidatedBalanceSheetsunaudit_070313"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="66%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;data)</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">As&nbsp;of<br />
December&nbsp;31,&nbsp;2017</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">As&nbsp;of<br />
March&nbsp;31,&nbsp;2018</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Assets</font></b></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Current assets:</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Cash and cash equivalents</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:13.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">86,769</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">89,441</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Short-term investments</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">110</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">110</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other receivables</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5,402</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">6,436</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Contract asset</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,500</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Prepaid expenses</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,558</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,016</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total current assets</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">93,839</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">98,503</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Property, plant and equipment, net</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,327</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,376</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Intangible assets, net</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">172</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">155</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Long-term receivables</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">425</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">428</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Total assets</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">95,763</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="10%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">100,462</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Liabilities and
equity</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Current liabilities:</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accounts payable</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="13%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5,136</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,807</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accrued expense and other current
liabilities</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">8,124</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">7,577</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total current liabilities</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">13,260</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">11,384</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Non-current liabilities</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Long-term debt</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">232</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">411</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other non-current liabilities</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">203</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">225</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total non-current liabilities</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">435</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">636</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Total
liabilities</font></b></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">13,695</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">12,020</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Commitments and contingencies (Note
10)</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Stockholders’ Equity:</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Ordinary shares, nominal value $0.01,
1,000,000,000 ordinary shares authorized at March&nbsp;31, 2018;
36,707,685 and 40,233,867 issued and outstanding at
December&nbsp;31, 2017 and March&nbsp;31, 2018,
respectively</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">367</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">402</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Preferred shares, par value $0.01, 100,000,000
shares authorized at March&nbsp;31, 2018; None issued and
outstanding</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Additional paid in capital</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">360,872</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">380,553</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accumulated other comprehensive
income</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">27</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">27</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accumulated deficit</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(279,198</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(292,540</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Total stockholders’
equity</font></b></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">82,068</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">88,442</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Total liabilities and
stockholders’ equity</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">95,763</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="10%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">100,462</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">The accompanying notes
form an integral part of these consolidated financial
statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
5<a name="PB_5_070426_572" id="PB_5_070426_572"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\105924\18-8686-1\task8884538\8686-1-fa.htm',USER='105924',CD='May  4 20:55 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">NABRIVA THERAPEUTICS
plc</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Consolidated Statements of
Operations and Comprehensive Income (Loss)
(unaudited)</font></b><a name=
"ConsolidatedStatementsofOperatio_070454" id=
"ConsolidatedStatementsofOperatio_070454"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="70%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="26%" colspan="5" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br />

March&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="70%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Revenues:</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Collaboration revenue</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">6,500</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Research premium and grant revenue</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,678</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,051</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Total Revenue</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,678</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">7,551</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Operating
expenses:</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Research and development</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(12,660</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(10,279</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">General and administrative</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(4,218</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(10,136</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total operating expenses</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(16,878</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(20,415</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Loss from
operations</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(15,200</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(12,864</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Other income
(expense):</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other income, net</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">206</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">23</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Interest income</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">121</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">9</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Interest expense</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(1</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(4</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Loss before income
taxes</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(14,874</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(12,836</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Income tax expense</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(349</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(506</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Net loss</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(15,223</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(13,342</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Other comprehensive income
(loss), net of tax</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Unrealized losses on available-for-sale
securities</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(16</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Reclassification to net income</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other comprehensive income (loss), net of
tax</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(16</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Comprehensive
loss</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="10%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(15,239</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="10%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(13,342</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 2.25pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="70%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Loss&nbsp;per&nbsp;share</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Basic and Diluted</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(0.56</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(0.36</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Weighted average number of
shares:</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Basic and Diluted</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">27,204,230</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">36,911,604</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr height="0">
<td width="496" style="border:none;"></td>
<td width="18" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="77" style="border:none;"></td>
<td width="18" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="77" style="border:none;"></td>
<td width="7" style="border:none;"></td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">The accompanying notes
form an integral part of these consolidated financial
statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
6<a name="PB_6_070625_5796" id="PB_6_070625_5796"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\105924\18-8686-1\task8884538\8686-1-fa.htm',USER='105924',CD='May  4 20:55 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">NABRIVA THERAPEUTICS
plc</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Consolidated Statements of
Cash Flows (unaudited)</font></b><a name=
"ConsolidatedStatementsofCashFlow_070459" id=
"ConsolidatedStatementsofCashFlow_070459"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="70%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="26%" colspan="5" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br />

March&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="70%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Cash flows from operating
activities</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
loss</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(15,223</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(13,342</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Adjustments to reconcile net loss to net cash
used in operating activities:</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Non-cash other expense, net</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(266</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(112</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Non-cash interest income</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(30</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(10</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Depreciation and amortization
expense</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">76</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">133</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Stock-based compensation</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">684</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,244</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Deferred income taxes</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">178</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other, net</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">86</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(6</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Changes in operating assets and
liabilities:</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Changes in long-term receivables</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(5</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(3</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Changes in other receivables and prepaid
expenses</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(1,586</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(1,992</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Changes in accounts payable</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,789</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(1,413</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Changes in accrued expenses and other
liabilities</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(383</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(1,311</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Changes in other non-current
liabilities</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">6</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">22</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Changes in income tax liabilities</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(10</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">451</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.4pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
cash used in operating activities</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(14,684</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(16,339</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Cash flows from investing
activities</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Purchases of plant and equipment and intangible
assets</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(25</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(160</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Proceeds from sales of property, plant and
equipment</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Proceeds from sales of available-for-sale
securities</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">10,000</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.4pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
cash provided by (used in) investing activities</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">9,977</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(160</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Cash flows from financing
activities</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Proceeds from sale of ordinary
shares</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">19,388</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Proceeds from long-term debt</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">229</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">189</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Proceeds from exercise of stock
options</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">10</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Equity transaction costs</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(1,410</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(518</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.4pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
cash provided by (used in) financing activities</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(1,171</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">19,059</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Effects of foreign currency translation on cash
and cash equivalents</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">266</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">112</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
(decrease) increase in cash and cash equivalents</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(5,612</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2,672</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" style=
"padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Cash and cash equivalents at beginning of
period</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">32,778</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">86,769</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Cash and cash equivalents at end of
period</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">27,166</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">89,441</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">The accompanying notes
form an integral part of these consolidated financial
statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
7<a name="PB_7_070708_2897" id="PB_7_070708_2897"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\105924\18-8686-1\task8884538\8686-1-fa.htm',USER='105924',CD='May  4 20:55 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">NABRIVA THERAPEUTICS
plc</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes
to the Unaudited Consolidated Financial
Statements</font></b><a name=
"NotestotheUnauditedConsolidatedF_075753" id=
"NotestotheUnauditedConsolidatedF_075753"></a></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(in thousands, except
per share data)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">1.</font></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>Organization and Business Activities</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Nabriva
Therapeutics plc (“Nabriva Ireland”), together with its wholly
owned and consolidated subsidiaries, Nabriva Therapeutics GmbH (
“Nabriva Austria”), Nabriva Therapeutics US,&nbsp;Inc., Nabriva
Therapeutics Ireland DAC, and Nabriva Therapeutics One DAC (In
Voluntary Liquidation) (collectively, “Nabriva”, the “Nabriva Group”
 or the “Company”) is a clinical stage biopharmaceutical company
engaged in the research and development of novel anti-infective
agents to treat serious infections, with a focus on the
pleuromutilin class of antibiotics. The Company’s headquarters are
located at 25-28 North Wall Quay, Dublin,&nbsp;Ireland.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">On
March&nbsp;1, 2017, Nabriva Ireland was incorporated in Ireland
under the name Hyacintho 2 plc, and was renamed to Nabriva
Therapeutics plc on April&nbsp;10, 2017, in order to effectuate the
change of the jurisdiction of incorporation of the ultimate parent
company of the Nabriva Group from Austria to Ireland. Nabriva
Ireland replaced Nabriva Austria as the ultimate parent company on
June&nbsp;23, 2017, following the conclusion of a tender offer (the
“Exchange Offer”) in which holders of 98.5% of the outstanding
share capital of Nabriva Austria exchanged their holdings for
ordinary shares, $0.01 nominal value per share, of Nabriva Ireland
(the “Redomiciliation Transaction”).&nbsp; The ordinary shares of
Nabriva Ireland were issued on a one-for-ten basis to the holders
of the Nabriva Austria common shares (“Nabriva Austria common
shares”) and on a one-for-one basis to the holders of the Nabriva
Austria American Depositary Shares (“Nabriva Austria ADSs”)
participating in the Exchange Offer. On June&nbsp;26, 2017, the
ordinary shares of Nabriva Ireland began trading on the Nasdaq
Global Market under the symbol “NBRV,” the same symbol under which
the American Depositary Shares of Nabriva Austria were previously
traded.&nbsp; This transaction was accounted for as a merger
between entities under common control; accordingly, the historical
financial statements of Nabriva Austria for periods prior to this
transaction are considered to be the historical financial
statements of Nabriva Ireland.&nbsp; As of August&nbsp;18, 2017,
100%&nbsp;of Nabriva Austria share capital had been exchanged for
ordinary shares of Nabriva Ireland.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Nabriva
Austria was incorporated in Austria as a spin-off from Sandoz GmbH
in October&nbsp;2005 and commenced operations in February&nbsp;2006
as Nabriva Therapeutics AG. On October&nbsp;19, 2017, Nabriva
Austria was converted into a private limited liability company
under Austrian law and renamed Nabriva Therapeutics GmbH. Nabriva
Therapeutics US,&nbsp;Inc. was founded and began operations in the
United States in August&nbsp;2014. In February&nbsp;2017, Nabriva
Austria purchased all shares issued in the capital of Hyacintho
DAC, a designated activity company incorporated by a nominee
company in December&nbsp;2016; it renamed the company to Nabriva
Therapeutics Ireland DAC on April&nbsp;10, 2017 and renamed the
company again to Nabriva Therapeutics One DAC on October&nbsp;13,
2017 (“One DAC”). From April&nbsp;2017, One DAC held a license of
all of the intellectual property rights of the Nabriva Group from
Nabriva Austria. In October&nbsp;2017, the Company purchased all
shares issued in the capital of a new Irish designated activity
company, Nabriva Therapeutics Ireland DAC (“Nabriva DAC”) from a
nominee company. On October&nbsp;19, 2017, Nabriva Austria
terminated the intellectual property rights license in place with
One DAC and put in place a new intellectual property rights license
with Nabriva DAC in respect of all of the intellectual property
rights of the Nabriva Group.&nbsp;&nbsp; On February&nbsp;8, 2018,
Nabriva Austria passed a shareholder resolution to approve the
voluntary and solvent liquidation of One DAC.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Certain share
and per share amounts have been retrospectively adjusted to reflect
the Exchange Offer and the Redomiciliation Transaction.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Liquidity</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Since its
inception, the Company has incurred net losses and generated
negative cash flows from its operations. To date, it has financed
its operations through the sale of equity securities, including its
initial public offering of Nabriva Austria ADSs, public offerings
of our ordinary shares and private placements of its Nabriva
Austria common shares, convertible debt financings and research and
development support from governmental grants and loans. As of
March&nbsp;31, 2018, the Company had cash, cash equivalents and
short-term investments of $89.6 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">The Company
follows the provisions of Financial Accounting Standards Board (
“FASB”) Accounting Standards Codification (“ASC”) Topic 205-40,
Presentation of Financial Statements - Going Concern (“ASC 205-40”
), which requires management to assess the Company’s ability to
continue as a going concern for one year after the date the
financial statements are issued. As of December&nbsp;31, 2017, in
accordance with the requirements of ASC 205-40, the Company’s
management had concluded that substantial doubt existed about the
Company’s ability to continue as a going concern for one year from
the date the consolidated financial statements included in the
Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2017, were issued.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
8<a name="PB_8_073205_9284" id="PB_8_073205_9284"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\C902550\18-8686-1\task8887152\8686-1-fn.htm',USER='C902550',CD='May  7 17:10 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">NABRIVA THERAPEUTICS
plc</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes
to the Unaudited Consolidated Financial Statements
(continued)</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(in thousands, except
per share data)</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
March&nbsp;2018, the Company entered into a Controlled Equity
Offering</font><font size="1" style=
"font-size:6.5pt;position:relative;top:-3.0pt;">SM</font>&nbsp;Sales
Agreement (the “ATM Agreement”), with Cantor Fitzgerald&nbsp;&amp;
Co. (“Cantor”), pursuant to which, from time to time, the Company
may offer and sell our ordinary shares having aggregate gross
proceeds of up to $50.0 million through Cantor. As of
March&nbsp;31, 2018, the Company has issued and sold an aggregate
of 3,517,511 ordinary shares under the ATM Agreement, for gross
proceeds of $19.4 million, and net proceeds of $18.9 million, after
deducting commissions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Since the
filing of the Company’s Annual Report, the Company has re-evaluated
the need for the previously planned expansion of its commercial
organization, medical education, and supply chain activities and
anticipates that the Company’s expenses for 2018 will decrease as
compared to its expenses for 2017 as the Company winds down its
Phase 3 clinical trial program for lefamulin for the treatment of
community-acquired bacterial pneumonia (“CABP”). The Company
expects to continue to invest in critical pre-commercialization
activities prior to receiving marketing approval and making
lefamulin available to patients.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">As of
March&nbsp;31, 2018, management assessed the Company’s ability to
continue as a going concern and determined that it now expects that
its existing cash, cash equivalents and short-term investments will
be sufficient to enable the Company to fund its operating expenses
and capital expenditure requirements into the first quarter of
2020.&nbsp;The Company has based this estimate on assumptions that
may prove to be wrong, and the Company could use its capital
resources sooner than it currently expects.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">The Company’s
expenses will increase if it suffers any delays in its Phase 3
clinical program, including regulatory delays, or is required to
conduct additional clinical trials to satisfy regulatory
requirements. If the Company obtains marketing approval for
lefamulin or any other product candidate that it develops, it
expects to incur significant commercialization expenses related to
product sales, marketing, distribution and
manufacturing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">The
Company expects to seek additional funding in future periods for
purposes of investment in its commercial and medical affairs
organization</font>, including the expansion of a targeted hospital
based sales force and related infrastructure, as well as investing
in its supply chain, in an effort to enhance the potential
commercial launch of lefamulin.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">2.</font></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>Summary of Significant Accounting Policies</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Basis
of Preparation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The unaudited
consolidated financial statements have been prepared in accordance
with generally accepted accounting principles in the United States
of America (“US GAAP”) for interim financial information and U.S.
Securities and Exchange Commission (“SEC”) regulations for
quarterly reporting. The unaudited consolidated financial
statements include the accounts of the Company and its wholly-owned
subsidiaries. All intercompany accounts and transactions have been
eliminated in consolidation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The accompanying
consolidated financial information as of March&nbsp;31,&nbsp;2018
and for the three months ended March&nbsp;31,&nbsp;2017 and 2018 is
unaudited. The December&nbsp;31, 2017 balance sheet was derived
from audited consolidated financial statements but does not include
all disclosures required by US GAAP. The interim unaudited
consolidated financial statements have been prepared on the same
basis as the annual audited consolidated financial statements and,
in the opinion of management, reflect all adjustments, which
include only normal recurring adjustments, necessary for the fair
statement of the Company’s financial position as of
March&nbsp;31,&nbsp;2018 and for the three months ended
March&nbsp;31,&nbsp;2017 and 2018. The financial data and other
information disclosed in these notes related to the three months
ended March&nbsp;31,&nbsp;2017 and 2018 are not necessarily
indicative of the results to be expected for the year ending
December&nbsp;31, 2018, any other interim periods or any future
year or period. These unaudited consolidated financial statements
should be read in conjunction with the audited consolidated
financial statements and the notes thereto for the year ended
December&nbsp;31,&nbsp;2017 contained in the Company’s Annual
Report on Form&nbsp;10-K, as filed with the SEC on March&nbsp;16,
2018.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company’s
significant accounting policies are described in Note 2 of the
notes to the consolidated financial statements included in the
Company’s Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31,&nbsp;2017. Since the date of those financial
statements, there have been no changes to the Company’s significant
accounting policies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recent
Accounting Pronouncements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:14.2pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">From time to
time, new accounting pronouncements are issued by the FASB or other
standard setting bodies that the Company adopts as of the specified
effective date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
9<a name="PB_9_073250_7056" id="PB_9_073250_7056"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\C902550\18-8686-1\task8887152\8686-1-fn.htm',USER='C902550',CD='May  7 17:10 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">NABRIVA THERAPEUTICS
plc</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes
to the Unaudited Consolidated Financial Statements
(continued)</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(in thousands, except
per share data)</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Adopted as of the current
period:</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 28.35pt;text-indent:-14.15pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
In May&nbsp;2014, the FASB issued Accounting Standards Update (ASU)
2014-09, <i>Revenue from Contracts with Customers</i>, an updated
standard on revenue recognition. ASU 2014-09 provides enhancements
to the quality and consistency of how revenue is reported by
companies&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; while also improving
comparability in the financial statements of companies reporting
using International Financial Reporting Standards or US GAAP. The
main purpose of the new standard is for companies to recognize
revenue to depict the transfer of goods or services to customers in
amounts that reflect the consideration to which a company expects
to be entitled in exchange for those goods or services. The new
standard also will result in enhanced revenue disclosures, provide
guidance for transactions that were not previously addressed
comprehensively and improve guidance for multiple-element
arrangements. The effective date of ASU 2014-09 for the Company is
the first quarter of fiscal year 2018.&nbsp; The adoption of ASU
2014-09 did not have an impact on the consolidated financial
statements of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
In May&nbsp;2017, the FASB issued ASU 2017-09, <i>Compensation—
Stock Compensation</i>: <i>Scope of Modification Accounting</i>.
ASU 2017-09 clarifies which changes to the terms or conditions of a
share-based payment award require an entity to apply modification
accounting in Topic 718, <i>Compensation—Stock Compensation</i>.
ASU 2017-09 is effective for annual periods beginning after
December&nbsp;15, 2017. An entity should apply the amendments
prospectively to a modification that occurs on or after the
adoption date. The impact of adopting this standard did not have a
material effect on the Company’s financial position, results of
operation or cash flow and related disclosures.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-style:italic;">To be
adopted in future periods:</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 27.5pt;text-indent:-12.1pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
In February&nbsp;2016, the FASB issued ASU 2016-02, <i>Leases</i>
(Topic 842). ASU 2016-02 establishes a right-of-use (“ROU”) model
that requires a lessee to record a ROU asset and a lease liability
on the balance sheet for all leases with terms longer than 12
months. Leases will be classified as either finance or operating,
with classification affecting the pattern of expense recognition in
the income statement. ASU 2016-02 is effective for annual periods
beginning after December&nbsp;15, 2018, and interim periods within
those fiscal years, with early adoption permitted. A modified
retrospective transition approach is required for lessees of
capital and operating leases existing at, or entered into after,
the beginning of the earliest comparative period presented in the
financial statements, with certain practical expedients available.
The Company is currently evaluating the impact that the standard
will have on its financial position, results of operation or cash
flow and related disclosures.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">3.</font></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>Fair Value Measurement</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:14.3pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">US GAAP
establishes a valuation hierarchy for disclosure of the inputs to
valuation used to measure fair value. This hierarchy prioritizes
the inputs into three broad levels as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 27.5pt;text-indent:-13.2pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
Level 1: Quoted prices (unadjusted) in active markets for identical
assets or liabilities.</p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 27.5pt;text-indent:-13.2pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
Level 2: Inputs other than quoted prices included within Level 1
that are observable for the asset or liability, either directly (as
prices) or indirectly (as exchange rates).</p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 27.5pt;text-indent:-13.2pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
Level 3: Valuation techniques that include inputs for the asset or
liability that are not based on observable market data (those are
unobservable inputs) and significant to the overall fair value
measurement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:14.3pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">The following
table presents the financial instruments measured at fair value and
classified by level according to the fair value measurement
hierarchy:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%"
style="border-collapse:collapse;">
<tr>
<td width="36%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:36.94%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Level&nbsp;1</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Level&nbsp;2</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Level&nbsp;3</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Total</font></b></p>
</td>
<td width="0%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:.92%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:36.94%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">December&nbsp;31,
2017</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" style=
"padding:0in 0in 0in 0in;width:36.94%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Assets:</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="0%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:36.94%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Short-term investments:</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" style=
"padding:0in 0in 0in 0in;width:36.94%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Available-for-sale securities</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">—</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">50</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">—</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">50</font></p>
</td>
<td width="0%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:36.94%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Term deposits</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">60</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">60</font></p>
</td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" style=
"padding:0in 0in 0in 0in;width:36.94%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Total Assets</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">60</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">50</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">—</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.64%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">110</font></b></p>
</td>
<td width="0%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%"
style="border-collapse:collapse;">
<tr>
<td width="36%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:36.96%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Level&nbsp;1</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Level&nbsp;2</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Level&nbsp;3</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Total</font></b></p>
</td>
<td width="0%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:.9%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:36.96%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">March&nbsp;31,
2018</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" style=
"padding:0in 0in 0in 0in;width:36.96%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Assets:</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="0%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:36.96%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Short-term investments:</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" style=
"padding:0in 0in 0in 0in;width:36.96%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Available-for-sale securities</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">—</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">50</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">—</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">50</font></p>
</td>
<td width="0%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:36.96%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Term deposits</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">60</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">60</font></p>
</td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="36%" valign="top" style=
"padding:0in 0in 0in 0in;width:36.96%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Total Assets</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">60</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">50</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">—</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.64%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">110</font></b></p>
</td>
<td width="0%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
10<a name="PB_10_073457_5335" id="PB_10_073457_5335"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\C902550\18-8686-1\task8887152\8686-1-fn.htm',USER='C902550',CD='May  7 17:10 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">NABRIVA THERAPEUTICS
plc</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes
to the Unaudited Consolidated Financial Statements
(continued)</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(in thousands, except
per share data)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As of
March&nbsp;31, 2018 and December&nbsp;31, 2017, the Company held
short-term investments classified as both Level 1 and Level 2, and
the Company did not hold any Level 3 financial instruments measured
at fair value. There were no transfers between Level 1 and 2 in the
three months ended March&nbsp;31, 2018 or the year ended
December&nbsp;31, 2017. There were no changes in valuation
techniques during the three months ended March&nbsp;31,
2018.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As of
March&nbsp;31, 2018 and December&nbsp;31, 2017, the Company did not
hold any financial instruments as liabilities that were held at
fair value. Other receivables and accounts payable are carried at
their historical cost which approximates fair value due to their
short-term nature.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">4.</font></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>Accrued Expenses and Other Liabilities</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="96%"
style="border-collapse:collapse;">
<tr>
<td width="65%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:65.86%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.58%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="15%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">As&nbsp;of<br />
December&nbsp;31,&nbsp;2017</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.58%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.42%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">As&nbsp;of<br />
March&nbsp;31,&nbsp;2018</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.04%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:65.86%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Research and development related
costs</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:14.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2,308</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:11.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2,479</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" style=
"padding:0in 0in 0in 0in;width:65.86%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Payroll and related costs</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">4,426</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">2,651</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:65.86%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Accounting, tax and audit services</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">231</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">586</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" style=
"padding:0in 0in 0in 0in;width:65.86%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,159</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="12%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,861</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:65.86%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Total other current
liabilities</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">8,124</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">7,577</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">5.</font></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>Revenue</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%"
style="border-collapse:collapse;">
<tr>
<td width="66%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="29%" colspan="5" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:29.44%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br />

March&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.1%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="66%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.1%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Collaboration revenue</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:12.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">—</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:12.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">6,500</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Research premium</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,505</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">770</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Government grants</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">147</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">281</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Grants from WWFF</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">26</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">—</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Total</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">1,678</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">7,551</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The collaboration
revenue for the three months ended March&nbsp;31, 2018 reflects the
amounts recorded from the Sinovant License Agreement (see Note 9)
and includes the $5.0 million non-refundable upfront payment
received as consideration for entering into the license agreement
with Sinovant as well as $1.5 million of variable consideration
related a future milestone payment that the Company believes is
probable to be met and received.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">6.</font></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>Share-Based Payments</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:-22.0pt;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Stock Option
Plan 2015</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.0pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">On
April&nbsp;2, 2015, the Company’s shareholders, management board
and supervisory board adopted the Stock Option Plan 2015 (the “SOP
2015”) and the shareholders approved an amended and restated
version of the SOP 2015 on June&nbsp;30, 2015. An amendment to the
amended and restated SOP 2015 was approved by the shareholders on
July&nbsp;22, 2015. SOP 2015 became effective on July&nbsp;3, 2015
upon the registration with the commercial register in Austria of
the conditional capital increase approved by the shareholders on
June&nbsp;30, 2015. The SOP 2015 initially provided for the grant
of options for up to 95,000 Nabriva Austria common shares to the
Company’s employees, including members of the management board, and
to members of the supervisory board. Following the closing of the
initial public offering of the Company, the overall number of
options increased to 177,499 Nabriva Austria common shares.
Following approval by the Company’s shareholders at its 2016 annual
general meeting, the number of shares available for issuance under
the SOP 2015 was increased to 346,235 Nabriva Austria common
shares. In connection with the Redomiciliation Transaction, the SOP
2015 was amended to take account of certain requirements under
Irish law and assumed by Nabriva Ireland, with each option to
acquire one Nabriva Austria common share becoming an option to
acquire ten ordinary shares of Nabriva Ireland on the same terms
and conditions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.0pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Each vested
option grants the beneficiary the right to acquire one share in the
Company. The vesting period for the options is four years following
the grant date. On the last day of the last calendar month of the
first year of the vesting period, 25% of the options attributable
to each beneficiary are automatically vested. During the second,
third and fourth years of the vesting period, the
remaining</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
11<a name="PB_11_073633_5796" id="PB_11_073633_5796"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\C902550\18-8686-1\task8887152\8686-1-fn.htm',USER='C902550',CD='May  7 17:10 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">NABRIVA THERAPEUTICS
plc</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes
to the Unaudited Consolidated Financial Statements
(continued)</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(in thousands, except
per share data)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">75% of the options vest
on a monthly pro rata basis (i.e. 2.083% per month). Options
granted under the SOP 2015 have a term of no more than ten years
from the beneficiary’s date of participation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">The following table
summarizes information regarding our stock option awards under the
SOP 2015 for the three months ended March&nbsp;31, 2018:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%"
style="border-collapse:collapse;">
<tr>
<td width="50%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.56%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Stock&nbsp;Option&nbsp;Plan&nbsp;2015</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Options</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Weighted<br />
average<br />
exercise<br />
price&nbsp;in&nbsp;$<br />
per&nbsp;share</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Aggregate<br />
intrinsic&nbsp;value</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.08%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.56%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Outstanding as of
January&nbsp;1, 2018</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,044,899</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">8.35</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.56%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Granted</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.56%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Exercised</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.56%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Forfeited</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(29,050</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">7.49</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.56%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Outstanding as of
March&nbsp;31, 2018</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">3,015,849</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">8.35</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">3</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.56%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Vested and exercisable as of
March&nbsp;31, 2018</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">1,337,202</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">7.88</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">1</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Stock-based
compensation expense under the SOP 2015 was $0.7 million and $0.9
million for the three months ended March&nbsp;31, 2017 and 2018,
respectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The weighted
average remaining contractual life of the options as of
March&nbsp;31, 2018 is 8.2 years.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.0pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">As of
March&nbsp;31, 2018, there was $8.9 million of total unrecognized
compensation expense, related to unvested options granted under the
SOP 2015, which will be recognized over the weighted-average
remaining vesting period of 1.2 years.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:-22.0pt;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">2017 Share
Incentive Plan</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.0pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">On
July&nbsp;26, 2017, the Company’s board of directors adopted the
2017 Share Incentive Plan (the “2017 Plan”) and the shareholders
approved the 2017 Plan at the Company’s Extraordinary General
Meeting of Shareholders on September&nbsp;15, 2017. Following
shareholder approval of the 2017 Plan, the Company ceased making
awards under the SOP 2015, and future awards will be made under the
2017 Plan.&nbsp; However, all outstanding awards under SOP 2015
will remain in effect and continue to be governed by the terms of
the SOP 2015. The 2017 Plan permits the award of share options
(both incentive and nonstatutory options), share appreciation
rights (“SARs”), restricted shares, restricted share units (“RSUs”
), and other share-based awards to the Company’s employees,
officers, directors, consultants and advisers. The 2017 Plan is
administered by the Company’s board of directors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.0pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Under the 2017
Plan, the number of ordinary shares that will be reserved for
issuance will be the sum of (1)&nbsp;3,000,000 ordinary shares;
plus (2)&nbsp;a number of ordinary shares (up to 3,438,990 ordinary
shares) which is equal to the sum of the number of the Company’s
ordinary shares then available for issuance under the SOP 2015 and
the number of ordinary shares subject to outstanding awards under
the SOP 2015 that expire, terminate or are otherwise surrendered,
cancelled, forfeited or repurchased by the Company at their
original issuance price pursuant to a contractual repurchase right;
plus (3)&nbsp;an annual increase, to be added on the first day of
each fiscal year beginning in the fiscal year ending
December&nbsp;31, 2018 and continuing until, and including, the
fiscal year ending December&nbsp;31, 2027, equal to the least of
(i)&nbsp;2,000,000 ordinary shares, (ii)&nbsp;4% of the number of
outstanding ordinary shares on such date and (iii)&nbsp;an amount
determined by the board of directors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.0pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">At
March&nbsp;31, 2018, 4,891,442 ordinary shares were available for
issuance under the 2017 Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.0pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Options and
SARs granted will be exercisable at such times and subject to such
terms and conditions as the board may specify in the applicable
option agreement; provided, however, that no option or SAR will be
granted with a term in excess of ten years. The board will also
determine the terms and conditions of restricted shares and RSUs,
including the conditions for vesting and repurchase (or forfeiture)
and the issue price, if any.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">The following table
summarizes information regarding our stock option awards under the
2017 Plan for the three months ended March&nbsp;31,
2018:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
12<a name="PB_12_073744_2897" id="PB_12_073744_2897"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\C902550\18-8686-1\task8887152\8686-1-fn.htm',USER='C902550',CD='May  7 17:10 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">NABRIVA THERAPEUTICS
plc</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes
to the Unaudited Consolidated Financial Statements
(continued)</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(in thousands, except
per share data)</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%"
style="border-collapse:collapse;">
<tr>
<td width="50%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.56%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017&nbsp;Plan</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Options</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Weighted<br />
average<br />
exercise<br />
price&nbsp;in&nbsp;$<br />
per&nbsp;share</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Aggregate<br />
intrinsic&nbsp;value</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.08%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.56%;">
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Outstanding as of
January&nbsp;1, 2018</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">294,100</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">6.92</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.56%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Granted</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,543,400</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">6.18</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.56%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Exercised</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.56%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Forfeited</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:50.56%;">
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Outstanding as of
March&nbsp;31, 2018</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">1,837,500</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">6.29</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">—</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.56%;">
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Vested and exercisable as of
March&nbsp;31, 2018</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">—</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">—</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">—</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr height="0">
<td width="322" style="border:none;"></td>
<td width="18" style="border:none;"></td>
<td width="85" style="border:none;"></td>
<td width="18" style="border:none;"></td>
<td width="85" style="border:none;"></td>
<td width="18" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="77" style="border:none;"></td>
<td width="7" style="border:none;"></td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Stock-based
compensation expense under the 2017 Plan was $0.4 million for the
three months ended March&nbsp;31, 2018. The weighted average fair
value of the options granted during the three months ended
March&nbsp;31, 2018 was $3.60 per share. The options granted in the
three months ended March&nbsp;31, 2018 were valued based on a Black
Scholes option pricing model using the following assumptions. The
significant inputs into the model were as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="63%"
style="border-collapse:collapse;">
<tr>
<td width="75%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:75.52%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Input&nbsp;parameters</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.96%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="18%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:18.96%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.56%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="75%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:75.52%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Range of expected volatility</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.96%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:18.96%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">60.9% -
61.0%</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="75%" valign="top" style=
"padding:0in 0in 0in 0in;width:75.52%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Expected term of options (in years)</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.96%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="18%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:18.96%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">6.1</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="75%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:75.52%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Range of risk-free interest rate</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.96%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:18.96%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">2.6% - 2.7%</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="75%" valign="top" style=
"padding:0in 0in 0in 0in;width:75.52%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Dividend yield</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.96%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="18%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:18.96%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">—</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The expected price
volatility is based on historical trading volatility for the
publicly traded peer companies under consideration of the remaining
life of the options. The risk-free interest rate is based on the
average of five and seven-year market yield on U.S. treasury
securities in effect at the time of grant.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The weighted
average remaining contractual life of the options as of
March&nbsp;31, 2018 is 9.8 years.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As of
March&nbsp;31, 2018, there was $6.3 million of total unrecognized
compensation expense, related to unvested options granted under the
2017 Plan, which will be recognized over the weighted-average
remaining vesting period of 1.9 years.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Restricted Stock
Units</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">During the three
months ended March&nbsp;31, 2018, the Company granted 339,550 RSUs
with a grant date fair value of $6.47 per share, which was the
closing price of the Company’s shares on the grant date. Vesting of
the RSUs is subject to U.S. Food and Drug Administration (“FDA”),
approval of a new drug application (“NDA”), for lefamulin.&nbsp;
Fifty percent (50%) of each RSU award will vest upon FDA approval
of an NDA for lefamulin, and the remaining fifty percent (50%) will
vest on the one-year anniversary of such approval. If the FDA does
not approve an NDA for lefamulin within two years of the grant
date, the RSU award will terminate in full. The award of 67,500
RSUs to our chief executive officer is contingent upon shareholder
approval of an amendment to the 2017 Plan. No compensation expense
was recognized for the RSUs as vesting is not probable at
March&nbsp;31, 2018.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">7.</font></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>Income tax (expense) benefit</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In accordance with
the FASB Accounting Standard Codification (ASC) Topic No.&nbsp;270 
“Interim Reporting” and ASC Topic No.&nbsp;740 “Income Taxes”
(Topic No.&nbsp;740) at the end of each interim period, the Company
is required to determine the best estimate of its annual effective
tax rate and then apply that rate in providing for income taxes on
a current year-to-date (interim period) basis. For the three months
ended March&nbsp;31,&nbsp;2017 and 2018, the Company recorded
income tax expense of $349,000 and $506,000,
respectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Deferred tax assets and deferred tax
liabilities are recognized based on temporary differences between
the financial reporting and tax bases of assets and liabilities
using statutory rates.&nbsp;Management of the Company has evaluated
the positive and negative evidence bearing upon the realizability
of its deferred tax assets, including the Company’s history of
losses and concluded that it is more likely than not that the
Company will not recognize the benefits of its deferred tax
assets.&nbsp; On the basis of this evaluation, as of March&nbsp;31,
2018 and December&nbsp;31, 2017, the Company has recorded a
valuation allowance of</font> $81.3 million and $80.1 million,
respectively. The amount of the deferred tax assets considered
realizable, however, could be adjusted if estimates of future
taxable income during the carryforward period are reduced or
increased or if objective negative evidence in the form of
cumulative losses is no longer present and additional weight is
given to subjective evidence such as the Company’s projections for
growth.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
13<a name="PB_13_073930_3020" id="PB_13_073930_3020"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\C902550\18-8686-1\task8887152\8686-1-fn.htm',USER='C902550',CD='May  7 17:10 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">NABRIVA THERAPEUTICS
plc</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes
to the Unaudited Consolidated Financial Statements
(continued)</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(in thousands, except
per share data)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">8.</font></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>Earnings (Loss) per Share</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Basic
and diluted loss per share</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">For the three
months ended March&nbsp;31, 2017 and 2018, basic and diluted net
loss per share was determined by dividing net loss attributable to
shareholders by the weighted average number of shares outstanding
during the period.&nbsp; Diluted net loss per share is the same as
basic net loss per share during the periods presented as the
effects of the Company’s potential common stock equivalents are
antidilutive and thus not included in the calculation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%"
style="border-collapse:collapse;">
<tr>
<td width="66%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="29%" colspan="5" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:29.44%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br />

March&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.1%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="66%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.1%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
loss for the period</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:12.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(15,223</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:12.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(13,342</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" style=
"padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Weighted average number of shares
outstanding</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">27,204,230</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">36,911,604</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="66%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:66.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Basic and diluted loss per
share</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(0.56</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(0.36</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">The following common
stock equivalents were excluded from the calculations of diluted
earnings per share as their effect would be
anti-dilutive:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="73%"
style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="59%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:59.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="36%" colspan="3" valign="bottom" style=
"padding:0in 0in 0in 0in;width:36.14%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="59%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:59.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="36%" colspan="3" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:36.14%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">March&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="59%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:59.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="16%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="59%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:59.08%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Stock options</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">278,579</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">4,853,349</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="59%" valign="top" style=
"padding:0in 0in 0in 0in;width:59.08%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Restricted stock units</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">—
</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="16%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">339,550</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">9.</font></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>License Agreement</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In
March&nbsp;2018, the Company entered into a license agreement (the 
“License Agreement”), with Sinovant Sciences,&nbsp;Ltd. or
Sinovant, an affiliate of Roivant Sciences,&nbsp;Ltd., to develop
and commercialize lefamulin in the greater China region. As part of
the License Agreement, Nabriva Therapeutics Ireland DAC and Nabriva
Therapeutics GmbH, our wholly owned subsidiaries, granted Sinovant
an exclusive license to develop and commercialize, and a
non-exclusive license to manufacture, certain products containing
lefamulin (the “Licensed Products”), in the People’s Republic of
China, Hong Kong, Macau, and Taiwan (together the “Territory”
).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Under the
License Agreement, Sinovant and the Company’s subsidiaries will
establish a joint development committee (the “JDC’), to review and
oversee development and commercialization plans in the Territory.
The Company received a non-refundable $5.0 million upfront payment
pursuant to the terms of the License Agreement and will be eligible
for up to an additional $91.5 million in milestone payments upon
the achievement of certain regulatory and commercial milestone
events related to lefamulin for CABP, plus an additional $4.0
million in milestone payments if any Licensed Product receives a
second or any subsequent regulatory approval in the People’s
Republic of China. The first milestone is a $1.5 million payment
for the submission of a clinical trial application (“CTA”), by
Sinovant to the Chinese Food and Drug Administration, which is
planned for the third quarter of 2018. The remaining milestone
payments are tied to additional regulatory approvals and annual
sales targets. In addition, the Company will be eligible to receive
low double-digit royalties on sales, if any, of Licensed Products
in the Territory.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Sinovant will be
solely responsible for all costs related to developing, obtaining
regulatory approval of and commercializing Licensed Products in the
Territory and is obligated to use commercially reasonable efforts
to develop, obtain regulatory approval for, and commercialize
Licensed Product in the Territory. The Company is obligated to use
commercially reasonable efforts to supply, pursuant to supply
agreements to be negotiated by the parties, to Sinovant sufficient
supply of lefamulin for Sinovant to manufacture finished drug
products for development and commercialization of the Licensed
Products in the Territory.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Unless earlier
terminated, the License Agreement will expire upon the expiration
of the last royalty term for the last Licensed Product in the
Territory, which the Company expects will occur in 2033. Following
the expiration of the last royalty term, the license granted to
Sinovant will become non-exclusive, fully-paid, royalty-free and
irrevocable. The License Agreement may be terminated in its
entirety by Sinovant upon 180 days’ prior written notice at any
time.&nbsp; Either party may, subject to specified cure periods,
terminate the License Agreement in the event of the other party’s
uncured material breach. Either party may also terminate the
License Agreement under specified circumstances relating to the
other party’s insolvency. The Company has the right to terminate
the License Agreement immediately if Sinovant does not reach
certain development milestones by certain specified dates (subject
to specified cure periods).&nbsp; The License Agreement
contemplates that the Company will enter into ancillary agreements
with Sinovant, including clinical and commercial supply agreements
and a pharmacovigilance agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
14<a name="PB_14_074111_7748" id="PB_14_074111_7748"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\C902550\18-8686-1\task8887152\8686-1-fn.htm',USER='C902550',CD='May  7 17:10 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">NABRIVA THERAPEUTICS
plc</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes
to the Unaudited Consolidated Financial Statements
(continued)</font></b></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">(in thousands, except
per share data)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company has
identified two performance obligations at inception: (1)&nbsp;the
delivery of the licenses to Sinovant; and, (2)&nbsp;the
participation in the JDC. The $5.0 million non-refundable upfront
payment was allocated to the delivery of the licenses as the JDC
deliverable was deemed to be de minimis. In addition, since the
first $1.5 million milestone payment related to the submission of
the CTA is within the control of the parties and is scheduled for
submission in the third quarter of this year, the Company recorded
such milestone as variable consideration allocated to the licenses
at the inception of the arrangement as the Company believes it is
probable to be met and received. The future regulatory and
commercial milestone payments will be accounted for on an “as
incurred basis” and recorded during the period the milestones are
achieved.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">10.</font></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>Commitments and Contingencies</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">During the three
months ended March&nbsp;31, 2018, there were no material changes
outside the ordinary course of the Company’s business to its
contractual obligations as disclosed in the Company’s Annual Report
on Form&nbsp;10-K for the year ended December&nbsp;31,
2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">The Company has no
contingent liabilities in respect of legal claims arising in the
ordinary course of business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">11.</font></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>Subsequent Events</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Company
evaluated all events or transactions that occurred subsequent to
March&nbsp;31, 2018 through the date the unaudited consolidated
financial statements were issued, and have not identified any such
events material to an understanding of the unaudited consolidated
financial statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
15<a name="PB_15_074136_141" id="PB_15_074136_141"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\C902550\18-8686-1\task8887152\8686-1-fn.htm',USER='C902550',CD='May  7 17:10 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM
2.&nbsp; MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</font></b><a name=
"ITEM2_MANAGEMENTSDISCUSSIONANDAN_080447" id=
"ITEM2_MANAGEMENTSDISCUSSIONANDAN_080447"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">You should read the following
discussion and analysis of our financial condition and results of
operations together with our consolidated financial statements and
the related notes appearing elsewhere in this Quarterly Report on
Form&nbsp;10-Q and our historical consolidated financial statements
and the related notes thereto appearing in our Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2017, filed
with the Securities and Exchange Commission on March&nbsp;16, 2018.
Some of the information contained in this discussion and analysis
or set forth elsewhere in this Quarterly Report, including
information with respect to our plans and strategy for our
business, includes forward-looking statements that involve risks
and uncertainties. As a result of many factors, including those
factors set forth in the “Risk Factors” section of this Quarterly
Report, our actual results could differ materially from the results
described in or implied by the forward-looking statements contained
in the following discussion and analysis.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are a clinical
stage biopharmaceutical company engaged in the research and
development of novel anti-infective agents to treat serious
infections, with a focus on the pleuromutilin class of antibiotics.
We are developing our lead product candidate, lefamulin, to be the
first pleuromutilin antibiotic available for systemic
administration in humans. We are developing both intravenous, or
IV, and oral formulations of lefamulin for the treatment of
community-acquired bacterial pneumonia, or CABP and may potentially
develop lefamulin for additional indications other than
CABP.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We initiated the
first of two pivotal, international Phase 3 clinical trials of
lefamulin, which we refer to as Lefamulin Evaluation Against
Pneumonia 1, or LEAP 1, in September&nbsp;2015 and initiated the
second trial, which we refer to as LEAP 2, in April&nbsp;2016. On
September&nbsp;18, 2017, we announced positive top-line results for
LEAP 1. In LEAP 1, which enrolled 551 patients, lefamulin met all
of the primary endpoints of non-inferiority compared to
moxifloxacin with or without linezolid as required by the U.S. Food
and Drug Administration, or FDA, and European Medicines Agency, or
EMA. Lefamulin also showed a favorable tolerability profile in the
LEAP 1 trial, with no unexpected safety signals or evidence of
off-target activity. We completed patient enrollment of 738 adult
patients in LEAP 2 in December&nbsp;2017 and expect to have
top-line data available from LEAP 2 in the spring of 2018. If the
results of LEAP 2 are also favorable, including achievement of the
primary efficacy endpoints of the trial, we expect to submit a new
drug application, or NDA, for marketing approval of lefamulin for
the treatment of CABP in adults in the United States in the fourth
quarter of 2018. We also expect to submit a marketing authorization
application, or MAA, for lefamulin for the treatment of CABP in
adults in Europe a few months after our NDA filing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">On
March&nbsp;1, 2017, Nabriva Therapeutics plc, or Nabriva Ireland,
was incorporated in Ireland under the name Hyacintho 2 plc, and was
renamed to Nabriva Therapeutics plc on April&nbsp;10, 2017, in
order to effectuate the change of the jurisdiction of incorporation
of the ultimate company of the group from Austria to Ireland.
Nabriva Ireland replaced Nabriva Therapeutics AG, or Nabriva
Austria, as the ultimate parent company on June&nbsp;23, 2017,
following the conclusion of a tender offer, or the Exchange Offer,
in which holders of 98.6% of the outstanding share capital of
Nabriva Austria exchanged their holdings for ordinary shares, $0.01
nominal value per share, of Nabriva Ireland, which we refer to as
the Redomiciliation Transaction. The ordinary shares of Nabriva
Ireland were issued on a one-for-ten basis to the holders of the
Nabriva Austria common shares and on a one-for-one basis to the
holders of the Nabriva Austria American Depositary Shares, or
Nabriva Austria ADSs, participating in the Exchange Offer. On
June&nbsp;26, 2017, the ordinary shares of Nabriva Ireland began
trading on the Nasdaq Global Market under the symbol “NBRV,” the
same symbol under which the Nabriva Austria ADSs were previously
traded.&nbsp; This transaction was accounted for as a merger
between entities under common control; accordingly, the historical
financial statements of Nabriva Austria for periods prior to this
transaction are considered to be the historical financial
statements of Nabriva Ireland.&nbsp;&nbsp; As of August&nbsp;18,
2017, 100%&nbsp;of Nabriva Austria share capital had been exchanged
for ordinary shares of Nabriva Ireland.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Nabriva
Austria was incorporated in October&nbsp;2005 in Austria under the
name Nabriva Therapeutics Forschungs GmbH, a limited liability
company organized under Austrian law, as a spin-off from Sandoz
GmbH and commenced operations in February&nbsp;2006. In 2007,
Nabriva Austria transformed into a stock corporation
(<i>Aktiengesellschaft</i>) under the name Nabriva Therapeutics AG.
On October&nbsp;19, 2017, Nabriva Austria was converted into a
limited liability company under Austrian law and renamed Nabriva
Therapeutics GmbH. In 2014, we established our wholly owned U.S.
subsidiary, which began operations in August&nbsp;2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Since
inception, we have incurred significant operating losses. As of
March&nbsp;31, 2018, we had an accumulated deficit of $292.5
million. To date, we have financed our operations primarily through
our 2018 “at-the-market” equity offering, our 2017 equity offering,
our 2016 rights offering, our 2015 initial public offering, private
placements of our</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
16<a name="PB_16_080509_5839" id="PB_16_080509_5839"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\JMS\C902549\18-8686-1\task8887116\8686-1-ga.htm',USER='C902549',CD='May  7 16:53 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">equity securities,
convertible loans and research and development support from
governmental grants and loans. We have devoted substantially all of
our efforts to research and development, including clinical trials.
Our ability to generate profits from operations and remain
profitable depends on our ability to successfully develop and
commercialize drugs that generate significant revenue.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
expect to continue to incur significant expenses and increasing
operating losses for at least the next several years. However,
we</font> have re-evaluated the need for the previously planned
expansion of our commercial organization, medical education, and
supply chain activities and we now anticipate that our expenses for
2018 will decrease as compared to our expenses for 2017 as we wind
down our Phase 3 clinical trial program for lefamulin for the
treatment of CABP. We expect to continue to invest in critical
pre-commercialization activities prior to receiving marketing
approval and making lefamulin available to patients.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Our expenses
will increase if we suffer any delays in our Phase 3 clinical
program, including regulatory delays, or are required to conduct
additional clinical trials to satisfy regulatory requirements. If
we obtain marketing approval for lefamulin or any other product
candidate that we develop, in-license or acquire, we expect to
incur significant commercialization expenses related to product
sales, marketing, distribution and manufacturing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Based on our
current plans, we do not expect to generate significant revenue
unless and until we obtain marketing approval for, and
commercialize, lefamulin. We do not expect to obtain marketing
approval before 2019, if at all. Accordingly, we will need to
obtain substantial additional funding in connection with our
continuing operations.&nbsp; Adequate additional financing may not
be available to us on acceptable terms, or at all. If we are unable
to raise capital when needed or on attractive terms, we could be
forced to delay, reduce or eliminate our research and development
programs or any future commercialization effort.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Financial Operations
Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Revenue</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">To date we
have not generated any revenues from product sales. and we do not
expect to generate any revenue from the sale of products in the
near future. We do not expect to generate significant revenue
unless and until we obtain marketing approval for, and
commercialize, lefamulin. We do not expect to obtain marketing
approval before 2019, if at all. If our development efforts result
in clinical success and regulatory approval, we may also enter into
collaboration agreements with third parties and we may generate
revenue from those agreements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
revenue consists principally of t</font>he collaboration revenues
recorded from the Sinovant License Agreement entered into in
March&nbsp;2018, discussed more fully below, and includes a $5.0
million non-refundable upfront payment received as consideration
for entering into the license agreement with Sinovant as well as
$1.5 million of variable consideration related a future milestone
payment that we believe is probable to be met and received. Revenue
also includes governmental research premiums, non-refundable
government grants and&nbsp;the benefit of government loans at
below-market interest rates, which are more fully described under 
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations— Critical Accounting Policies” in our Annual
Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2017.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Research and
Development Expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Research and
development expenses represented 75.0% and 50.4% of our total
operating expenses for the three months ended March&nbsp;31, 2017
and 2018, respectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">For each of
our research and development programs, we incur both direct and
indirect expenses. Direct expenses include third party expenses
related to these programs such as expenses for manufacturing
services, non-clinical and clinical studies and other third party
development services. Indirect expenses include salaries and
related costs, including stock-based compensation, for personnel in
research and development functions, infrastructure costs allocated
to research and development operations, costs associated with
obtaining and maintaining intellectual property associated with our
research and development operations, laboratory consumables,
consulting fees related to research and development activities and
other overhead costs. We utilize our research and development staff
and infrastructure resources across multiple programs, and many of
our indirect costs historically have not been specifically
attributable to a single program. Accordingly, we cannot state
precisely our total indirect costs incurred on a program-by-program
basis.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">The following
table summarizes our direct research and development expenses by
program and our indirect costs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
17<a name="PB_17_080534_7056" id="PB_17_080534_7056"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\JMS\C902549\18-8686-1\task8887116\8686-1-ga.htm',USER='C902549',CD='May  7 16:53 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%"
style="border-collapse:collapse;">
<tr>
<td width="65%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:65.38%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.9%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="30%" colspan="5" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.58%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br />

March&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="65%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:65.38%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.9%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:65.38%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Direct Costs</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" style=
"padding:0in 0in 0in 0in;width:65.38%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Lefamulin</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">9,491</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">6,507</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:65.38%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other programs and initiatives</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">13</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">29</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" style=
"padding:0in 0in 0in 0in;width:65.38%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Indirect Costs</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,156</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,743</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:65.38%;">
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Total</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">12,660</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">10,279</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We expect to
continue to incur research and development expenses in connection
with our activities related to our ongoing LEAP 2 clinical trial of
lefamulin for the treatment of CABP which is winding down as we
expect top-line date in the spring of 2018, our subsequent NDA and
MAA filings and the pursuit of the clinical development of
lefamulin for additional indications and engage in earlier stage
research and development activities. It is difficult to estimate
the duration and completion costs of our research and development
programs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">The successful
development and commercialization of our product candidates is
highly uncertain. This is due to the numerous risks and
uncertainties associated with product development and
commercialization, including the uncertainty of:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the scope, progress, costs and results of clinical trials and other
research and development activities;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs, timing and outcome of regulatory review of our product
candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the efficacy and potential advantages of our product candidates
compared to alternative treatments, including any standard of care,
and our ability to achieve market acceptance for any of our product
candidates that receive marketing approval;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs and timing of commercialization activities, including
product sales, marketing, distribution and manufacturing, for any
of our product candidates that receive marketing approval; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs and timing of preparing, filing and prosecuting patent
applications, maintaining, enforcing and protecting our
intellectual property rights and defending against any intellectual
property-related claims.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">A change in
the outcome of any of these variables with respect to the
development of our product candidates could result in a significant
change in the costs and timing associated with the development of
that product candidate. For example, if the FDA or another
regulatory authority were to require us to conduct clinical trials
or other testing beyond those that we have completed or currently
contemplate will be required for the completion of clinical
development of any product candidate, or if we experience
significant delays in enrollment in any of our clinical trials, we
could be required to expend significant additional resources and
time on the completion of clinical development of that product
candidate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">General and
Administrative Expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">General and
administrative expenses represented 25.0% and 49.6% of our total
operating expenses for the three months ended March&nbsp;31, 2017
and 2018, respectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">General and
administrative expenses consist primarily of salaries and related
costs, including share-based compensation not related to research
and development activities for personnel in our finance,
information technology, commercial, medical affairs and
administrative functions. General and administrative expenses also
include costs related to professional fees for auditors, lawyers
and tax advisors and consulting fees not related to research and
development operations, as well as functions that are partly or
fully outsourced by us, such as accounting, payroll processing and
information technology.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We expect to
incur significant marketing, commercial and manufacturing supply
chain costs if LEAP 2 data is positive and we obtain marketing
approval of lefamulin for the treatment of CABP.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
18<a name="PB_18_080755_5335" id="PB_18_080755_5335"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='18',FILE='C:\JMS\C902549\18-8686-1\task8887116\8686-1-ga.htm',USER='C902549',CD='May  7 16:53 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">License
Agreement with Sinovant Sciences</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In
March&nbsp;2018, we entered into a license agreement, or the
License Agreement, with Sinovant Sciences,&nbsp;Ltd. or Sinovant,
an affiliate of Roivant Sciences,&nbsp;Ltd., to develop and
commercialize lefamulin in the greater China region. As part of the
License Agreement, Nabriva Therapeutics Ireland DAC and Nabriva
Therapeutics GmbH, our wholly owned subsidiaries, granted Sinovant
an exclusive license to develop and commercialize, and a
non-exclusive license to manufacture, certain products containing
lefamulin, or the Licensed Products, in the People’s Republic of
China, Hong Kong, Macau, and Taiwan (together the “Territory”). We
retain development and commercialization rights in the rest of the
world.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Under the
License Agreement, Sinovant and our subsidiaries will establish a
joint development committee, or the JDC, to review and oversee
development and commercialization plans in the Territory. We
received a $5.0 million upfront payment pursuant to the terms of
the License Agreement and will be eligible for up to an additional
$91.5 million in milestone payments upon the achievement of certain
regulatory and commercial milestone events related to lefamulin for
CABP, plus an additional $4.0 million in milestone payments if any
Licensed Product receives a second or any subsequent regulatory
approval in the People’s Republic of China. The first milestone is
a $1.5 million payment for the submission of a clinical trial
application by Sinovant to the Chinese Food and Drug
Administration, which is planned for the third quarter of 2018. The
remaining milestone payments are tied to additional regulatory
approvals and annual sales targets. In addition, we will be
eligible to receive low double-digit royalties on sales, if any, of
Licensed Products in the Territory.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Sinovant will be
solely responsible for all costs related to developing, obtaining
regulatory approval of and commercializing Licensed Products in the
Territory and is obligated to use commercially reasonable efforts
to develop, obtain regulatory approval for, and commercialize
Licensed Product in the Territory. We are obligated to use
commercially reasonable efforts to supply, pursuant to supply
agreements to be negotiated by the parties, to Sinovant sufficient
supply of lefamulin for Sinovant to manufacture finished drug
products for development and commercialization of the Licensed
Products in the Territory.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Unless earlier
terminated, the License Agreement will expire upon the expiration
of the last royalty term for the last Licensed Product in the
Territory, which we expect will occur in 2033. Following the
expiration of the last royalty term, the license granted to
Sinovant will become non-exclusive, fully-paid, royalty-free and
irrevocable. The License Agreement may be terminated in its
entirety by Sinovant upon 180 days’ prior written notice at any
time.&nbsp; Either party may, subject to specified cure periods,
terminate the License Agreement in the event of the other party’s
uncured material breach. Either party may also terminate the
License Agreement under specified circumstances relating to the
other party’s insolvency. We have the right to terminate the
License Agreement immediately if Sinovant does not reach certain
development milestones by certain specified dates (subject to
specified cure periods).&nbsp; The License Agreement contemplates
that the we will enter into ancillary agreements with Sinovant,
including clinical and commercial supply agreements and a
pharmacovigilance agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We have identified
two performance obligations at inception: (1)&nbsp;the delivery of
the licenses to Sinovant; and, (2)&nbsp;the participation in the
JDC. The $5.0 million non-refundable upfront payment was allocated
entirely to the of the licenses as the JDC deliverable was deemed
to be de minimis. In addition, since the first $1.5 million
milestone payment related to the as the submission of the CTA is in
the control of the parties and is scheduled for submission in the
third quarter of this year, we recorded such milestone as variable
consideration allocated to the licenses at the inception of the
arrangement as we believe it is probable to be met and received.
The future regulatory and commercial milestone payments will be
accounted for on an “as incurred basis” and recorded during the
period the milestone is achieved.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Critical Accounting
Policies</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our consolidated
financial statements are prepared in accordance with U.S. generally
accepted accounting principles. The preparation of our financial
statements and related disclosures requires us to make estimates,
assumptions and judgments that affect the reported amount of
assets, liabilities, revenue, costs and expenses, and related
disclosures. Our critical accounting policies are described under
the heading “Management’s Discussion and Analysis of Financial
Condition and Results of Operations— Critical Accounting Policies”
in our Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2017.&nbsp; During the three months ended
March&nbsp;31, 2018, there were no material changes to our critical
accounting policies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
19<a name="PB_19_080824_5796" id="PB_19_080824_5796"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='19',FILE='C:\JMS\C902549\18-8686-1\task8887116\8686-1-ga.htm',USER='C902549',CD='May  7 16:53 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Results of
Operations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Comparison
of Three Months Ended March&nbsp;31, 2017 and
2018</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%"
style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="48%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="30%" colspan="5" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.66%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="48%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Change</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="48%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Consolidated Operations
Data:</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="48%" valign="top" style=
"padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Revenues</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="12%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">1,678</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="12%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">7,551</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="12%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5,873</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="48%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Costs and
Expenses:</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="48%" valign="top" style=
"padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Research and development</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(12,660</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(10,279</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(2,381</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="48%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">General and administrative</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(4,218</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(10,136</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5,918</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="48%" valign="top" style=
"padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt 30.3pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Total operating expenses</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(16,878</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(20,415</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">3,537</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="48%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Loss from
operations</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(15,200</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(12,864</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">2,336</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="48%" valign="top" style=
"padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Other income
(expense):</font></b></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="48%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Other income (expense), net</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">206</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">23</font></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(183</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="48%" valign="top" style=
"padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Interest income (expense), net</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">120</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">5</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(115</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="48%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Loss before income
taxes</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(14,874</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(12,836</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">2,038</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="48%" valign="top" style=
"padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Income tax expense</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(349</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(506</font></p>
</td>
<td width="2%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="13%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(157</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0.375pt 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="48%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Net loss</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(15,223</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(13,342</font></b></p>
</td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">1,881</font></b></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 17.85pt;text-indent:-17.85pt;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Revenues</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Revenues increased
by $5.9&nbsp;million from $1.7 million for the three months ended
March&nbsp;31, 2017 to $7.6 million for the three months ended
March&nbsp;31, 2018, primarily due to the $5.0 million upfront
payment received from our Sinovant License Agreement as well as
$1.5 million of variable consideration related a future milestone
payment that we believe is probable to be met and received and a
$0.1 million increase in grant income. The increase was partially
offset by a $0.7 million decrease in grant revenue from research
premiums provided to us by the Austrian government as a result of
lower applicable research and development expenses.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 17.85pt;text-indent:-17.85pt;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Research and Development
Expenses</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:17.85pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Research and
development expenses decreased by $2.4&nbsp;million from
$12.7&nbsp;million for the three months ended March&nbsp;31, 2017
to $10.3&nbsp;million for the three months ended March&nbsp;31,
2018. The decrease was primarily due to a $3.8 million decrease in
research materials and purchased services related to the
development of lefamulin, offset by a $0.5 million increase in
research consulting fees, a $0.4 million increase in staff costs
due to the addition of employees, a $0.2 million increase in
stock-based compensation expense and a $0.2 million increase in
travel and infrastructure costs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;">General and Administrative
Expenses</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">General and administrative expense increased by
$5.9 million from $4.2&nbsp;million for the three months ended
March&nbsp;31, 2017 to $10.1&nbsp;million for the three months
ended March&nbsp;31, 2018. The increase was primarily due to</font>
a $2.7 million increase of advisory and external consultancy
expenses primarily related to pre-commercialization activities and
professional service fees, a $2.3 million increase in staff costs
due to the addition of employees, a $0.3 million increase in
share-based compensation expense due to the inclusion of additional
employees in our share-based compensation plan, a $0.3 million
increase in infrastructure costs and a $0.3 million increase in
travel and other corporate costs.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-style:italic;">Other
Income (Expense), net</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Other income
(expense), net decreased by $0.2 million from $0.2 million income
for the three months ended March&nbsp;31, 2017, to nil for the
three months ended March&nbsp;31, 2018 due to the effects of
re-measurements of our foreign currency account
balances.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Income Tax
Expense</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our income tax
expense was $0.3 million for the three months ended March&nbsp;31,
2017 compared to income tax expense of $0.5 million for the three
months ended March&nbsp;31, 2017.&nbsp; The income tax expense in
both periods represents the current tax expense of our foreign
subsidiaries.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
20<a name="PB_20_080933_2897" id="PB_20_080933_2897"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='20',FILE='C:\JMS\C902549\18-8686-1\task8887116\8686-1-ga.htm',USER='C902549',CD='May  7 16:53 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Liquidity and Capital
Resources</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Since our
inception, we have incurred net losses and generated negative cash
flows from our operations. To date, we have financed our operations
through the sale of equity securities, including our initial public
offering of ADSs, public offering of our ordinary shares and
private placements of our equity securities, convertible debt
financings and research and development support from governmental
grants and loans.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31,
2018, we had cash and cash equivalents and short-term investments
of $89.6 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:22.5pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
March&nbsp;2018, we entered into a Controlled Equity
Offering</font><font size="1" style=
"font-size:6.5pt;position:relative;top:-3.0pt;">SM</font>&nbsp;Sales
Agreement, or the ATM Agreement, with Cantor Fitzgerald&nbsp;&amp;
Co., or Cantor, pursuant to which, from time to time, we may offer
and sell our ordinary shares having aggregate gross proceeds of up
to $50.0 million through Cantor. As of March&nbsp;31, 2018, we
issued and sold an aggregate of 3,517,511 ordinary shares under the
ATM Agreement, for gross proceeds of $19.4 million, and net
proceeds of $18.9 million, after deducting commissions. From March
31, 2018 to the date of this filing, we issued and sold on
aggregate of 3,590,568 ordinary shares under the ATM agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cash
Flows</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Comparison
of Three Months Ended March&nbsp;31, 2017 and
2018</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%"
style="border-collapse:collapse;margin-left:.75in;">
<tr>
<td width="62%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="33%" colspan="5" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:33.12%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="62%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">(in&nbsp;thousands)</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="15%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2017</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="15%" colspan="2" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">2018</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">Net
cash provided by (used in):</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="62%" valign="top" style=
"padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Operating activities</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="13%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.6%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(14,684</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">$</font></p>
</td>
<td width="13%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:13.6%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(16,339</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Investing activities</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">9,977</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(160</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
</tr>
<tr>
<td width="62%" valign="top" style=
"padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Financing activities</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">(1,171</font></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">)</font></p>
</td>
<td width="15%" colspan="2" valign="bottom" style=
"padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">19,059</font></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Effects of foreign currency translation on
cash</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">266</font></p>
</td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF"
style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">112</font></p>
</td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style=
"background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="62%" valign="top" style=
"padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Net (decrease) increase in
cash</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.6%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">(5,612</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 2.25pt 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">)</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">$</font></b></p>
</td>
<td width="13%" valign="bottom" style=
"border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<b><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">2,672</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 17.85pt;text-indent:-17.85pt;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Operating
Activities</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Cash flow used
in operating activities increased by $1.7 million from
$14.7&nbsp;million for the three months ended March&nbsp;31, 2017
to $16.4 million for the three months ended March&nbsp;31, 2018
primarily due to a $2.4&nbsp;million decrease in net loss, after
adjustments for non-cash amounts included in net income, offset by
higher working capital of $4.1 million primarily due to changes in
accrued expenses and other current liabilities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 17.85pt;text-indent:-17.85pt;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Investing
Activities</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:17.85pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Cash flow
generated from investing activities decreased by $10.1&nbsp;million
from cash provided of $10.0 million for the three months ended
March&nbsp;31, 2017 to cash used of $0.1&nbsp;million for the three
months ended March&nbsp;31, 2018 primarily due to changes in
proceeds from sale of available-for-sale financial assets to fund
operational cash out flows.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 17.85pt;text-indent:-17.85pt;">
<i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">Financing
Activities</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:17.85pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Cash flow
generated from financing activities increased by $20.2 million from
a use of $1.2&nbsp;million for the three months ended
March&nbsp;31, 2017 to cash provided of $19.1&nbsp;million for the
three months ended March&nbsp;31, 2017 consisting of proceeds, net
of commissions, related to our ATM Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Operating and Capital
Expenditure Requirements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We have
re-evaluated the need for the previously planned expansion of our
commercial organization, medical education, and supply chain
activities and we now anticipate that our expenses for 2018 will
decrease as compared to our expenses for 2017 as we wind down our
Phase 3 clinical trial program for lefamulin for the treatment of
CABP. We expect to continue to invest in critical
pre-commercialization activities prior to receiving marketing
approval and making lefamulin available to patients.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Our expenses
will increase if we suffer any delays in our Phase 3 clinical
program, including regulatory delays, or are required to conduct
additional clinical trials to satisfy regulatory requirements. If
we obtain marketing approval for lefamulin or any other product
candidate that we develop, in-license or acquire, we expect to
incur significant commercialization expenses related to product
sales, marketing, distribution and manufacturing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
21<a name="PB_21_081050_3020" id="PB_21_081050_3020"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='21',FILE='C:\JMS\C902549\18-8686-1\task8887116\8686-1-ga.htm',USER='C902549',CD='May  7 16:53 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">In addition,
our expenses will increase if and as we:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
initiate or continue the research and development of lefamulin for
additional indications and of our other product candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
seek to discover and develop additional product candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
seek marketing approval for any product candidates that
successfully complete clinical development;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
continue to establish a medical affairs, sales, marketing and
distribution infrastructure and build up inventory of finished
product and its components to commercialize any product candidates
for which we receive marketing approval;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
in-license or acquire other products, product candidates or
technologies;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
maintain, expand and protect our intellectual property
portfolio;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.6pt;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
establish and expand manufacturing arrangements with third
parties;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
expand our physical presence in the United States and Ireland;
and,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
add operational, financial and management information systems and
personnel, including personnel to support our product development,
our operations as a public company and our planned future
commercialization efforts.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We expect that
our existing cash, cash equivalents and short-term investments will
be sufficient to enable us to fund our operating expenses and
capital expenditure requirements into the first quarter of 2020. We
have based this estimate on assumptions that may prove to be wrong,
and we could use our capital resources sooner than we currently
expect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We expect to
seek additional funding in future periods for purposes of
investment in our commercial and medical affairs organization,
including the expansion of a targeted hospital based sales force
and related infrastructure, as well as investing in our supply
chain, in an effort to enhance the potential commercial launch of
lefamulin.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Our future
capital requirements will depend on many factors,
including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the progress, costs and results of our clinical trials for
lefamulin, including our LEAP 2 trial;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs and timing of process development and manufacturing
scale-up activities associated with lefamulin;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs, timing and outcome of regulatory review of
lefamulin;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs of commercialization activities for lefamulin if we
receive, or expect to receive, marketing approval, including the
costs and timing of establishing product sales, marketing,
distribution and outsourced manufacturing capabilities, including
the costs of building finished product inventory and its components
in preparation of initial marketing of lefamulin;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
subject to receipt of marketing approval, revenue received from
commercial sales of lefamulin;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs of developing lefamulin for the treatment of additional
indications;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our ability to establish collaborations on favorable terms, if at
all;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the scope, progress, results and costs of product development of
any other product candidates that we may develop;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the extent to which we in-license or acquire rights to other
products, product candidates or technologies;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
22<a name="PB_22_081220_7748" id="PB_22_081220_7748"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='22',FILE='C:\JMS\C902549\18-8686-1\task8887116\8686-1-ga.htm',USER='C902549',CD='May  7 16:53 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs of preparing, filing and prosecuting patent applications,
maintaining and protecting our intellectual property rights and
defending against intellectual property-related claims;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the continued availability of Austrian governmental grants;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the rate of the expansion of our physical presence in the United
States and Ireland; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 48.95pt;text-indent:-18.35pt;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs of operating as a public company in the United
States.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Conducting
clinical trials is a time-consuming, expensive and uncertain
process that takes years to complete, and we may never generate the
necessary data or results required to obtain marketing approval and
achieve product sales. Our commercial revenues, if any, will be
derived from sales of lefamulin or any other products that we
successfully develop, in-license or acquire, none of which we
expect to be commercially available for more than a year, if at
all. In addition, if approved, lefamulin or any other product
candidate that we develop, in-license or acquire may not achieve
commercial success. Accordingly, we will need to obtain substantial
additional financing to achieve our business objectives. Adequate
additional financing may not be available to us on acceptable
terms, or at all. In addition, we may seek additional capital due
to favorable market conditions or strategic considerations, even if
we believe that we have sufficient funds for our current or future
operating plans.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Until such
time, if ever, as we can generate substantial product revenues, we
expect to finance our cash needs through a combination of equity
offerings, debt financings, collaborations, and funding from local
and international government entities and non-government
organizations in the disease areas addressed by our product
candidates and marketing, distribution or licensing arrangements.
To the extent that we raise additional capital through the sale of
equity or convertible debt securities, the ownership interest of
our shareholders will be diluted, and the terms of these securities
may include liquidation or other preferences that adversely affect
the rights of our shareholders. Debt financing, if available, may
involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional
debt, making capital expenditures or declaring
dividends.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">If we raise
additional funds through collaborations, strategic alliances or
marketing, distribution or licensing arrangements with third
parties, we may have to relinquish valuable rights to our
technologies, future revenue streams, research programs or product
candidates or to grant licenses on terms that may not be favorable
to us. If we are unable to raise additional funds through equity or
debt financings when needed, we may be required to delay, limit,
reduce or terminate our product development or future
commercialization efforts or grant rights to develop and market
product candidates that we would otherwise prefer to develop and
market ourselves.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Contractual Obligations and
Commitments</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.8pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We enter into
contracts in the normal course of business with clinical research
organizations for clinical trials and clinical supply manufacturing
and with vendors for pre-clinical research studies, research
supplies and other services and products for operating purposes. We
also lease our office and laboratory facilities. These contracts
generally provide for termination on notice and therefore we
believe that our non-cancelable obligations under these agreements
are not material.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.8pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">During the
three months ended March&nbsp;31, 2018, there have been no material
changes to our contractual obligations and commitments outside the
ordinary course of business from those specified in our 2017 Annual
Report on Form&nbsp;10-K.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">We have no contingent
liabilities in respect of legal claims arising in the ordinary
course of business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Capital
Expenditures</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Capital
expenditures were $25,000 and $160,000 for the three months ended
March&nbsp;31, 2017 and 2018, respectively. We made no significant
investments in intangible assets during the three months ended
March&nbsp;31, 2017 and 2018. Currently, there are no material
capital projects planned in 2018.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Off-Balance Sheet
Arrangements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
did not have during the periods presented, and we do not currently
have, any off</font><font face="Times New Roman">-</font>balance
sheet arrangements, as defined under SEC rules, other than our
operating lease obligations for our facilities in Austria and the
United States.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
23<a name="PB_23_081253_141" id="PB_23_081253_141"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='23',FILE='C:\JMS\C902549\18-8686-1\task8887116\8686-1-ga.htm',USER='C902549',CD='May  7 16:53 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM
3.&nbsp; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK</font></b><a name="ITEM3_QUANTITATIVEANDQUALITATIVE_081327"
id="ITEM3_QUANTITATIVEANDQUALITATIVE_081327"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We are exposed
to a variety of financial risks in the ordinary course of our
business: market risk, credit risk and liquidity risk. Our overall
risk management program focuses on preservation of capital given
the unpredictability of financial markets. These market risks are
principally limited to interest rate and foreign currency
fluctuations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Market
Risk</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We do not have
any significant credit risk exposure to any single counterparty or
any group of counterparties having similar characteristics. The
credit risk on liquid funds (bank accounts, cash balances,
marketable securities and term deposits) is limited because the
counterparties are banks with high credit ratings from
international credit rating agencies. The primary objective of our
investment activities is to preserve principal and liquidity while
maximizing income without significantly increasing risk. We do not
enter into investments for trading or speculative
purposes.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We are exposed
to foreign exchange risk arising from various currency exposures,
primarily with respect to the euro and the British pound. Our
functional currency is the U.S. dollar, but we receive payments and
acquire materials, in each of these other currencies. We have not
established any formal practice to manage the foreign exchange risk
against our functional currency. However, we attempt to minimize
our net exposure by buying or selling foreign currencies at spot
rates upon receipt of new funds to facilitate committed or
anticipated foreign currency transactions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.3pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Interest rate
risk may arise from short-term or long-term debt. As of
March&nbsp;31, 2018, we had no debt that exposed us to interest
rate risk. As of March&nbsp;31, 2018, we had neither significant
long-term interest-bearing assets nor significant long-term
interest-bearing liabilities, other than a de minimis government
loan we have received at a below-market rate of interest from the
Austrian Research Promotion Agency (<i>Österreichische
Forschungsförderungsgesellschaft, or FFG</i>). Due to the
short-term nature of our investment portfolio, we do not believe an
immediate 10% increase in interest rates would have a material
effect on the fair market value of our portfolio, and accordingly
we do not expect our operating results or cash flows to be
materially affected by a sudden change in market interest
rates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Liquidity
Risk</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.3pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Since our
inception, we have incurred net losses and generated negative cash
flows from our operations. Based on our current operating plans, we
believe that our existing cash, cash equivalents and short-term
investments will be sufficient to enable us to fund our operating
expenses and capital expenditure requirements into the first
quarter of 2020. We have based this estimate on assumptions that
may prove to be wrong, and we could use our capital resources
sooner than we currently expect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have re-evaluated the need for the previously planned expansion of
our commercial organization, medical education, and supply chain
activities and we anticipate that our expenses for 2018 will
decrease as compared to our expenses for 2017 as we wind down our
Phase 3 clinical trial program for lefamulin for the treatment of
CABP. We expect to continue to invest in critical
pre-commercialization activities prior to receiving marketing
approval and making lefamulin available to patients. We expect to
seek additional funding in future periods for purposes of
investment in our commercial and medical affairs
organization</font>, including the expansion of a targeted hospital
based sales force and related infrastructure, as well as investing
in our supply chain in an effort to enhance the potential
commercial launch of lefamulin.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">If we obtain
marketing approval for lefamulin or any other product candidate
that we develop, in-license or acquire, we expect to incur
significant additional commercialization expenses related to
product sales, marketing, distribution and manufacturing.&nbsp; Our
expenses will increase if we suffer any delays in our Phase 3
clinical program, including regulatory delays, or are required to
conduct additional clinical trials to satisfy regulatory
requirements. We have developed plans to mitigate this risk, which
primarily consist of raising additional capital through a
combination of equity or debt financings, new collaborations, and
reducing cash expenditures.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.3pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">However, there
can be no assurance that we will be successful in acquiring
additional capital at level sufficient to fund our operations or on
terms favorable to us. If we are unable to raise capital when
needed or on attractive terms, we could be forced to delay, reduce
to eliminate our research and development programs or any future
commercialization effort.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
24<a name="PB_24_081351_7608" id="PB_24_081351_7608"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\C902549\18-8686-1\task8887116\8686-1-ga.htm',USER='C902549',CD='May  7 16:53 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM
4.&nbsp; CONTROLS AND PROCEDURES</font></b><a name=
"ITEM4_CONTROLSANDPROCEDURES_081353" id=
"ITEM4_CONTROLSANDPROCEDURES_081353"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Conclusions Regarding the
Effectiveness of Disclosure Controls and Procedures</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We have
carried out an evaluation of the effectiveness of the design and
operation of our disclosure controls and procedures (as such term
is defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under
the Exchange Act) under the supervision and the participation of
the company’s management, which is responsible for the management
of the internal controls, and which includes our Chief Executive
Officer and Chief Financial Officer (our principal executive
officer and principal financial officer, respectively). The term 
“disclosure controls and procedures,” as defined in
Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the Securities
Exchange Act of 1934, means controls and other procedures of a
company that are designed to ensure that information required to be
disclosed by a company in the reports that it files or submits
under the Securities Exchange Act of 1934 is recorded, processed,
summarized and reported within the time periods specified in the
Securities and Exchange Commission’s rules&nbsp;and
forms.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Disclosure
controls and procedures include, without limitation, controls and
procedures designed to ensure that information required to be
disclosed by a company in the reports that it files or submits
under the Securities Exchange Act of 1934 is accumulated and
communicated to the company’s management, including its principal
executive and principal financial officers, as appropriate to allow
timely decisions regarding required disclosure. There are inherent
limitations to the effectiveness of any system of disclosure
controls and procedures, including the possibility of human error
and the circumvention or overriding of the controls and procedures.
Accordingly, even effective disclosure controls and procedures can
only provide reasonable assurance of achieving their control
objectives. Based upon our evaluation of our disclosure controls
and procedures as of March&nbsp;31, 2018, our Chief Executive
Officer and Chief Financial Officer concluded that, as of such
date, our disclosure controls and procedures were effective at a
reasonable level of assurance.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Changes in Internal Control
over Financial Reporting</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">There were no
changes in our internal control over financial reporting (as
defined in Exchange Act Rule&nbsp;13a-15(f)) that occurred during
the three months ended March&nbsp;31, 2018 that have materially
affected, or are reasonably likely to materially affect, our
internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
25<a name="PB_25_081415_8146" id="PB_25_081415_8146"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\C902549\18-8686-1\task8887116\8686-1-ga.htm',USER='C902549',CD='May  7 16:53 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">PART&nbsp;II</font></b><a name="PARTII_122059"
id="PARTII_122059"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM
1.&nbsp; LEGAL PROCEEDINGS</font></b><a name=
"ITEM1_LEGALPROCEEDINGS_081550" id=
"ITEM1_LEGALPROCEEDINGS_081550"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM
1A.&nbsp;&nbsp; RISK FACTORS</font></b><a name=
"ITEM1A_RISKFACTORS_081553" id="ITEM1A_RISKFACTORS_081553"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;">You should consider carefully
the risks and uncertainties described below, together with all of
the other information in this Form&nbsp;10-Q. If any of the
following risks are realized, our business, financial condition,
results of operations and prospects could be materially and
adversely affected. The risks described below are not the only
risks facing us. Risks and uncertainties not currently known to us
or that we currently deem to be immaterial also may materially
adversely affect our business, financial condition, results of
operations and/or prospects.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks
Related to Our Financial Position and Need for Additional
Capital</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We have
incurred significant losses since our inception. We expect to incur
losses for at least the next several years and may never generate
profits from operations or maintain
profitability.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Since inception, we have incurred significant
operating losses. Our net losses were $13.3 million for the three
months ended March&nbsp;31, 2018,</font> $74.4 million for the year
ended December&nbsp;31, 2017, $54.9 million for the year ended
December&nbsp;31, 2016 and $47.0 million for the year ended
December&nbsp;31, 2015. As of March&nbsp;31, 2018, we had an
accumulated deficit of $292.5 million. To date, we have financed
our operations primarily through the sale of our equity securities,
convertible loans and research and development support from
governmental grants and loans. We have devoted substantially all of
our efforts to research and development, including clinical trials.
We have not completed development of any drugs. We expect to
continue to incur significant expenses and increasing operating
losses for at least the next several years. The net losses we incur
may fluctuate significantly from quarter-to-quarter and
year-to-year.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have re-evaluated the need for the previously planned expansion of
our commercial organization, medical education, and supply chain
activities and we now anticipate that our expenses for 2018 will
decrease as compared to our expenses for 2017 as we wind down our
Phase 3 clinical trial program for lefamulin for the treatment of
community-acquired bacterial pneumonia, or CABP. We expect to
continue to invest in critical pre-commercialization activities
prior to receiving marketing approval and making lefamulin
available to patients.</font> &nbsp;We initiated the first of our
Phase 3 clinical trials, which we refer to as LEAP 1, in
September&nbsp;2015 and initiated the second trial, which we refer
to as LEAP 2, in April&nbsp;2016. In September&nbsp;2017, we
announced positive top-line results for LEAP 1. In
December&nbsp;2017, we announced completion of enrollment for LEAP
2.&nbsp; If the results of LEAP 2 are also favorable, including
achievement of the primary efficacy endpoints of the trials, we
expect to submit a new drug application, or NDA, for marketing
approval of lefamulin for the treatment of CABP in adults in the
United States in the fourth quarter of 2018. We also expect to
submit a marketing authorization application, or MAA, for lefamulin
for the treatment of CABP in adults in Europe a few months after
our NDA filing. We also continue to characterize the clinical
pharmacology of lefamulin. If we obtain marketing approval of
lefamulin for CABP or another indication, we also expect to incur
significant additional sales, marketing, distribution and
manufacturing expenses.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition, our
expenses will increase if and as we:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
initiate or continue the research and development of lefamulin for
additional indications and of our other product candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seek to
discover and develop additional product candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seek
marketing approval for any product candidates that successfully
complete clinical development;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
continue to establish a medical affairs, sales, marketing and
distribution infrastructure and scale up manufacturing capabilities
to commercialize any product candidates for which we receive
marketing approval;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
in-license or acquire other products, product candidates or
technologies;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
maintain, expand and protect our intellectual property
portfolio;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
26<a name="PB_26_081624_4312" id="PB_26_081624_4312"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\C902550\18-8686-1\task8887164\8686-1-gc.htm',USER='C902550',CD='May  7 17:21 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; expand
our physical presence in the United States and Ireland;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
establish and expand manufacturing arrangements with third parties;
and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
add operational, financial and management information systems and
personnel, including personnel to support our product development,
our operations as a public company and our planned future
commercialization efforts.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our ability to
generate profits from operations and remain profitable depends on
our ability to successfully develop and commercialize drugs that
generate significant revenue. Based on our current plans, we do not
expect to generate significant revenue unless and until we obtain
marketing approval for, and commercialize, lefamulin. We do not
expect to obtain marketing approval before 2019, if at all. This
will require us to be successful in a range of challenging
activities, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
obtaining favorable results from our LEAP 2 clinical trial of
lefamulin for the treatment of CABP;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
subject to obtaining favorable results from our LEAP 2 clinical
trial, applying for and obtaining marketing approval for
lefamulin;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
expanding medical affairs, sales, marketing and distribution
capabilities to effectively market and sell lefamulin in the United
States;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
establishing and maintaining collaboration, distribution or other
marketing arrangements with third parties to commercialize
lefamulin in markets outside the United States;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
protecting our rights to our intellectual property portfolio
related to lefamulin;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
contracting for the manufacture of and obtaining commercial
quantities of lefamulin; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
negotiating and securing adequate reimbursement from third-party
payors for lefamulin.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We may never
succeed in these activities and, even if we do, may never generate
revenues that are significant enough to generate profits from
operations. Even if we do generate profits from operations, we may
not be able to sustain or increase profitability on a quarterly or
annual basis. Our failure to generate profits from operations and
remain profitable would decrease the value of our company and could
impair our ability to raise capital, expand our business, maintain
our research and development efforts, diversify our product
offerings or continue our operations. A decline in the value of our
company could also cause our shareholders to lose all or part of
their investment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We will need
substantial additional funding. If we are unable to raise capital
when needed or on acceptable terms, we could be forced to delay,
reduce or eliminate our product development programs or future
commercialization efforts.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We expect to
continue to incur substantial costs in connection with our ongoing
activities, particularly as we potentially seek marketing approval
for lefamulin and, possibly, other product candidates and continue
our research activities. Our expenses will increase if we suffer
any delays in our Phase 3 clinical program for lefamulin for CABP,
including regulatory delays or are required to conduct additional
clinical trials to satisfy regulatory requirements. If we obtain
marketing approval for lefamulin or any other product candidate
that we develop, in-license or acquire, we expect to incur
significant commercialization expenses related to product sales,
marketing, distribution and manufacturing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Furthermore, we
expect to continue to incur additional costs associated with
operating as a public company. Accordingly, we will need to obtain
substantial additional funding in connection with our continuing
operations. If we are unable to raise capital when needed or on
attractive terms, we could be forced to delay, reduce or eliminate
our research and development programs or any future
commercialization efforts.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We expect that our
existing cash, cash equivalents and short-term investments will be
sufficient to fund our operating expenses and capital expenditures
into the first quarter of 2020.&nbsp; We have based this estimate
on assumptions that may prove to be wrong, and we could use our
capital resources sooner than we currently expect. This estimate
assume, among other things, that we do not obtain any additional
funding through grants and clinical trial support, collaboration
agreements, equity or debt financings.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
27<a name="PB_27_081704_7091" id="PB_27_081704_7091"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\C902550\18-8686-1\task8887164\8686-1-gc.htm',USER='C902550',CD='May  7 17:21 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We expect to seek
additional funding in future periods for purposes of investment in
our commercial and medical affairs organization</font>, including
the expansion of a targeted hospital based sales force and related
infrastructure, as well as investing in our supply chain in an
effort to enhance the potential commercial launch of lefamulin.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our future capital
requirements will depend on many factors, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the progress, costs and results of our clinical trials for
lefamulin, including our LEAP 2 trial;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs and timing of process development and manufacturing
scale-up activities associated with lefamulin;</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs, timing and outcome of regulatory review of
lefamulin;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs of commercialization activities for lefamulin if we
receive, or expect to receive, marketing approval, including the
costs and timing of establishing product sales, marketing,
distribution and outsourced manufacturing capabilities, including
the costs of building finished product inventory and its components
in preparation of initial marketing of lefamulin;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
subject to receipt of marketing approval, revenue received from
commercial sales of lefamulin;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs of developing lefamulin for the treatment of additional
indications;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our ability to establish collaborations on favorable terms, if at
all;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the scope, progress, results and costs of product development of
any other product candidates that we may develop;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the extent to which we in-license or acquire rights to other
products, product candidates or technologies;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs of preparing, filing and prosecuting patent applications,
maintaining and protecting our intellectual property rights and
defending against intellectual property-related claims;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the continued availability of Austrian governmental grants;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the rate of the expansion of our physical presence in the United
States and Ireland; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the costs of operating as a public company in the United
States.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Conducting
clinical trials is a time consuming, expensive and uncertain
process that takes years to complete, and we may never generate the
necessary data or results required to obtain marketing approval and
achieve product sales. Our commercial revenues, if any, will be
derived from sales of lefamulin or any other products that we
successfully develop, in-license or acquire, none of which we
expect to be commercially available for more than a year, if at
all. In addition, if approved, lefamulin or any other product
candidate that we develop, in-license or acquire may not achieve
commercial success. Accordingly, we will need to obtain substantial
additional financing to achieve our business objectives.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Adequate
additional financing may not be available to us on acceptable
terms, or at all. In addition, we may seek additional capital due
to favorable market conditions or strategic considerations, even if
we believe that we have sufficient funds for our current or future
operating plans.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Raising
additional capital may cause dilution to our security holders,
restrict our operations or require us to relinquish rights to our
technologies or product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Until such time,
if ever, as we can generate substantial product revenues, we expect
to finance our cash needs through a combination of equity
offerings, debt financings, collaborations, and funding from local
and international government entities and non-government
organizations in the disease areas addressed by our product
candidates and marketing, distribution or licensing arrangements.
To the extent that we raise additional capital through the sale of
equity or convertible debt securities, your ownership interest will
be diluted, and the terms of these securities may include
liquidation or other preferences that adversely affect your rights
as a security holder. Debt financing, if</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
28<a name="PB_28_081739_455" id="PB_28_081739_455"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\C902550\18-8686-1\task8887164\8686-1-gc.htm',USER='C902550',CD='May  7 17:21 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">available, may involve
agreements that include covenants limiting or restricting our
ability to take specific actions, such as incurring additional
debt, making capital expenditures or declaring dividends. In
addition, debt service obligations under any debt financings may
limit the availability of our cash for other purposes, and we may
be unable to make interest payments or repay the principal of such
debt financings when due.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If we raise
additional funds through collaborations, strategic alliances or
marketing, distribution or licensing arrangements with third
parties, we may have to relinquish valuable rights to our
technologies, future revenue streams, research programs or product
candidates or to grant licenses on terms that may not be favorable
to us.&nbsp; If we are unable to raise additional funds through
equity or debt financings when needed, we may be required to delay,
limit, reduce or terminate our product development or future
commercialization efforts or grant rights to develop and market
product candidates that we would otherwise prefer to develop and
market ourselves.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our limited
operating history may make it difficult for you to evaluate the
success of our business to date and to assess our future
viability.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our operations to
date have been limited to organizing and staffing our company,
developing and securing our technology, raising capital and
undertaking preclinical studies and clinical trials of our product
candidates.&nbsp; We have not yet demonstrated our ability to
successfully complete development of any product candidates, obtain
marketing approvals, manufacture a commercial scale product, or
arrange for a third party to do so on our behalf, or conduct sales
and marketing activities necessary for successful product
commercialization.&nbsp; Consequently, any predictions you make
about our future success or viability may not be as accurate as
they could be if we had a longer operating history.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition, as a
new business, we may encounter unforeseen expenses, difficulties,
complications, delays and other known and unknown factors. We will
need to transition from a company with a research and development
focus to a company capable of supporting commercial activities. We
may not be successful in such a transition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We have
relied on, and expect to continue to rely on, certain government
grants and funding from the Austrian government. Should these funds
cease to be available, or our eligibility be reduced, or if we are
required to repay any of these funds, this could impact our ongoing
need for funding and the timeframes within which we currently
expect additional funding will be required.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As a company that
carries out extensive research and development activities, we
benefit from the Austrian research and development support regime,
under which we are eligible to receive a research premium from the
Austrian government equal to 14% (12% for the fiscal years 2016 and
2017 and 10%, in the case of fiscal years prior to 2016) of a
specified research and development cost base. Qualifying
expenditures largely comprise research and development activities
conducted in Austria, however, the research premium is also
available for certain related third-party expenses with additional
limitations. We received research premiums of $5.9 million for the
year ended December&nbsp;31, 2016 and $4.3 million for the year
ended December&nbsp;31, 2015. We have not received any research
premium for our qualified 2017 expenditures as of March&nbsp;31,
2018. As we increase our personnel and expand our business outside
of Austria, we may not be able to continue to claim research
premiums to the same extent as we have in previous years, as some
research and development activities may no longer be considered to
occur in Austria. As research premiums that have been paid out
already may be audited by the tax authorities, there is a risk that
parts of the submitted cost base may not be considered as eligible
and therefore repayments may have to be made.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">The intended
efficiency of our corporate structure depends on the application of
the tax laws and regulations in the countries where we operate, and
we may have exposure to additional tax liabilities or our effective
tax rate could change, which could have a material impact on our
results of operations and financial position.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:17.25pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">As a company
with international operations, we are subject to income taxes, as
well as non-income based taxes, in both the United States and
various foreign jurisdictions. We have designed our corporate
structure, the manner in which we develop and use our intellectual
property, and our intercompany transactions between our
subsidiaries in a way that is intended to enhance our operational
and financial efficiency. The application of the tax laws and
regulations of various countries in which we operate and to our
global operations is subject to interpretation. We also must
operate our business in a manner consistent with our corporate
structure to realize such efficiencies. The tax authorities of the
countries in which we operate may challenge our methodologies for
valuing developed technology or for transfer pricing. If, for one
or more of these reasons, tax authorities determine that the manner
in which we operate results in our business not achieving the
intended tax consequences, our effective tax rate could increase
and harm our financial position and results of
operations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
29<a name="PB_29_081758_4141" id="PB_29_081758_4141"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\C902550\18-8686-1\task8887164\8686-1-gc.htm',USER='C902550',CD='May  7 17:21 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:17.25pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">A change in
the tax law in the jurisdictions in which we do business, including
an increase in tax rates, an adverse change in the treatment of an
item of income or expense, a decrease in tax rates in a
jurisdiction in which we have significant deferred tax assets, or a
new or different interpretation of applicable tax law, could result
in a material increase in tax expense.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks
Related to Product Development and Commercialization</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We depend
heavily on the success of our lead product candidate, lefamulin,
which we are developing for CABP and other indications. If we are
unable to complete our Phase 3 clinical program for lefamulin for
CABP as and when expected and obtain marketing approvals for
lefamulin, or if thereafter we fail to commercialize lefamulin or
experience significant delays in doing so, our business will be
materially harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have invested a significant portion of our efforts and financial
resources in the development of lefamulin. There remains a
significant risk that we will fail to successfully develop
lefamulin for CABP or any other indication.</font> In
September&nbsp;2017, we announced positive top-line results for
LEAP 1, the first of our two pivotal, international Phase 3
clinical trials of lefamulin for the treatment of CABP. Patient
enrollment for our second Phase 3 clinical trial of lefamulin for
the treatment of CABP was completed in December&nbsp;2017. We
currently expect availability of top-line data for LEAP 2 in the
spring of 2018.&nbsp; Our ability to meet our target timing will
depend on data analysis for LEAP 2. A significant delay in data
analysis would result in delays to our development timelines and
additional development costs beyond what we have budgeted. If we
ultimately obtain favorable results from LEAP 2, we expect to
submit an NDA for marketing approval for lefamulin for the
treatment of CABP in adults in the United States in the fourth
quarter of 2018. We also expect to submit an MAA for lefamulin for
the treatment of CABP in adults in Europe a few months after our
NDA filing.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our ability to
generate product revenues, which may not occur for several years,
if ever, will depend heavily on our obtaining marketing approval
for and commercializing lefamulin. The success of lefamulin will
depend on a number of factors, including the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
obtaining favorable safety and efficacy results from clinical
trials, particularly LEAP 2;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
making arrangements with third-party manufacturers for commercial
supply and receiving regulatory approval of our manufacturing
processes and our third-party manufacturers’ facilities from
applicable regulatory authorities;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
receipt of marketing approvals from applicable regulatory
authorities for lefamulin for the treatment of CABP;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
launching commercial sales of lefamulin, if and when approved, in
collaboration with third parties;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
acceptance of lefamulin, if and when approved, by patients, the
medical community and third- party payors;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
effectively competing with other therapies;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
maintaining a continued acceptable safety profile of lefamulin
following approval;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
obtaining and maintaining patent and trade secret protection and
regulatory exclusivity; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
protecting our rights in our intellectual property portfolio.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Successful
development of lefamulin for the treatment of additional
indications, if any, or for use in other patient populations and
our ability, if it is approved, to broaden the label for lefamulin
will depend on similar factors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If we do not
achieve one or more of these factors in a timely manner or at all,
we could experience significant delays or an inability to
successfully commercialize lefamulin for CABP or for any additional
indications, which would materially harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If clinical
trials of lefamulin or any of our other product candidates fail to
demonstrate safety and efficacy to the satisfaction of the U.S.
Food and Drug Administration, or FDA, regulatory authorities in the
European Union, or other regulatory authorities or do not otherwise
produce favorable results, we may incur additional costs or
experience delays in completing, or ultimately be unable to
complete, the development and commercialization of lefamulin or any
other product candidate.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
30<a name="PB_30_081832_8627" id="PB_30_081832_8627"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\C902550\18-8686-1\task8887164\8686-1-gc.htm',USER='C902550',CD='May  7 17:21 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Before obtaining
marketing approval from regulatory authorities for the sale of any
product candidate, we must complete preclinical development and
early clinical trials, including Phase 1 clinical trials, in
addition to extensive later-stage Phase 3 clinical trials, to
demonstrate the safety and efficacy of our product candidates in
humans. Clinical testing is expensive, difficult to design and
implement, can take many years to complete and is uncertain as to
outcome. A failure of one or more clinical trials can occur at any
stage of testing. The outcome of preclinical testing and early
clinical trials may not be predictive of the success of later
clinical trials, and interim results of a clinical trial do not
necessarily predict final results. The design of a clinical trial
can determine whether its results will support approval of a
product, and flaws in the design of a clinical trial may not become
apparent until the clinical trial is well advanced or completed.
Moreover, preclinical and clinical data are often susceptible to
varying interpretations and analyses, and many companies that have
believed their product candidates performed satisfactorily in
preclinical studies and clinical trials have nonetheless failed to
obtain marketing approval of their products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">LEAP 2 and other
clinical trials we conduct may not be successful, and the results
of our completed clinical trials may not predict success in LEAP 2
or any other clinical trials. Notably, the LEAP 1 and LEAP 2 trial
designs are not the same, as the LEAP 2 trial is evaluating a
patient population with CABP that is less severe than those
patients evaluated in LEAP 1, and LEAP 2 is only investigating oral
lefamulin, among other differences. Positive results from LEAP 1 do
not guarantee favorable results from LEAP 2. Although we believe
that the collective data from prior trials and our preclinical
studies provide support for concluding that lefamulin is well
suited for treatment of CABP, we may fail to obtain favorable
results in our LEAP 2 clinical trial of lefamulin for CABP or
regulatory authorities could disagree with our interpretations or
analyses of our clinical data. If the results of our LEAP 2
clinical trial are not favorable, including failure to achieve the
primary efficacy endpoints of the trial, or regulatory authorities
disagree with our interpretations or analyses of our clinical data,
we may need to conduct additional clinical trials at significant
cost or altogether abandon development of lefamulin for
CABP.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If we are required
to conduct additional clinical trials or other testing of lefamulin
or any other product candidate that we develop beyond those that we
contemplate, if we are unable to successfully complete our clinical
trials or other testing, if the results of these trials or tests
are not positive or are only modestly positive or if there are
safety concerns, we may:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
be delayed in obtaining marketing approval for our product
candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
not obtain marketing approval at all;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
obtain approval for indications or patient populations that are not
as broad as intended or desired;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
obtain approval with labeling that includes significant use or
distribution restrictions or safety warnings, including boxed
warnings;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
be subject to additional post-marketing testing requirements or
restrictions; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
have the product removed from the market after obtaining marketing
approval.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The occurrence of
any of the developments listed above could materially harm our
business, financial condition, results of operations and
prospects.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If we
experience any of a number of possible unforeseen events in
connection with our LEAP 2 clinical trial of lefamulin for CABP or
other clinical trials, the potential marketing approval or
commercialization of lefamulin or other product candidates could be
delayed or prevented.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We may experience
numerous unforeseen events during, or as a result of, our LEAP 2
clinical trial of lefamulin for CABP or other clinical trials we
conduct that could delay or prevent our ability to receive
marketing approval or commercialize lefamulin or our other product
candidates, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
clinical trials of lefamulin or our other product candidates may
produce negative or inconclusive results, and we may decide, or
regulators may require us, to conduct additional clinical trials or
abandon product development programs;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
31<a name="PB_31_082025_7906" id="PB_31_082025_7906"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\C902550\18-8686-1\task8887164\8686-1-gc.htm',USER='C902550',CD='May  7 17:21 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the number of patients required for lefamulin for other indications
or our other product candidates may be larger than we anticipate,
enrollment in these clinical trials may be slower than we
anticipate or participants may drop out of these clinical trials at
a higher rate than we anticipate;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our third-party contractors may fail to comply with regulatory
requirements or meet their contractual obligations to us in a
timely manner, or at all;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
regulators, institutional review boards or independent ethics
committees may not authorize us or our investigators to commence a
clinical trial or conduct a clinical trial at a prospective trial
site or may require that we or our investigators suspend or
terminate clinical research for various reasons, including
noncompliance with regulatory requirements or a finding that the
participants are being exposed to unacceptable health risks;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
we may experience delays in reaching or fail to reach agreement on
acceptable clinical trial contracts or clinical trial protocols
with prospective trial sites;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
we may have to suspend or terminate clinical trials of our product
candidates for various reasons, including a finding that the
participants are being exposed to unacceptable health or safety
risks;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the cost of clinical trials of our product candidates may be
greater than we anticipate;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the supply or quality of our product candidates or other materials
necessary to conduct clinical trials of our product candidates may
be insufficient or inadequate; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our product candidates may have undesirable side effects or other
unexpected characteristics, causing us or our investigators,
regulators, institutional review boards or independent ethics
committees to suspend or terminate the trials.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our product
development costs will increase if we experience delays in
enrollment in our clinical development program or our non-clinical
development program or in obtaining marketing approvals. We do not
know whether any additional non-clinical tests or clinical trials
will be required, or if they will begin as planned, or if they will
need to be restructured or will be completed on schedule, or at
all. Significant non-clinical development program delays, including
chemistry, manufacturing and control activities, or clinical trial
delays also could shorten any periods during which we may have the
exclusive right to commercialize our product candidates or allow
our competitors to bring products to market before we do and impair
our ability to successfully commercialize our product candidates
and may harm our business and results of operations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If we
experience delays or difficulties in the enrollment of patients in
our clinical trials, our receipt of necessary marketing approvals
could be delayed or prevented.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We may not be able
to initiate or continue clinical trials of lefamulin or any other
product candidate that we develop if we are unable to locate and
enroll a sufficient number of eligible patients to participate in
these clinical trials. Some of our competitors have ongoing
clinical trials for product candidates that could be competitive
with lefamulin, and patients who would otherwise be eligible for
our clinical trials may instead enroll in clinical trials of our
competitors’ product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Patient enrollment
is affected by other factors including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
severity of the disease under investigation;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
eligibility criteria for the clinical trial in question;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
perceived risks and benefits of the product candidate under
study;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
approval of other therapies to treat the disease under
investigation;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
efforts to facilitate timely enrollment in clinical trials;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
patient referral practices of physicians;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
32<a name="PB_32_082127_3736" id="PB_32_082127_3736"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='32',FILE='C:\JMS\C902550\18-8686-1\task8887164\8686-1-gc.htm',USER='C902550',CD='May  7 17:21 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the time of year in which the trial is initiated or conducted;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the geographic distribution of global trial sites, given the timing
of pneumonia season globally, and the seasonal variation in the
number of patients suffering from pneumonia, including a decline in
the number of patients with CABP during the summer months;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the ability to monitor patients adequately during and after
treatment;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
proximity and availability of clinical trial sites for prospective
patients;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
delays in the receipt of required regulatory approvals, or the
failure to receive required regulatory approvals, in the
jurisdictions in which clinical trials are expected to be
conducted; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
delays in the receipt of approvals, or the failure to receive
approvals, from the relevant institutional review board or ethics
committee at clinical trial sites.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Enrollment delays
in our clinical trials may result in increased development costs
for our product candidates, which would cause the value of the
company to decline and limit our ability to obtain additional
financing. Our inability to enroll a sufficient number of patients
in any of our clinical trials would result in significant delays or
may require us to abandon one or more clinical trials
altogether.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If serious
adverse or undesirable side effects are identified during the
development of lefamulin or any other product candidate that we
develop, we may need to abandon or limit our development of that
product candidate.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">All of our product
candidates are in clinical or preclinical development and their
risk of failure is high. It is impossible to predict when or if any
of our product candidates will prove effective or safe in humans or
will receive marketing approval. If our product candidates are
associated with undesirable side effects or have characteristics
that are unexpected, we may need to abandon their development or
limit development to certain uses or subpopulations in which the
undesirable side effects or other characteristics are less
prevalent, less severe or more acceptable from a risk-benefit
perspective. Many compounds that initially showed promise in
clinical or earlier stage testing have later been found to cause
side effects or other safety issues that prevented further
development of the compound.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
LEAP 1, lefamulin was generally well tolerated and exhibited a
similar rate of treatment-emergent adverse events to the comparator
drug.&nbsp; However, 104 patients in</font> the lefamulin arm of
the trial reported at least one treatment-emergent adverse event
and eight patients withdrew from the trial following an adverse
event.&nbsp; Furthermore, at least 2.0% of patients in LEAP 1 who
were dosed with lefamulin reported the following adverse events:
hypokalemia, nausea, insomnia, infusion site pain and infusion site
phlebitis.&nbsp; Fewer than 2.0% of trial patients dosed with
lefamulin also experienced hypertension and an increase in alanine
aminotransaminase, although no patients met Hy’s Law criteria,
which is an indicator for severe liver damage.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition,
lefamulin was well tolerated in our Phase 2 clinical trial for
ABSSSI. No patient in the trial suffered any serious adverse events
that were found to be related to lefamulin, and no patient in the
trial died. Some patients experienced adverse events that were
assessed by the investigator as possibly or probably related to
study medication. The majority of their symptoms were mild in
severity. Four patients discontinued study medication following a
drug-related event, three of whom were in a lefamulin treatment
group: one patient experienced events of hyperhidrosis, vomiting
and headache; one patient experienced infusion site pain; and one
patient experienced dyspnea.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Because the
potential for mild effect on electrocardiogram, or ECG,
measurements was observed in preclinical studies, we have continued
to assess this potential in all human clinical trials we have
conducted. In the Phase 2 clinical trial, no change in ECG
measurements was considered to be of clinical significance, and no
drug-related cardiovascular adverse event was reported. Both
lefamulin and vancomycin treatment were associated with a small
increase in the QT interval. The QT interval is a measure of the
heart’s electrical cycle, and a prolonged QT interval is a risk
factor for a potential ventricular arrhythmia. In LEAP 1, while
changes in QT that were of potential clinical concern were
uncommon, one patient treated with lefamulin had an increase in
absolute QT interval to greater than 500 msec.&nbsp; We are
continuing to evaluate the effect of lefamulin on the QT interval
in LEAP 2.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">There were no
systemic adverse events of clinical concern and no drug-related
serious adverse events observed in any of our completed Phase 1
clinical trials of lefamulin. In these trials, the most commonly
observed adverse effects with oral administration of lefamulin were
related to the gastrointestinal tract, including nausea and
abdominal</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
33<a name="PB_33_082207_9621" id="PB_33_082207_9621"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='33',FILE='C:\JMS\C902550\18-8686-1\task8887164\8686-1-gc.htm',USER='C902550',CD='May  7 17:21 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">discomfort, while the
most commonly observed adverse effects related to IV administration
were related to irritation at the infusion site. In addition,
lefamulin produced a transient, predictable and reproducible
prolongation of the QT interval based on the maximum concentration
of the drug in the blood plasma. At the doses administered in the
Phase 3 clinical trials for lefamulin for CABP, we expect that the
drug will not produce large effects on the QT interval that would
be of clinical relevance. We did not observe any drug-related
cardiac adverse events, such as increase in ectopic ventricular
activity or other cardiac arrhythmia, or clinically relevant ECG
findings during the conduct of any of our completed Phase 1
clinical trials. If we observe clinically relevant effects on the
QT interval in our Phase 3 clinical trials of lefamulin for CABP or
in any other clinical trial of lefamulin, our ability to
successfully develop lefamulin for CABP or any other indication may
be significantly delayed or prevented.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If we elect or are
forced to suspend or terminate any clinical trial of lefamulin or
any other product candidates that we are developing, the commercial
prospects of lefamulin or such other product candidates will be
harmed and our ability to generate product revenues, if at all,
from lefamulin or any of these other product candidates will be
delayed or eliminated. Any of these occurrences could materially
harm our business, financial condition, results of operations and
prospects.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Even if
lefamulin or any other product candidate receives marketing
approval, it may fail to achieve the degree of market acceptance by
physicians, patients, third-party payors and others in the medical
community necessary for commercial success and the market
opportunity for lefamulin may be smaller than we
estimate.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If lefamulin or
any of our other product candidates receive marketing approval, it
or they may nonetheless fail to gain sufficient market acceptance
by physicians, patients, third-party payors and others in the
medical community. For example, current treatments for pneumonia,
including generic options, are well established in the medical
community, and doctors may continue to rely on these treatments
without lefamulin. In addition, our efforts to effectively
communicate lefamulin’s differentiating characteristics and key
attributes to clinicians and hospital pharmacies with the goal of
establishing favorable formulary status for lefamulin may fail or
may be less successful than we expect. If lefamulin does not
achieve an adequate level of acceptance, we may not generate
significant product revenues or any profits from operations. The
degree of market acceptance of our product candidates, if approved
for commercial sale, will depend on a number of factors,
including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the efficacy and potential advantages compared to alternative
treatments;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
lefamulin’s ability to limit the development of bacterial
resistance in the pathogens it targets;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the prevalence and severity of any side effects;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the ability to offer our product candidates for sale at competitive
prices, including in comparison to generic competition;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
convenience and ease of administration compared to alternative
treatments;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the willingness of the target patient population to try new
therapies, physicians to prescribe these therapies and hospitals to
approve the cost and use by their physicians of these
therapies;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our investment in and the strength of marketing and distribution
support;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the availability of third-party coverage and adequate
reimbursement; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the timing of any marketing approval in relation to other product
approvals.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Although we
believe that the mechanism of action for pleuromutilin antibiotics
may result in a low propensity for development of bacterial
resistance to lefamulin or our other pleuromutilin product
candidates, bacteria might nevertheless develop resistance to
lefamulin or our other pleuromutilin product candidates more
rapidly or to a greater degree than we anticipate. If bacteria
develop such resistance or if lefamulin is not effective against
drug-resistant bacteria, the efficacy of these product candidates
would decline, which would negatively affect our potential to
generate revenues from these product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our ability to
negotiate, secure and maintain third-party coverage and
reimbursement may be affected by political, economic and regulatory
developments in the United States, the European Union and other
jurisdictions. Governments continue to impose cost containment
measures, and third-party payors are increasingly challenging
prices charged for</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
34<a name="PB_34_082226_8715" id="PB_34_082226_8715"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='34',FILE='C:\JMS\C902550\18-8686-1\task8887164\8686-1-gc.htm',USER='C902550',CD='May  7 17:21 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">medicines and examining
their cost effectiveness, in addition to their safety and efficacy.
If the level of reimbursement is below our expectations, our
revenue and gross margins would be adversely affected. Obtaining
formulary approval from third-party payors can be an expensive and
time-consuming process. We cannot be certain if and when we will
obtain formulary approval to allow us to sell lefamulin or any
future product candidates into our target markets. Even if we do
obtain formulary approval, third-party payors, such as government
or private health care insurers, carefully review and increasingly
question the coverage of, and challenge the prices charged for,
drugs. These and other similar developments could significantly
limit the degree of market acceptance of lefamulin or any of our
other product candidates that receive marketing
approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If we are
unable to establish sales, marketing and distribution capabilities
or enter into sales, marketing and distribution agreements with
third parties, we may not be successful in commercializing
lefamulin or any other product candidate if and when they are
approved.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We have only a
very limited sales, marketing and distribution infrastructure, and
as a company we have no experience in the sale, marketing or
distribution of pharmaceutical products. To achieve commercial
success for any approved product, we must either establish an
adequate sales, marketing and distribution organization or
outsource these functions to third parties. If lefamulin receives
marketing approval, we plan to commercialize it in the United
States with our own targeted hospital sales and marketing
organization that we plan to expand, subject to our ability to
raise additional capital. In addition, we expect to utilize a
variety of types of collaboration, distribution and other marketing
arrangements with one or more third parties to commercialize
lefamulin in markets outside the United States.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">There are risks
involved with establishing our own sales, marketing and
distribution capabilities and entering into arrangements with third
parties to perform these services. If we do not establish adequate
sales, marketing and distribution capabilities prior to or in
connection with the commercial launch of any of our products, such
products may fail to gain sufficient market acceptance by
physicians, patients, third-party payors and others in the medical
community and may fail commercially or be less successful than we
expect. If the commercial launch of a product candidate for which
we establish marketing and distribution capabilities is delayed or
does not occur for any reason, we would have prematurely or
unnecessarily incurred these commercialization expenses. This may
be costly, and our investment would be lost if we cannot retain or
reposition our sales and marketing personnel.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Factors that may
inhibit our efforts to commercialize our products on our own
include:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
our inability to recruit, train and retain adequate numbers of
effective sales and marketing personnel;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the inability of sales personnel to obtain access to or persuade
adequate numbers of physicians to prescribe any future
products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the lack of complementary products to be offered by sales
personnel, which may put our sales representatives at a competitive
disadvantage relative to sales representatives from companies with
more extensive product lines; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
unforeseen costs and expenses associated with creating an
independent sales, marketing and distribution organization.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If we enter into
arrangements with third parties to perform sales, marketing and
distribution services, our product revenues or the profitability of
these product revenues to us are likely to be lower than if we were
to market, sell and distribute ourselves any products that we
develop. In addition, we may not be successful in entering into
arrangements with third parties to sell, market and distribute our
product candidates or may be unable to do so on terms that are
favorable to us. We likely will have little control over such third
parties, and any of them may fail to devote the necessary resources
and attention to sell and market our products effectively. If we do
not establish sales, marketing and distribution capabilities
successfully, either on our own or in collaboration with third
parties, we will not be successful in commercializing our product
candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We face
substantial competition, which may result in others discovering,
developing or commercializing products before or more successfully
than we do.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The development
and commercialization of new drug products is highly competitive.
We face competition with respect to lefamulin and any other
products we may seek to develop or commercialize in the future from
major pharmaceutical companies, specialty pharmaceutical companies
and biotechnology companies worldwide. Potential competitors also
include academic institutions, government agencies and other public
and private research organizations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
35<a name="PB_35_082257_563" id="PB_35_082257_563"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='35',FILE='C:\JMS\C902550\18-8686-1\task8887164\8686-1-gc.htm',USER='C902550',CD='May  7 17:21 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">that conduct research,
seek patent protection and establish collaborative arrangements for
research, development, manufacturing and
commercialization.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">There are a
variety of available therapies marketed for the treatment of CABP.
Currently the treatment of CABP is dominated by generic products.
For hospitalized patients, combination therapy is frequently used.
Many currently approved drugs are well-established therapies and
are widely accepted by physicians, patients and third-party payors.
We also are aware of various drugs under development for the
treatment of CABP, including omadacycline (under Phase 3 clinical
development by Paratek Pharmaceuticals Inc.), delafloxacin (under
Phase 3 clinical development by Melinta Therapeutics Inc.) and oral
nafithromycin (under Phase 2 clinical development by Wockhardt
Ltd.).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our commercial
opportunity could be reduced or eliminated if our competitors
develop and commercialize products that are safer, more effective,
have fewer or less severe side effects, are approved for broader
indications or patient populations, are more convenient or are less
expensive than any products that we may develop. Our competitors
may also obtain marketing approvals for their products more rapidly
than we may obtain approval for ours, which could result in our
competitors establishing a strong market position before we are
able to enter the market. In addition, our ability to compete may
be affected because in some cases insurers or other third-party
payors seek to encourage the use of generic products. This may have
the effect of making branded products less attractive, from a cost
perspective, to buyers. We expect that if lefamulin is approved for
CABP, it will be priced at a significant premium over competitive
generic products. This may make it difficult for us to replace
existing therapies with lefamulin. The key competitive factors
affecting the success of our product candidates are likely to be
their efficacy, safety, convenience, price and the availability of
coverage and reimbursement from government and other third-party
payors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Many of our
competitors may have significantly greater financial resources and
expertise in research and development, manufacturing, preclinical
testing, conducting clinical trials, obtaining approvals from
regulatory authorities and marketing approved products than we do.
Mergers and acquisitions in the pharmaceutical and biotechnology
industries may result in even more resources being concentrated
among a smaller number of our competitors. Smaller and other early
stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and
established companies. These third parties compete with us in
recruiting and retaining qualified scientific and management
personnel, establishing clinical trial sites and patient
registration for clinical trials, as well as in acquiring
technologies complementary to or necessary for our
programs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Even if we
are able to commercialize lefamulin or any other product candidate
that we develop, the product may become subject to unfavorable
pricing regulations, third-party reimbursement practices or
healthcare reform initiatives, which would harm our
business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The regulations
that govern marketing approvals, pricing, coverage and
reimbursement for new drug products vary widely from country to
country. Current and future legislation may significantly change
the approval requirements in ways that could involve additional
costs and cause delays in obtaining approvals. Some countries
require approval of the sale price of a drug before it can be
marketed. In many countries, the pricing review period begins after
marketing or product licensing approval is granted. In some foreign
markets, prescription pharmaceutical pricing remains subject to
continuing governmental control even after initial approval is
granted. As a result, we might obtain marketing approval for a
product in a particular country, but then be subject to price
regulations that delay our commercial launch of the product,
possibly for lengthy time periods, and negatively impact the
revenues we are able to generate from the sale of the product in
that country. Adverse pricing limitations may hinder our ability to
recoup our investment in one or more product candidates, even if
our product candidates obtain marketing approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our ability to
commercialize lefamulin or any other product candidate successfully
also will depend in part on the extent to which coverage and
adequate reimbursement for these products and related treatments
will be available from government health administration
authorities, private health insurers and other organizations.
Government authorities and other third-party payors, such as
private health insurers and health maintenance organizations,
decide which medications they will pay for and establish
reimbursement levels. A major trend in the healthcare industries in
the European Union and the United States and elsewhere is cost
containment. Government authorities and other third-party payors
have attempted to control costs by limiting coverage and the amount
of reimbursement for particular medications. Increasingly,
third-party payors are requiring that drug companies provide them
with predetermined discounts from list prices and are challenging
the prices charged for medical products. We cannot be sure that
coverage and reimbursement will be available for lefamulin or any
other product that we commercialize and, if coverage and
reimbursement are available, the level of reimbursement.
Reimbursement may impact the demand for, or the price of, any
product candidate for which we obtain marketing approval. Obtaining
and maintaining adequate reimbursement for lefamulin may be
particularly difficult because of the number of generic drugs,
which are typically available at lower prices, that are available
to treat CABP. In addition, third-party payors are likely to impose
strict requirements for</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
36<a name="PB_36_090422_3501" id="PB_36_090422_3501"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='36',FILE='C:\JMS\C902526\18-8686-1\task8887117\8686-1-ge.htm',USER='C902526',CD='May  7 16:45 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">reimbursement of a
higher priced drug, such as lefamulin. If reimbursement is not
available or is available only to limited levels, we may not be
able to successfully commercialize lefamulin or other product
candidates for which we obtain marketing approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">There may be
significant delays in obtaining coverage and reimbursement for
newly approved drugs, and coverage may be more limited than the
purposes for which the drug is approved by the applicable
regulatory authority. Moreover, eligibility for coverage and
reimbursement does not imply that any drug will be paid for in all
cases or at a rate that covers our costs, including research,
development, manufacture, sale and distribution. Interim
reimbursement levels for new drugs, if applicable, may also not be
sufficient to cover our costs and may not be made permanent.
Reimbursement rates may vary according to the use of the drug and
the clinical setting in which it is used, may be based on
reimbursement levels already set for lower cost drugs, and may be
incorporated into existing payments for other services. Net prices
for drugs may be reduced by mandatory discounts or rebates required
by government healthcare programs or private payors and by any
future relaxation of laws that presently restrict imports of drugs
from countries where they may be sold at lower prices than in the
United States. In the United States, third-party payors often rely
upon Medicare coverage policy and payment limitations in setting
their own reimbursement policies. In the European Union, reference
pricing systems and other measures may lead to cost containment and
reduced prices. Our inability to promptly obtain coverage and
adequate reimbursement rates from both government-funded and
private payors for any approved products that we develop could have
a material adverse effect on our operating results, our ability to
raise capital needed to commercialize products and our overall
financial condition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Product
liability lawsuits against us could divert our resources, cause us
to incur substantial liabilities and to limit commercialization of
any products that we may develop or in-license.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We face an
inherent risk of product liability exposure related to the testing
of lefamulin and any other product candidate that we develop in
human clinical trials and will face an even greater risk if we
commercially sell any products that we may develop or in-license.
If we cannot successfully defend ourselves against claims that our
product candidates or products caused injuries, we will incur
substantial liabilities. Regardless of merit or eventual outcome,
liability claims may result in:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced
resources of our management to pursue our business strategy;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
decreased demand for any product candidates or products that we may
develop;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injury
to our reputation and significant negative media attention;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
withdrawal of clinical trial participants;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
significant costs to defend the related litigation;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
substantial monetary awards to trial participants or patients;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of
revenue; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the
inability to commercialize any products that we may develop.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We maintain
clinical trial liability insurance that covers bodily injury to
patients participating in our clinical trials up to a $10.0 million
annual aggregate limit and subject to a per event deductible. This
amount of insurance may not be adequate to cover all liabilities
that we may incur. We will need to increase our insurance coverage
when and if we begin commercializing lefamulin or any other product
candidate that receives marketing approval. Insurance coverage is
increasingly expensive. We may not be able to maintain insurance
coverage at a reasonable cost or in an amount adequate to satisfy
any liability that may arise.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks
Related to Our Dependence on Third Parties</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Use of third
parties to manufacture our product candidates may increase the risk
that we will not have sufficient quantities of our product
candidates or products or such quantities at an acceptable quality
or cost, which could delay, prevent or impair our development or
commercialization efforts.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We do not own or
operate manufacturing facilities for the production of lefamulin
that could be used in product candidate development, including
clinical trial supply, or for commercial supply, or for the supply
of any other</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
37<a name="PB_37_090453_7056" id="PB_37_090453_7056"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='37',FILE='C:\JMS\C902526\18-8686-1\task8887117\8686-1-ge.htm',USER='C902526',CD='May  7 16:45 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">compound that we are
developing or evaluating in our research program. We have limited
personnel with experience in drug manufacturing and lack the
resources and the capabilities to manufacture any of our product
candidates on a clinical or commercial scale. We currently rely on
third parties for supply of lefamulin, and our strategy is to
outsource all manufacturing, packaging, testing, serialization and
distribution of our product candidates and products to third
parties.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have entered into agreements, and expect to enter into additional
agreements, with third-party manufacturers for the long-term
commercial supply of lefamulin. We obtained the pleuromutilin
starting material for the clinical trial supply of lefamulin from a
single third-party manufacturer, Sandoz GmbH, or Sandoz, a division
of Novartis AG, or Novartis. Novartis stopped manufacturing
pleuromutilin for us in June&nbsp;2015 and will not be a commercial
supplier of pleuromutilin for us. We have identified an alternative
supplier that we believe will be able to provide pleuromutilin
starting material for the commercial supply of lefamulin.</font>
However, our current operating plans do not include engaging an
alternative supplier unless we obtain additional funding. Another
third-party manufacturer synthesizes lefamulin from the
pleuromutilin starting material and provides our supply of the
active pharmaceutical ingredient. We engage separate manufacturers
to provide tablets, sterile vials, and sterile diluent that we are
using in our clinical trials of lefamulin. We may be unable to
conclude agreements for commercial supply with additional
third-party manufacturers, or may be unable to do so on acceptable
terms.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Even if we are
able to establish and maintain arrangements with third-party
manufacturers, reliance on third-party manufacturers entails
additional risks, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reliance
on the third party for regulatory compliance and quality
assurance;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
an event at one of our manufacturers or suppliers causing an
unforeseen disruption of the manufacture or supply of our product
candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the
possible breach of the manufacturing agreement by the third
party;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the
possible misappropriation of our proprietary information, including
our trade secrets and know-how; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the
possible termination or nonrenewal of the agreement by the third
party at a time that is costly or inconvenient for us.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Third-party
manufacturers may not be able to comply with current good
manufacturing practice, or cGMP, regulations or similar regulatory
requirements outside the United States. Our failure, or the failure
of our third-party manufacturers, to comply with applicable
regulations could result in sanctions being imposed on us,
including fines, injunctions, civil penalties, delays, suspension
or withdrawal of approvals, license revocation, seizures or recalls
of product candidates or products, operating restrictions and
criminal prosecutions, any of which could significantly and
adversely affect supplies of our product candidates and
products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our product
candidates and any products that we may develop may compete with
other product candidates and products for access to manufacturing
facilities. There are a limited number of manufacturers that
operate under cGMP regulations and that might be capable of
manufacturing for us.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">If
the third parties that we engage to supply any materials or
manufacture product for our non-clinical testing and clinical
trials should cease to continue to do so for any reason, we likely
would experience delays in advancing these trials while we identify
and qualify replacement suppliers and we may be unable to obtain
replacement supplies on terms that are favorable to us. For
example, there are only a limited number of known manufacturers
that produce the pleuromutilin starting material used in the
synthesis of lefamulin. In early 2015, Novartis completed the sale
of its animal health division, including its veterinary products,
to a third party. As a result, we have identified an alternative
supplier that currently manufactures pleuromutilin starting
material for veterinary products, that we believe will be able to
provide pleuromutilin starting material for the commercial scale
manufacture of lefamulin.</font> However, our current operating
plans do not include engaging an alternative supplier unless we
obtain additional funding. In addition, if we are not able to
obtain adequate supplies of our product candidates or the drug
substances used to manufacture them, it will be more difficult for
us to develop our product candidates and compete effectively.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our current and
anticipated future dependence upon others for the manufacture of
our product candidates may adversely affect our future profit
margins and our ability to develop product candidates and
commercialize any products that receive marketing approval on a
timely and competitive basis.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
38<a name="PB_38_090529_5335" id="PB_38_090529_5335"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='38',FILE='C:\JMS\C902526\18-8686-1\task8887117\8686-1-ge.htm',USER='C902526',CD='May  7 16:45 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We rely on
third parties to conduct our clinical trials and those third
parties may not perform satisfactorily, including failing to meet
deadlines for the completion of such trials.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We do not
independently conduct clinical trials for our product candidates.
We rely on third parties, such as contract research organizations,
clinical data management organizations, medical institutions and
clinical investigators, to perform this function. We expect to
continue to rely on such third parties in conducting our clinical
trials of lefamulin, and expect to rely on these third parties to
conduct clinical trials of any other product candidate that we
develop. Any of these third parties may terminate their engagements
with us at any time. If we need to enter into alternative
arrangements, it would delay our product development
activities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our reliance on
these third parties for clinical development activities reduces our
control over these activities but does not relieve us of our
responsibilities. For example, we remain responsible for ensuring
that each of our clinical trials is conducted in accordance with
the general investigational plan and protocols for the trial.
Moreover, the FDA requires us to comply with standards, commonly
referred to as Good Clinical Practices, or GCP, for conducting,
recording and reporting the results of clinical trials to assure
that data and reported results are credible and accurate and that
the rights, integrity and confidentiality of trial participants are
protected. We also are required to register ongoing clinical trials
and post the results of completed clinical trials on a U.S.
government-sponsored database, ClinicalTrials.gov, within certain
timeframes. Failure to do so can result in fines, adverse publicity
and civil and criminal sanctions. Similar GCP and transparency
requirements apply in the European Union. Failure to comply with
such requirements, including with respect to clinical trials
conducted outside the European Union, can also lead regulatory
authorities to refuse to take into account clinical trial data
submitted as part of an MAA.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Furthermore, third
parties that we rely on for our clinical development activities may
also have relationships with other entities, some of which may be
our competitors. If these third parties do not successfully carry
out their contractual duties, meet expected deadlines or conduct
our clinical trials in accordance with regulatory requirements or
our stated protocols, we will not be able to obtain, or may be
delayed in obtaining, marketing approvals for our product
candidates and will not be able to, or may be delayed in our
efforts to, successfully commercialize our product candidates. Our
product development costs will increase if we experience delays in
testing or obtaining marketing approvals.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We also rely on
other third parties to store and distribute drug supplies for our
clinical trials. Any performance failure on the part of our
distributors could delay clinical development or marketing approval
of our product candidates or commercialization of our products,
producing additional losses and depriving us of potential product
revenue.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We have
entered into and may enter into additional collaborations with
third parties for the development or commercialization of lefamulin
and our other product candidates. If those collaborations are not
successful, we may not be able to capitalize on the market
potential of these product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If lefamulin
receives marketing approval, we plan to commercialize it in the
United States with our own targeted hospital sales and marketing
organization. Outside the United States, we expect to utilize a
variety of types of collaboration, distribution and other marketing
arrangements with one or more third parties to commercialize
lefamulin. For example, we have entered into a license agreement
with Sinovant pursuant to which we granted Sinovant certain rights
to manufacture and commercialize lefamulin in the People’s Republic
of China, Hong Kong, Macau and Taiwan. We also may seek third-party
collaborators for development and commercialization of other
product candidates or for lefamulin for indications other than
CABP.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our likely future
collaborators for any sales, marketing, distribution, development,
licensing or broader collaboration arrangements include large and
mid-size pharmaceutical companies, regional and national
pharmaceutical companies and biotechnology companies. Under our
license agreement with Sinovant we have, and under any such
arrangements we enter into with any third parties in the future we
will likely have, limited control over the amount and timing of
resources that our collaborators dedicate to the development or
commercialization of our product candidates. Our ability to
generate revenues from these arrangements will depend on our
collaborators’ abilities and efforts to successfully perform the
functions assigned to them in these arrangements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our current
collaborations involving our product candidates pose, and any
future collaborations likely will pose, numerous risks to us,
including the following:</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
collaborators have significant discretion in determining the
efforts and resources that they will apply to these collaborations
and may not perform their obligations as expected;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
39<a name="PB_39_090614_5796" id="PB_39_090614_5796"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='39',FILE='C:\JMS\C902526\18-8686-1\task8887117\8686-1-ge.htm',USER='C902526',CD='May  7 16:45 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
collaborators may deemphasize or not pursue development and
commercialization of our product candidates or may elect not to
continue or renew development or commercialization programs based
on clinical trial results, changes in the collaborators’ strategic
focus, product and product candidate priorities, available funding,
or external factors such as an acquisition that diverts resources
or creates competing priorities;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
collaborators may delay clinical trials, provide insufficient
funding for a clinical trial program, stop a clinical trial or
abandon a product candidate, repeat or conduct new clinical trials
or require a new formulation of a product candidate for clinical
testing;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
collaborators could independently develop, or develop with third
parties, products that compete directly or indirectly with our
products or product candidates if the collaborators believe that
competitive products are more likely to be successfully developed
or can be commercialized under terms that are more economically
attractive than ours;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
a collaborator with marketing and distribution rights to one or
more products may not commit sufficient resources to the marketing
and distribution of such product or products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
collaborators may not properly maintain or defend our intellectual
property rights or may use our proprietary information in such a
way as to invite litigation that could jeopardize or invalidate our
intellectual property or proprietary information or expose us to
potential litigation;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
collaborators may infringe the intellectual property rights of
third parties, which may expose us to litigation and potential
liability;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
disputes may arise between the collaborator and us as to the
ownership of intellectual property arising during the
collaboration;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
we may grant exclusive rights to our collaborators, which would
prevent us from collaborating with others;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
collaborators may be unable to enforce our intellectual property
rights in territories where we have licensed, or may license, them
such rights, which may expose us to material adverse tax and other
consequences;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
disputes may arise between the collaborators and us that result in
the delay or termination of the research, development or
commercialization of our products or product candidates or that
result in costly litigation or arbitration that diverts management
attention and resources; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
collaborations may be terminated and, if terminated, may result in
a need for additional capital to pursue further development or
commercialization of the applicable product candidates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">For example, under
our license agreement with Sinovant, if any court, tribunal or
governmental agency in the People’s Republic of China, Hong Kong,
Macau or Taiwan determines that the exclusive license granted to
Sinovant pursuant to the license agreement is not sufficiently
exclusive such that Sinovant does not have sufficient rights to
enforce the licensed patent rights in such territories, we and our
subsidiary, Nabriva Therapeutics GmbH, have agreed to take such
commercially reasonable steps as Sinovant reasonably requests to
grant Sinovant such rights.&nbsp; If a court in such jurisdictions
were to determine that our license to Sinovant was not sufficiently
exclusive and that Sinovant did not have the rights to enforce the
licensed patent rights in the licensed territories, Sinovant may
require us to take such actions that it deems reasonable but that
we do not and which may have a material adverse effect on our
business, including requiring us to make changes to our
organizational structure that may result in adverse tax and other
consequences, or to conduct other activities that may cause us to
incur significant expenses;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Collaboration
agreements may not lead to development or commercialization of
product candidates in the most efficient manner or at all. If a
collaborator of ours were to be involved in a business combination,
the continued pursuit and emphasis on our product development or
commercialization program could be delayed, diminished or
terminated.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If we are
not able to establish additional collaborations, we may have to
alter our development and commercialization
plans.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The potential
commercialization of lefamulin and the development and potential
commercialization of other product candidates will require
substantial additional cash to fund expenses. For some of our
product candidates, we may decide to further collaborate with
pharmaceutical and biotechnology companies for the development and
potential commercialization of those product candidates. For
example, we intend to seek to commercialize lefamulin through a
variety of types of additional collaboration arrangements outside
the United States.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We face
significant competition in seeking appropriate collaborators.
Whether we reach a definitive agreement for additional
collaborations outside greater China will depend, among other
things, upon our assessment of the collaborator’s resources and
expertise, the terms and conditions of the proposed collaboration
and the proposed collaborator’s evaluation of a number of factors.
Those factors may include the design or results of clinical trials,
the likelihood of approval by the FDA or similar regulatory
authorities outside the United States, the potential market for the
subject product candidate, the costs and complexities of
manufacturing and delivering such product candidate to patients,
the potential of competing products, the existence of uncertainty
with respect to our ownership of technology, which can exist if
there is a challenge to such ownership without regard to the merits
of the challenge, and industry and market conditions generally. The
collaborator may also consider alternative product candidates or
technologies for similar indications that may be available to
collaborate on and whether such a collaboration could be more
attractive than the one with us for our product candidate. We may
also be restricted under future license agreements from
entering</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
40<a name="PB_40_090653_2897" id="PB_40_090653_2897"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='40',FILE='C:\JMS\C902526\18-8686-1\task8887117\8686-1-ge.htm',USER='C902526',CD='May  7 16:45 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">into agreements on
certain terms with potential collaborators. Collaborations are
complex and time-consuming to negotiate and document. In addition,
there have been a significant number of recent business
combinations among large pharmaceutical companies that have
resulted in a reduced number of potential future
collaborators.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If we are unable
to reach agreements with suitable collaborators on a timely basis,
on acceptable terms, or at all, we may have to curtail the
development of a product candidate, reduce or delay its development
program or one or more of our other development programs, delay its
potential commercialization or reduce the scope of any sales or
marketing activities, or increase our expenditures and undertake
development or commercialization activities at our own expense. If
we elect to fund and undertake development or commercialization
activities on our own, we may need to obtain additional expertise
and additional capital, which may not be available to us on
acceptable terms or at all. If we fail to enter into additional
collaborations and do not have sufficient funds or expertise to
undertake the necessary development and commercialization
activities, we may not be able to further develop our product
candidates or bring them to market and generate product
revenue.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks
Related to Our Intellectual Property</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If we are
unable to obtain and maintain patent protection for our technology
and products, or if the scope of the patent protection is not
sufficiently broad, our competitors could develop and commercialize
technology and products similar or identical to ours, and our
ability to successfully commercialize our technology and products
may be adversely affected.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our success
depends in large part on our ability to obtain and maintain patent
protection in the United States and other countries with respect to
our proprietary technology and products. We seek to protect our
proprietary position by filing patent applications in the United
States, Europe and in certain additional foreign jurisdictions
related to our novel technologies and product candidates that are
important to our business. This process is expensive and
time-consuming, and we may not be able to file and prosecute all
necessary or desirable patent applications at a reasonable cost or
in a timely manner. It is also possible that we will fail to
identify patentable aspects of our research and development output
before it is too late to obtain patent protection. Moreover, if we
license technology or product candidates from third parties in the
future, these license agreements may not permit us to control the
preparation, filing and prosecution of patent applications, or to
maintain or enforce the patents, covering this intellectual
property. These agreements could also give our licensors the right
to enforce the licensed patents without our involvement, or to
decide not to enforce the patents at all. Therefore, in these
circumstances, these patents and applications may not be prosecuted
and enforced in a manner consistent with the best interests of our
business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The patent
position of biotechnology and pharmaceutical companies generally is
highly uncertain, involves complex legal and factual questions and
has in recent years been the subject of much litigation. As a
result, the issuance, scope, validity, enforceability and
commercial value of our patent rights are highly uncertain. Our
pending and future patent applications may not result in patents
being issued which protect our technology or products, in whole or
in part, or which effectively prevent others from commercializing
competitive technologies and products. Changes in either the patent
laws or interpretation of the patent laws in the United States and
other countries may diminish the value of our patents or narrow the
scope of our patent protection.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The laws of
foreign countries may not protect our rights to the same extent as
the laws of the United States. For example, European patent law
restricts the patentability of methods of treatment of the human
body more than U.S. law does. We also may not pursue or obtain
patent protection in all major markets or may not obtain protection
that enables us to prevent the entry of third parties onto the
market. Assuming the other requirements for patentability are met,
currently, the first to file a patent application is generally
entitled to the patent. However, prior to March&nbsp;16, 2013, in
the United States, the first to invent was entitled to the patent.
Publications of discoveries in the scientific literature often lag
behind the actual discoveries, and patent applications in the
United States and other jurisdictions are typically not published
until 18 months after filing, or in some cases not at all.
Therefore, we cannot know with certainty whether we were the first
to make the inventions claimed in our U.S. patents or pending U.S.
patent applications, or that we were the first to file for patent
protection of such inventions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Moreover, we may
be subject to a third-party pre-issuance submission of prior art to
the U.S. Patent and Trademark Office, or USPTO, or become involved
in opposition, derivation, reexamination, <i>inter partes</i>
review, post grant review, interference proceedings or other patent
office proceedings or litigation, in the United States or
elsewhere, challenging our patent rights or the patent rights of
others. An adverse determination in any such submission, proceeding
or litigation could reduce the scope of, or invalidate, our patent
rights, allow third parties to commercialize our technology or
products and compete directly with us, without payment to us, or
result in our inability to manufacture or commercialize products
without infringing third-party patent rights. In addition, if the
breadth or strength of protection</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
41<a name="PB_41_090711_3020" id="PB_41_090711_3020"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='41',FILE='C:\JMS\C902526\18-8686-1\task8887117\8686-1-ge.htm',USER='C902526',CD='May  7 16:45 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">provided by our patents
and patent applications is threatened, it could dissuade companies
from collaborating with us to license, develop or commercialize
current or future product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Even if our patent
applications issue as patents, they may not issue in a form that
will provide us with any meaningful protection, prevent competitors
from competing with us or otherwise provide us with any competitive
advantage. Our competitors may be able to circumvent our owned or
any future licensed patents by developing similar or alternative
technologies or products in a non-infringing manner. In addition,
other companies may attempt to circumvent any regulatory data
protection or market exclusivity that we obtain under applicable
legislation, which may require us to allocate significant resources
to preventing such circumvention. Legal and regulatory developments
in the European Union and elsewhere may also result in clinical
trial data submitted as part of an MAA becoming publicly available.
Such developments could enable other companies to circumvent our
intellectual property rights and use our clinical trial data to
obtain marketing authorizations in the European Union and in other
jurisdictions. Such developments may also require us to allocate
significant resources to prevent other companies from circumventing
or violating our intellectual property rights. Our attempts to
prevent third parties from circumventing our intellectual property
and other rights may ultimately be unsuccessful. We may also fail
to take the required actions or pay the necessary fees to maintain
our patents.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The issuance of a
patent is not conclusive as to its inventorship, scope, validity or
enforceability, and our owned and licensed patents may be
challenged in the courts or patent offices in the United States and
abroad. Such challenges may result in loss of exclusivity or
freedom to operate or in patent claims being narrowed, invalidated
or held unenforceable, in whole or in part, which could limit our
ability to stop others from using or commercializing similar or
identical technology and products, or limit the duration of the
patent protection of our technology and products. Given the amount
of time required for the development, testing and regulatory review
of new product candidates, patents protecting such candidates might
expire before or shortly after such candidates are commercialized.
As a result, our patent portfolio may not provide us with
sufficient rights to exclude others from commercializing products
similar or identical to ours.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We may
become involved in lawsuits to protect or enforce our patents or
other intellectual property, which could be expensive, time
consuming and unsuccessful.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Competitors may
infringe our patents, trademarks, copyrights or other intellectual
property. To counter such infringement or unauthorized use, we may
be required to file claims, which can be expensive and time
consuming. Any claims we assert against perceived infringers could
provoke these parties to assert counterclaims against us alleging
that we infringe their intellectual property. In addition, in a
patent infringement proceeding, a court may decide that a patent of
ours is invalid or unenforceable, in whole or in part, construe the
patent’s claims narrowly or may refuse to stop the other party from
using the technology at issue on the grounds that our patents do
not cover the technology in question.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Third
parties may initiate legal proceedings alleging that we are
infringing their intellectual property rights, the outcome of which
would be uncertain and could have a material adverse effect on the
success of our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our commercial
success depends upon our ability and the ability of our
collaborators to develop, manufacture, market and sell our product
candidates and use our proprietary technologies without infringing
the intellectual property and other proprietary rights of third
parties. There is considerable intellectual property litigation in
the biotechnology and pharmaceutical industries, and we may become
party to, or threatened with, future adversarial proceedings or
litigation regarding intellectual property rights with respect to
our products and technology, including interference, derivation,
<i>inter partes</i> review or post-grant review proceedings before
the USPTO. The risks of being involved in such litigation and
proceedings may increase as our product candidates approach
commercialization, and as we gain greater visibility as a public
company. Third parties may assert infringement claims against us
based on existing or future intellectual property rights. We may
not be aware of all such intellectual property rights potentially
relating to our product candidates. Any freedom-to-operate search
or analysis previously conducted may not have uncovered all
relevant patents and patent applications, and there may be pending
or future patent applications that, if issued, would block us from
commercializing lefamulin. Thus, we do not know with certainty
whether lefamulin, any other product candidate, or our
commercialization thereof, does not and will not infringe any third
party’s intellectual property.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If we are found to
infringe a third party’s intellectual property rights, or to avoid
or settle litigation, we could be required to obtain a license to
continue developing and marketing our products and technology.
However, we may not be able to obtain any required license on
commercially reasonable terms or at all. Even if we were able to
obtain a license, it could be non-exclusive, thereby giving our
competitors access to the same technologies licensed to us, and
could require us to make substantial payments. We could be forced,
including by court order, to cease commercializing the infringing
technology or product. In addition, we could be found liable for
monetary damages, including treble</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
42<a name="PB_42_090728_7748" id="PB_42_090728_7748"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='42',FILE='C:\JMS\C902526\18-8686-1\task8887117\8686-1-ge.htm',USER='C902526',CD='May  7 16:45 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">damages and attorneys’
fees if we are found to have willfully infringed a patent or other
intellectual property right. A finding of infringement could
prevent us from commercializing our product candidates or force us
to cease some of our business operations, which could materially
harm our business. Claims that we have misappropriated the
confidential information or trade secrets of third parties could
have a similar negative impact on our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We may be
subject to claims by third parties asserting that we or our
employees have misappropriated their intellectual property, or
claiming ownership of what we regard as our own intellectual
property.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Many of our
employees were previously employed at universities or other
biotechnology or pharmaceutical companies, including our
competitors or potential competitors. Although we try to ensure
that our employees do not use the proprietary information or
know-how of others in their work for us, we may be subject to
claims that we or these employees have used or disclosed
intellectual property, including trade secrets or other proprietary
information, of any such employee’s former employer. Litigation may
be necessary to defend against these claims.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition, while
we typically require our employees and contractors who may be
involved in the development of intellectual property to execute
agreements assigning such intellectual property to us, we may be
unsuccessful in executing such an agreement with each party who in
fact develops intellectual property that we regard as our own. Our
business was founded as a spin-off from Sandoz. Although all patent
applications are fully owned by us and were either filed by Sandoz
with all rights fully transferred to us, or filed in our sole name,
because we acquired certain of our patents from Sandoz, we must
rely on their prior practices, with regard to the assignment of
such intellectual property. Our and their assignment agreements may
not be self-executing or may be breached, and we may be forced to
bring claims against third parties, or defend claims they may bring
against us, to determine the ownership of what we regard as our
intellectual property.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If we fail in
prosecuting or defending any such claims, in addition to paying
monetary damages, we may lose valuable intellectual property rights
or personnel. Even if we are successful in prosecuting or defending
against such claims, litigation could result in substantial costs
and be a distraction to management.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Intellectual
property litigation could cause us to spend substantial resources
and could distract our personnel from their normal
responsibilities.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Even if resolved
in our favor, litigation or other legal proceedings relating to
intellectual property claims may cause us to incur significant
expenses, and could distract our technical and management personnel
from their normal responsibilities. In addition, there could be
public announcements of the results of hearings, motions or other
interim proceedings or developments. If securities analysts or
investors perceive these results to be negative, it could have a
substantial adverse effect on the price of our ordinary shares.
Such litigation or proceedings could substantially increase our
operating losses and reduce the resources available for
development, sales, marketing or distribution activities. We may
not have sufficient financial or other resources to adequately
conduct such litigation or proceedings. Some of our competitors may
be able to sustain the costs of such litigation or proceedings more
effectively than we can because of their greater financial
resources. Uncertainties resulting from the initiation and
continuation of patent litigation or other proceedings could have a
material adverse effect on our ability to compete in the
marketplace.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If we are
unable to protect the confidentiality of our trade secrets, our
business and competitive position would be
harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition to
seeking patents for some of our technology and products, we also
rely on trade secrets, including unpatented know-how, technology
and other proprietary information, to maintain our competitive
position. We seek to protect these trade secrets, in part, by
entering into non-disclosure and confidentiality agreements with
parties who have access to them, such as our employees, corporate
collaborators, outside scientific collaborators, contract
manufacturers, consultants, advisors and other third parties. We
also enter into confidentiality and invention or patent assignment
agreements with our employees and consultants. However, we cannot
guarantee that we have executed these agreements with each party
that may have or have had access to our trade secrets or that the
agreements we have executed will provide adequate protection. Any
party with whom we have executed such an agreement may breach that
agreement and disclose our proprietary information, including our
trade secrets, and we may not be able to obtain adequate remedies
for such breaches. Enforcing a claim that a party illegally
disclosed or misappropriated a trade secret is difficult, expensive
and time-consuming, and the outcome is unpredictable. In addition,
some courts inside and outside the United States are less willing
or unwilling to protect trade secrets. If any of our trade secrets
were to be lawfully obtained or independently developed by a
competitor, we would have no right to prevent them, or those to
whom they communicate it, from using that technology or information
to compete with us. If any of our trade secrets were to be obtained
or independently developed by a competitor, our competitive
position would be harmed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
43<a name="PB_43_090747_141" id="PB_43_090747_141"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='43',FILE='C:\JMS\C902526\18-8686-1\task8887117\8686-1-ge.htm',USER='C902526',CD='May  7 16:45 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We have not
yet registered our trademarks in all of our potential markets, and
failure to secure those registrations could adversely affect our
business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our trademark
applications may not be allowed for registration, and our
registered trademarks may not be maintained or enforced. During
trademark registration proceedings, we may receive rejections.
Although we are given an opportunity to respond to those
rejections, we may be unable to overcome such rejections. In
addition, in the USPTO and in comparable agencies in many foreign
jurisdictions, third parties are given an opportunity to oppose
pending trademark applications and to seek to cancel registered
trademarks. Opposition or cancellation proceedings may be filed
against our trademarks, and our trademarks may not survive such
proceedings. If we do not secure registrations for our trademarks,
we may encounter more difficulty in enforcing them against third
parties than we otherwise would.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks
Related to Regulatory Approval and Marketing of Our Product
Candidates and Other Legal Compliance Matters</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Even if we
complete the necessary non-clinical studies and clinical trials,
the marketing approval process is expensive, time-consuming and
uncertain and may prevent us from obtaining approvals for the
commercialization of some or all of our product candidates. If we
are not able to obtain, or if there are delays in obtaining,
required regulatory approvals, in particular in the United States
or the European Union, we will not be able to commercialize our
product candidates in those markets, and our ability to generate
revenue will be materially impaired.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our product
candidates, including lefamulin, and the activities associated with
their development and commercialization, including their design,
testing, manufacture, safety, efficacy, recordkeeping, labeling,
storage, approval, advertising, promotion, sale and distribution,
are subject to comprehensive regulation by the FDA and by
comparable authorities in other countries. Failure to obtain
marketing approval for a product candidate will prevent us from
commercializing the product candidate. We have not received
approval to market lefamulin or any of our other product candidates
from regulatory authorities in any jurisdiction.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We have no
experience in filing and supporting the applications necessary to
obtain marketing approvals for product candidates and expect to
rely on third-parties to assist us in this process. Securing
marketing approval requires the submission of extensive
non-clinical and clinical data and supporting information to
various regulatory authorities for each therapeutic indication to
establish the product candidate’s safety and efficacy. Securing
marketing approval also requires the submission of information
about the product manufacturing process to, and inspection of
manufacturing facilities by, the regulatory authorities. Regulatory
authorities may determine that lefamulin or any of our other
product candidates are not effective or only moderately effective,
or have undesirable or unintended side effects, toxicities, safety
profiles or other characteristics that preclude us from obtaining
marketing approval or that prevent or limit commercial
use.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">The
process of obtaining marketing approvals is expensive, may take
many years, if approval is obtained at all, and can vary
substantially based upon a variety of factors, including the type,
complexity and novelty of the product candidates involved. Changes
in marketing approval policies during the development period,
changes in or the enactment of additional statutes or regulations,
or changes in regulatory review for each submitted product
application, may cause delays in the approval or rejection of an
application. For example, on June&nbsp;23, 2016, eligible members
of the electorate in the United Kingdom decided by referendum to
leave the European Union, commonly referred to as “Brexit”.</font>
On March&nbsp;29, 2017, the United Kingdom formally notified the
European Union of its intention to withdraw pursuant to
Article&nbsp;50 of the Lisbon Treaty. Because a significant
proportion of the regulatory framework in the United Kingdom is
derived from European Union directives and regulations, the
referendum could materially change the regulatory regime applicable
to the approval of any of our product candidates in the United
Kingdom. In addition, because the European Medicines Agency, or
EMA, is currently located in the United Kingdom but expected to
move to the Netherlands as a result of the Brexit, the implications
for the regulatory review process in the European Union has not
been fully clarified and could result in disruption to the EMA
review process.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The FDA and
comparable regulatory authorities in other countries have
substantial discretion in the approval process and may refuse to
accept any application or may decide that our data are insufficient
for approval and require additional preclinical, clinical or other
studies. In addition, varying interpretations of the data obtained
from non-clinical and clinical testing could delay, limit or
prevent marketing approval of a product candidate. Any marketing
approval we ultimately obtain may be limited or subject to
restrictions or post-approval commitments that render the approved
product not commercially viable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
44<a name="PB_44_090812_7608" id="PB_44_090812_7608"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='44',FILE='C:\JMS\C902526\18-8686-1\task8887117\8686-1-ge.htm',USER='C902526',CD='May  7 16:45 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Accordingly, if we
or our collaborators experience delays in obtaining approval or if
we or they fail to obtain approval of our product candidates, the
commercial prospects for our product candidates may be harmed and
our ability to generate revenues will be materially
impaired.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our failure
to obtain marketing approval in jurisdictions other than the United
States and Europe would prevent our product candidates from being
marketed in these other jurisdictions, and any approval we are
granted for our product candidates in the United States and Europe
would not assure approval of product candidates in other
jurisdictions.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In order to market
and sell lefamulin and our other product candidates in
jurisdictions other than the United States and Europe, we must
obtain separate marketing approvals and comply with numerous and
varying regulatory requirements. The approval process varies among
countries and can involve additional testing. The time required to
obtain approval may differ from that required to obtain FDA
approval or approvals from regulatory authorities in the European
Union. The regulatory approval process outside the United States
and Europe generally includes all of the risks associated with
obtaining FDA approval or approvals from regulatory authorities in
the European Union. In addition, some countries outside the United
States and Europe require approval of the sales price of a drug
before it can be marketed. In many countries, separate procedures
must be followed to obtain reimbursement and a product may not be
approved for sale in the country until it is also approved for
reimbursement. We may not obtain marketing, pricing or
reimbursement approvals outside the United States and Europe on a
timely basis, if at all. Approval by the FDA or regulatory
authorities in the European Union does not ensure approval by
regulatory authorities in other countries or jurisdictions, and
approval by one regulatory authority outside the United States and
Europe does not ensure approval by regulatory authorities in other
countries or jurisdictions or by the FDA or regulatory authorities
in the European Union. We may not be able to file for marketing
approvals and may not receive necessary approvals to commercialize
our products in any market. Marketing approvals in countries
outside the United States and Europe do not ensure pricing
approvals in those countries or in any other countries, and
marketing approvals and pricing approvals do not ensure that
reimbursement will be obtained.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Even if we
obtain marketing approvals for our product candidates, the terms of
approvals and ongoing regulation of our products may limit how we
manufacture and market our products and compliance with such
requirements may involve substantial resources, which could
materially impair our ability to generate
revenue.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Even if marketing
approval of a product candidate is granted, an approved product and
its manufacturer and marketer are subject to ongoing review and
extensive regulation, including the potential requirements to
implement a risk evaluation and mitigation strategy or to conduct
costly post-marketing studies or clinical trials and surveillance
to monitor the safety or efficacy of the product. We must also
comply with requirements concerning advertising and promotion for
any of our product candidates for which we obtain marketing
approval. Promotional communications with respect to prescription
drugs are subject to a variety of legal and regulatory restrictions
and must be consistent with the information in the product’s
approved labeling. Thus, we will not be able to promote any
products we develop for indications or uses for which they are not
approved. In addition, manufacturers of approved products and those
manufacturers’ facilities are required to comply with extensive FDA
requirements including ensuring that quality control and
manufacturing procedures conform to cGMP, which include
requirements relating to quality control and quality assurance as
well as the corresponding maintenance of records and documentation
and reporting requirements. We and our contract manufacturers could
be subject to periodic unannounced inspections by the FDA to
monitor and ensure compliance with cGMP.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Accordingly,
assuming we receive marketing approval for one or more of our
product candidates, we and our contract manufacturers will continue
to expend time, money and effort in all areas of regulatory
compliance, including manufacturing, production, product
surveillance and quality control. If we are not able to comply with
post-approval regulatory requirements, we could have the marketing
approvals for our products withdrawn by regulatory authorities and
our ability to market any future products could be limited, which
could adversely affect our ability to achieve or sustain
profitability. Thus, the cost of compliance with post-approval
regulations may have a negative effect on our operating results and
financial condition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Any product
candidate for which we obtain marketing approval will be subject to
strict enforcement of post-marketing requirements and we could be
subject to substantial penalties, including withdrawal of our
product from the market, if we fail to comply with all regulatory
requirements or if we experience unanticipated problems with our
product candidates, when and if any of them are
approved.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Any product
candidate for which we obtain marketing approval, along with the
manufacturing processes, post-approval clinical data, labeling,
advertising and promotional activities for such product, will be
subject to continual requirements of and review by the FDA and
other regulatory authorities. These requirements include, but are
not limited</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
45<a name="PB_45_090829_8146" id="PB_45_090829_8146"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='45',FILE='C:\JMS\C902526\18-8686-1\task8887117\8686-1-ge.htm',USER='C902526',CD='May  7 16:45 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">to, restrictions
governing promotion of an approved product, submissions of safety
and other post-marketing information and reports, registration and
listing requirements, cGMP requirements relating to manufacturing,
quality control, quality assurance and corresponding maintenance of
records and documents, and requirements regarding the distribution
of samples to physicians and recordkeeping. In addition, even if
marketing approval of a product candidate is granted, the approval
may be subject to limitations on the indicated uses for which the
product may be marketed or to the conditions of
approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The FDA and other
federal and state agencies, including the U.S. Department of
Justice, or DOJ, closely regulate compliance with all requirements
governing prescription drug products, including requirements
pertaining to marketing and promotion of drugs in accordance with
the provisions of the approved labeling and manufacturing of
products in accordance with cGMP requirements. The</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">FDA and DOJ impose
stringent restrictions on manufacturers’ communications regarding
off-label use and if we do not market our products for their
approved indications, we may be subject to enforcement action for
off-label marketing. Violations of such requirements may lead to
investigations alleging violations of the Food, Drug and Cosmetic
Act and other statutes, including the False Claims Act and other
federal and state health care fraud and abuse laws as well as state
consumer protection laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our failure to
comply with all regulatory requirements, and later discovery of
previously unknown adverse events or other problems with our
products, manufacturers or manufacturing processes, may yield
various results, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
litigation involving patients taking our products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
restrictions on such products, manufacturers or manufacturing
processes;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
restrictions on the labeling or marketing of a product;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
restrictions on product distribution or use;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
requirements to conduct post-marketing studies or clinical
trials;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warning
or untitled letters;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
withdrawal of the products from the market;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; refusal
to approve pending applications or supplements to approved
applications that we submit;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; recall
of products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fines,
restitution or disgorgement of profits or revenues;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
suspension or withdrawal of marketing approvals;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage
to relationships with any potential collaborators;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
unfavorable press coverage and damage to our reputation;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; refusal
to permit the import or export of our products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; product
seizure; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
injunctions or the imposition of civil or criminal penalties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Non-compliance by
us or any future collaborator with regulatory requirements
regarding safety monitoring or pharmacovigilance, and with
requirements related to the development of products for the
pediatric population, can also result in significant financial
penalties. Similarly, failure to comply with regulatory
requirements regarding the protection of personal information can
also lead to significant penalties and sanctions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
46<a name="PB_46_102325_8779" id="PB_46_102325_8779"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='46',FILE='C:\JMS\105590\18-8686-1\task8878263\8686-1-gg.htm',USER='105590',CD='May  2 05:03 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Non-compliance
with European Union requirements regarding safety monitoring or
pharmacovigilance, and with requirements related to the development
of products for the pediatric population, also can result in
significant financial penalties. Similarly, failure to comply with
the European Union’s requirements regarding the protection of
personal information can also lead to significant penalties and
sanctions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Governments
outside the United States tend to impose strict price controls,
which may adversely affect our revenues, if any.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In some countries,
particularly the member states of the European Union, the pricing
of prescription pharmaceuticals is subject to governmental control.
In these countries, pricing negotiations with governmental
authorities can take considerable time after the receipt of
marketing approval for a product. Also, there can be considerable
pressure by governments and other stakeholders on prices and
reimbursement levels, including as part of cost containment
measures. Political, economic and regulatory developments may
further complicate pricing negotiations, and pricing negotiations
may continue after reimbursement has been obtained. Reference
pricing used by various European Union member states and parallel
distribution, or arbitrage between low-priced and high-priced
member states, can further reduce prices. In some countries, we may
be required to conduct a clinical trial or other studies that
compare the cost-effectiveness of our product candidate to other
available therapies to obtain or maintain reimbursement or pricing
approval. Publication of discounts by third-party payors or
authorities may lead to further pressure on prices or reimbursement
levels within the country of publication and other countries. If
reimbursement of our products is unavailable or limited in scope or
amount, or if pricing is set at unsatisfactory levels, our business
could be adversely affected.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">The FDA’s
agreement to a Special Protocol Assessment, or SPA, with respect to
the study design of our first Phase 3 clinical trial of lefamulin
for CABP does not guarantee any particular outcome from regulatory
review, including ultimate approval, and may not lead to a faster
development or regulatory review or approval
process.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We reached
agreement with the FDA in September&nbsp;2015 on a SPA, which was
later amended in April&nbsp;2016, regarding the study design of our
first Phase 3 clinical trial of lefamulin for the treatment of
CABP. The SPA process is designed to facilitate the FDA’s review
and approval of drugs by allowing the FDA to evaluate the proposed
design and size of Phase 3 clinical trials that are intended to
form the primary basis for determining a product candidate’s
efficacy and safety. Upon specific request by a clinical trial
sponsor, the FDA will evaluate the protocol and respond to a
sponsor’s questions regarding, among other things, primary efficacy
endpoints, trial conduct and data analysis, within 45 days of
receipt of the request. The FDA ultimately assesses whether the
protocol design and planned analysis of the trial are acceptable to
support regulatory approval of the product candidate with respect
to the effectiveness in the indication studied.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our agreement with
the FDA regarding the SPA may not lead to faster development,
regulatory review or approval for lefamulin. Once the FDA and an
applicant reach an agreement under the special protocol assessment
process regarding the design and size of a clinical trial, the
agreement generally cannot be changed after the clinical trial
begins. Nevertheless, the FDA may revoke or alter a SPA under
defined circumstances, such as changes in the relevant data or
assumptions provided by the sponsor or the emergence of new public
health concerns. A revocation or alteration in our SPA could
significantly delay or prevent approval of any marketing
applications we submit for lefamulin.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Fast track
designation by the FDA may not actually lead to a faster
development or regulatory review or approval process and does not
assure FDA approval of our product candidate.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If a drug is
intended for the treatment of a serious or life threatening
condition and the drug demonstrates the potential to address unmet
medical need for this condition, the drug sponsor may apply for FDA
fast track designation. The FDA has designated each of the IV and
oral formulations of lefamulin as a qualified infectious disease
product, or QIDP, and granted fast track designations to each of
these formulations of lefamulin. However, neither the QIDP nor the
fast track designation ensures that lefamulin will receive
marketing approval or that approval will be granted within any
particular timeframe. We may also seek fast track designation for
our other product candidates. We may not experience a faster
development process, review or approval compared to conventional
FDA procedures. In addition, the FDA may withdraw fast track
designation if it believes that the designation is no longer
supported by data from our clinical development program. Fast track
designation alone does not guarantee qualification for the FDA’s
priority review procedures.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
47<a name="PB_47_102344_7056" id="PB_47_102344_7056"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='47',FILE='C:\JMS\105590\18-8686-1\task8878263\8686-1-gg.htm',USER='105590',CD='May  2 05:03 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Priority
review designation by the FDA may not lead to a faster regulatory
review or approval process and, in any event, does not assure FDA
approval of our product candidate.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If the FDA
determines that a product candidate offers major advances in
treatment or provides a treatment where no adequate therapy exists,
the FDA may designate the product candidate for priority review. A
priority review designation means that the FDA’s goal to review an
application is six months, rather than the standard review period
of ten months. Because the FDA designated each of the IV and oral
formulations of lefamulin as a QIDP, lefamulin also will receive
priority review. We may also request priority review for other
product candidates. The FDA has broad discretion with respect to
whether or not to grant priority review status to a product
candidate, so even if we believe a particular product candidate is
eligible for such designation or status, the FDA may decide not to
grant it. Moreover, a priority review designation does not
necessarily mean a faster regulatory review process or necessarily
confer any advantage with respect to approval compared to
conventional FDA procedures. Receiving priority review from the FDA
does not guarantee approval within the six-month review cycle or
thereafter.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Designation
of our product candidate, lefamulin, as a Qualified Infectious
Disease Product does not assure FDA approval of this product
candidate.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">A QIDP is an
antibacterial or antifungal drug intended to treat serious or
life-threatening infections, including those caused by an
antibacterial or antifungal resistant pathogen, including novel or
emerging infectious pathogens or certain ‘‘qualifying pathogens.’’
Upon the approval of an NDA for a drug product designated by the
FDA as a QIDP, the product is granted an additional period of five
years of regulatory exclusivity. Even though we have received QIDP
designation for the IV and oral formulations of lefamulin, there is
no assurance that this product candidate will be approved by the
FDA.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Under the
CURES Act and the Trump Administration’s regulatory reform
initiatives, the FDA’s policies, regulations and guidance may be
revised or revoked and that could prevent, limit or delay
regulatory approval of our product candidates, which would impact
our ability to generate revenue.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">In
December&nbsp;2016, the 21st Century Cures Act, or Cures Act, was
signed into law. The Cures Act, among other things, is intended to
modernize the regulation of drugs and spur innovation, but its
ultimate implementation is unclear. If we are slow or unable to
adapt to changes in existing requirements or the adoption of new
requirements or policies, or if we are not able to maintain
regulatory compliance, we may lose any marketing approval that we
may have obtained and we may not achieve or sustain profitability,
which would adversely affect our business, prospects, financial
condition and results of operations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We also cannot
predict the likelihood, nature or extent of government regulation
that may arise from future legislation or administrative or
executive action, either in the United States or abroad. For
example, certain policies of the Trump administration may impact
our business and industry. Namely, the Trump administration has
taken several executive actions, including the issuance of a number
of Executive Orders, that could impose significant burdens on, or
otherwise materially delay, the FDA’s ability to engage in routine
regulatory and oversight activities such as implementing statutes
through rulemaking, issuance of guidance, and review and approval
of marketing applications. An under-staffed FDA could result in
delays in the FDA’s responsiveness or in its ability to review
submissions or applications, issue regulations or guidance, or
implement or enforce regulatory requirements in a timely fashion or
at all. Moreover, on January&nbsp;30, 2017, President Trump issued
an Executive Order, applicable to all executive agencies, including
the FDA, which requires that for each notice of proposed rulemaking
or final regulation to be issued in fiscal year 2017, the agency
shall identify at least two existing regulations to be repealed,
unless prohibited by law. These requirements are referred to as the
“two-for-one” provisions. This Executive Order includes a budget
neutrality provision that requires the total incremental cost of
all new regulations in the 2017 fiscal year, including repealed
regulations, to be no greater than zero, except in limited
circumstances. For fiscal years 2018 and beyond, the Executive
Order requires agencies to identify regulations to offset any
incremental cost of a new regulation and approximate the total
costs or savings associated with each new regulation or repealed
regulation. In interim guidance issued by the Office of Information
and Regulatory Affairs within the Office of Management and Budget
on February&nbsp;2, 2017, the administration indicates that the 
“two-for-one” provisions may apply not only to agency regulations,
but also to significant agency guidance documents. In addition, on
February&nbsp;24, 2017, President Trump issued an executive order
directing each affected agency to designate an agency official as a
“Regulatory Reform Officer” and establish a “Regulatory Reform Task
Force” to implement the two-for-one provisions and other previously
issued executive orders relating to the review of federal
regulations, however it is difficult to predict how these
requirements will be implemented, and the extent to which they will
impact the FDA’s ability to exercise its regulatory authority. If
these executive actions impose constraints on the FDA’s ability to
engage in oversight and implementation activities in the normal
course, our business may be negatively impacted.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
48<a name="PB_48_102412_5335" id="PB_48_102412_5335"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='48',FILE='C:\JMS\105590\18-8686-1\task8878263\8686-1-gg.htm',USER='105590',CD='May  2 05:03 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our
relationships with healthcare providers, physicians and third-party
payors will be subject to applicable anti-kickback, fraud and abuse
and other healthcare laws and regulations, which in the event of a
violation could expose us to criminal sanctions, civil penalties,
contractual damages, reputational harm and diminished profits and
future earnings.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Healthcare
providers, physicians and third-party payors will play a primary
role in the recommendation and prescription of any product
candidates, including lefamulin, for which we obtain marketing
approval. Our future arrangements with healthcare providers,
physicians and third-party payors may expose us to broadly
applicable fraud and abuse and other healthcare laws and
regulations that may constrain the business or financial
arrangements and relationships through which we market, sell and
distribute any products for which we obtain marketing approval.
Restrictions under applicable federal and state healthcare laws and
regulations, include the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the federal Anti-Kickback Statute prohibits, among other things,
persons from knowingly and willfully soliciting, offering,
receiving or providing remuneration, directly or indirectly, in
cash or in kind, to induce or reward, or in return for, either the
referral of an individual for, or the purchase, order or
recommendation or arranging of, any good or service, for which
payment may be made under a federal healthcare program such as
Medicare and Medicaid;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the federal False Claims Act imposes criminal and civil penalties,
including through civil whistleblower or qui tam actions, against
individuals or entities for, among other things, knowingly
presenting, or causing to be presented, false or fraudulent claims
for payment by a federal healthcare program or making a false
statement or record material to payment of a false claim or
avoiding, decreasing or concealing an obligation to pay money to
the federal government, with potential liability including
mandatory treble damages and significant per-claim penalties,
currently set at $5,500 to $11,000 per false claim;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the federal Health Insurance Portability and Accountability Act of
1996, or HIPAA, imposes criminal and civil liability for executing
a scheme to defraud any healthcare benefit program or making false
statements relating to healthcare matters;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
HIPAA, as amended by the Health Information Technology for Economic
and Clinical Health Act and its implementing regulations, also
imposes obligations, including mandatory contractual terms, with
respect to safeguarding the privacy, security and transmission of
individually identifiable health information;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the federal Physician Payments Sunshine Act requires applicable
manufacturers of covered products to report payments and other
transfers of value to physicians and teaching hospitals, with data
collection beginning in August&nbsp;2013; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
analogous state and foreign laws and regulations, such as state
anti-kickback and false claims laws and transparency statutes, may
apply to sales or marketing arrangements and claims involving
healthcare items or services reimbursed by non-governmental third
party payors, including private insurers.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Some state laws
require pharmaceutical companies to comply with the pharmaceutical
industry’s voluntary compliance guidelines and the relevant
compliance guidance promulgated by the federal government and may
require product manufacturers to report information related to
payments and other transfers of value to physicians and other
healthcare providers or marketing expenditures. State and foreign
laws also govern the privacy and security of health information in
some circumstances, many of which differ from each other in
significant ways and often are not pre-empted by HIPAA, thus
complicating compliance efforts.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If our operations
are found to be in violation of any of the laws described above or
any governmental regulations that apply to us, we may be subject to
penalties, including civil and criminal penalties, damages, fines
and the curtailment or restructuring of our operations. Any
penalties, damages, fines, curtailment or restructuring of our
operations could adversely affect our financial results. We are
developing and implementing a corporate compliance program designed
to ensure that we will market and sell any future products that we
successfully develop from our product candidates in compliance with
all applicable laws and regulations, but we cannot guarantee that
this program will protect us from governmental investigations or
other actions or lawsuits stemming from a failure to be in
compliance with such laws or regulations. If any such actions are
instituted against us and we are not successful in defending
ourselves or asserting our rights, those actions could have a
significant impact on our business, including the imposition of
significant fines or other sanctions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Efforts to ensure
that our business arrangements with third parties will comply with
applicable healthcare laws and regulations will involve substantial
costs. It is possible that governmental authorities will conclude
that our business practices may not comply with current or future
statutes, regulations or case law involving applicable fraud and
abuse or other healthcare laws and regulations. If our operations
are found to be in violation of any of these laws or any
other</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
49<a name="PB_49_102519_5796" id="PB_49_102519_5796"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='49',FILE='C:\JMS\105590\18-8686-1\task8878263\8686-1-gg.htm',USER='105590',CD='May  2 05:03 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">governmental
regulations that may apply to us, we may be subject to significant
civil, criminal and administrative penalties, damages, fines,
imprisonment, exclusion of products from government funded
healthcare programs, such as Medicare and Medicaid, and the
curtailment or restructuring of our operations. If any of the
physicians or other healthcare providers or entities with whom we
expect to do business is found to be not in compliance with
applicable laws, they may be subject to criminal, civil or
administrative sanctions, including exclusions from government
funded healthcare programs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Current and
future legislation may increase the difficulty and cost for us and
any future collaborators to obtain marketing approval of and
commercialize our product candidates and affect the prices we, or
they, may obtain.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In the United
States and some foreign jurisdictions, there have been a number of
legislative and regulatory changes and proposed changes regarding
the healthcare system that could, among other things, prevent or
delay marketing approval of lefamulin or any of our other product
candidates, restrict or regulate post-approval activities and
affect our ability, or the ability of any collaborators, to
profitably sell any product candidates, including lefamulin, for
which we, or they, obtain marketing approval. We expect that
current laws, as well as other healthcare reform measures that may
be adopted in the future, may result in more rigorous coverage
criteria and in additional downward pressure on the price that we,
or any future collaborators, may receive for any approved
products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In
March&nbsp;2010, President Obama signed into law the Patient
Protection and Affordable Care Act, as amended by the Health Care
and Education Reconciliation Act, or collectively the ACA. Among
the provisions of the ACA of potential importance to our business
and our product candidates are the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
an annual, non-deductible fee on any entity that manufactures or
imports specified branded prescription products and biologic
agents;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
an increase in the statutory minimum rebates a manufacturer must
pay under the Medicaid Drug Rebate Program;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
expansion of healthcare fraud and abuse laws, including the civil
False Claims Act and the federal Anti-Kickback Statute, new
government investigative powers and enhanced penalties for
noncompliance;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
a new Medicare Part&nbsp;D coverage gap discount program, in which
manufacturers must agree to offer 50% point-of-sale discounts (and
70% starting January&nbsp;1, 2019) off negotiated prices;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
extension of manufacturers’ Medicaid rebate liability;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
expansion of eligibility criteria for Medicaid programs;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
expansion of the entities eligible for discounts under the Public
Health Service pharmaceutical pricing program;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
new requirements to report certain financial arrangements with
physicians and teaching hospitals;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
a new requirement to annually report product samples that
manufacturers and distributors provide to physicians; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
a new Patient-Centered Outcomes Research Institute to oversee,
identify priorities in, and conduct comparative clinical
effectiveness research, along with funding for such research.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition, other
legislative changes have been proposed and adopted since the ACA
was enacted. These changes include the Budget Control Act of 2011,
which among other things, led to aggregate reductions to Medicare
payments to providers of up to 2% per fiscal year that started
in&nbsp;April&nbsp;2013 and, due to subsequent legislative
amendments to the statutes, will stay in effect through 2027 unless
additional Congressional action is taken, and the American Taxpayer
Relief Act of 2012, which, among other things, reduced Medicare
payments to several types of providers and increased the statute of
limitations period for the government to recover overpayments to
providers from three to five years. These new laws may result in
additional reductions in Medicare and other healthcare funding and
otherwise affect the prices we may obtain for any of our product
candidates for which we may obtain regulatory approval or the
frequency with which any such product candidate is prescribed or
used. Further, there have been several recent U.S. congressional
inquiries and proposed state and federal legislation designed to,
among other things, bring</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
50<a name="PB_50_102607_2897" id="PB_50_102607_2897"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='50',FILE='C:\JMS\105590\18-8686-1\task8878263\8686-1-gg.htm',USER='105590',CD='May  2 05:03 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">more transparency to
drug pricing, review the relationship between pricing and
manufacturer patient programs, reduce the costs of drugs under
Medicare and reform government program reimbursement methodologies
for drug products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We expect that
these healthcare reforms, as well as other healthcare reform
measures that may be adopted in the future, may result in
additional reductions in Medicare and other healthcare funding,
more rigorous coverage criteria, new payment methodologies and
additional downward pressure on the price that we receive for any
approved product and/or the level of reimbursement physicians
receive for administering any approved product we might bring to
market. Reductions in reimbursement levels may negatively impact
the prices we receive or the frequency with which our products are
prescribed or administered.&nbsp; Any reduction in reimbursement
from Medicare or other government programs may result in a similar
reduction in payments from private payors.&nbsp; Since enactment of
the ACA, there have been numerous legal challenges and
Congressional actions to repeal and replace provisions of the
law.&nbsp; In May&nbsp;2017, the U.S. House of Representatives
passed legislation known as the American Health Care Act of
2017.&nbsp; Thereafter, the Senate Republicans introduced and then
updated a bill to replace the ACA known as the Better Care
Reconciliation Act of 2017. The Senate Republicans also introduced
legislation to repeal the ACA without companion legislation to
replace it, and a “skinny” version of the Better Care
Reconciliation Act of 2017.&nbsp; In addition, the Senate
considered proposed healthcare reform legislation known as the
Graham-Cassidy bill.&nbsp; None of these measures was passed by the
United States Senate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">With enactment of the legislation commonly
referred to as the Tax Cuts and Jobs Act of 2017, which was signed
by the President on December&nbsp;22, 2017, Congress repealed the 
“individual mandate.”&nbsp; The repeal of this provision, which
requires most Americans to carry a minimal level of health
insurance, will become effective in 2019.&nbsp; According to the
Congressional Budget Office, the repeal of the individual mandate
will cause 13 million fewer Americans to be insured in 2027 and
premiums in insurance markets may rise.</font> Additionally, on
January&nbsp;22, 2018, President Trump signed a continuing
resolution on appropriations for fiscal year 2018 that delayed the
implementation of certain ACA-mandated fees, including the
so-called “Cadillac” tax on certain high cost employer-sponsored
insurance plans, the annual fee imposed on certain health insurance
providers based on market share, and the medical device excise tax
on non-exempt medical devices.&nbsp; Further, the Bipartisan Budget
Act of 2018, among other things, amends the ACA, effective
January&nbsp;1, 2019, to increase from 50 percent to 70 percent the
point-of-sale discount that is owed by pharmaceutical manufacturers
who participate in Medicare Part&nbsp;D and to close the coverage
gap in most Medicare drug plans, commonly referred to as the “donut
hole.” Further, each chamber of the Congress has put forth multiple
bills designed to repeal or repeal and replace portions of the ACA.
Although none of these measures has been enacted by Congress to
date, Congress may consider other legislation to repeal and replace
elements of the ACA.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The Trump
Administration has also taken executive actions to undermine or
delay implementation of the ACA.&nbsp; In January&nbsp;2017,
President Trump signed an Executive Order directing federal
agencies with authorities and responsibilities under the ACA to
waive, defer, grant exemptions from, or delay the implementation of
any provision of the ACA that would impose a fiscal or regulatory
burden on states, individuals, healthcare providers, health
insurers, or manufacturers of pharmaceuticals or medical devices.
In October&nbsp;2017, the President signed a second Executive Order
allowing for the use of association health plans and short-term
health insurance, which may provide fewer health benefits than the
plans sold through the ACA exchanges.&nbsp; At the same time, the
Administration announced that it will discontinue the payment of
cost-sharing reduction (CSR) payments to insurance companies until
Congress approves the appropriation of funds for such CSR payments.
The loss of the CSR payments is expected to increase premiums on
certain policies issued by qualified health plans under the
ACA.&nbsp; A bipartisan bill to appropriate funds for CSR payments
was introduced in the Senate, but the future of that bill is
uncertain.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
will continue to evaluate the effect that the ACA and its
possible</font> repeal and replacement could have on our
business.&nbsp; It is possible that repeal and replacement
initiatives, if enacted into law, could ultimately result in fewer
individuals having health insurance coverage or in individuals
having insurance coverage with less generous benefits.&nbsp; While
the timing and scope of any potential future legislation to repeal
and replace ACA provisions is highly uncertain in many respects, it
is also possible that some of the ACA provisions that generally are
not favorable for the research-based pharmaceutical industry could
also be repealed along with ACA coverage expansion
provisions.&nbsp;&nbsp; Accordingly, such reforms, if enacted,
could have an adverse effect on anticipated revenue from product
candidates that we may successfully develop and for which we may
obtain marketing approval and may affect our overall financial
condition and ability to develop commercialize product
candidates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Further, there
have been several recent U.S. congressional inquiries and proposed
and enacted federal and state legislation designed to, among other
things, bring more transparency to drug pricing, review the
relationship between pricing and manufacturer patient programs,
reduce the costs of drugs under Medicare and reform government
program reimbursement methodologies for drug products. At the
federal level, the Trump administration’s budget proposal for
fiscal year 2019 contains further drug price control measures that
could be enacted during the 2019 budget process or in</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
51<a name="PB_51_102635_3020" id="PB_51_102635_3020"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='51',FILE='C:\JMS\105590\18-8686-1\task8878263\8686-1-gg.htm',USER='105590',CD='May  2 05:03 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">other future
legislation, including, for example, measures to permit Medicare
Part&nbsp;D plans to negotiate the price of certain drugs under
Medicare Part&nbsp;B, to allow some states to negotiate drug prices
under Medicaid, and to eliminate cost sharing for generic drugs for
low-income patients. While any proposed measures will require
authorization through additional legislation to become effective,
Congress and the Trump administration have each indicated that it
will continue to seek new legislative and/or administrative
measures to control drug costs. At the state level, individual
states are increasingly aggressive in passing legislation and
implementing regulations designed to control pharmaceutical and
biological product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain
product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. In addition, regional
health care authorities and individual hospitals are increasingly
using bidding procedures to determine what pharmaceutical products
and which suppliers will be included in their prescription drug and
other health care programs. These measures could reduce the
ultimate demand for our products, once approved, or put pressure on
our product pricing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Moreover,
legislative and regulatory proposals have also been made to expand
post-approval requirements and restrict sales and promotional
activities for pharmaceutical drugs. We cannot be sure whether
additional legislative changes will be enacted, or whether the FDA
regulations, guidance or interpretations will be changed, or what
the impact of such changes on the marketing approvals of our drug
candidates, if any, may be. In addition, increased scrutiny by the
United States Congress of the FDA’s approval process may
significantly delay or prevent marketing approval, as well as
subject us and any future collaborators to more stringent drug
labeling and post-marketing testing and other
requirements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We are
subject to anti-corruption laws, as well as export control laws,
customs laws, sanctions laws and other laws governing our
operations. If we fail to comply with these laws, we could be
subject to civil or criminal penalties, other remedial measures and
legal expenses, which could adversely affect our business, results
of operations and financial condition.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our operations are
subject to anti-corruption laws, including the U.S. Foreign Corrupt
Practices Act, or FCPA, and other anti-corruption laws that apply
in countries where we do business and may do business in the
future. The FCPA and these other laws generally prohibit us, our
officers, and our employees and intermediaries from bribing, being
bribed or making other prohibited payments to government officials
or other persons to obtain or retain business or gain some other
business advantage. We may in the future operate in jurisdictions
that pose a high risk of potential FCPA violations, and we may
participate in collaborations and relationships with third parties
whose actions could potentially subject us to liability under the
FCPA or local anti-corruption laws. In addition, we cannot predict
the nature, scope or effect of future regulatory requirements to
which our international operations might be subject or the manner
in that existing laws might be administered or
interpreted.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Compliance with
the FCPA is expensive and difficult, particularly in countries in
which corruption is a recognized problem. In addition, the FCPA
presents particular challenges in the pharmaceutical industry,
because, in many countries, hospitals are operated by the
government, and doctors and other hospital employees are considered
foreign officials. Certain payments to hospitals in connection with
clinical trials and other work have been deemed to be improper
payments to government officials and have led to FCPA enforcement
actions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are also
subject to other laws and regulations governing our international
operations, including regulations administered by the governments
of the United States, and authorities in the European Union,
including applicable export control regulations, economic sanctions
on countries and persons, customs requirements and currency
exchange regulations, collectively referred to as the trade control
laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">There is no
assurance that we will be effective in ensuring our compliance with
all applicable anti-corruption laws, including the FCPA or other
legal requirements, including trade control laws. If we are not in
compliance with the FCPA and other anti-corruption laws or trade
control laws, we may be subject to criminal and civil penalties,
disgorgement and other sanctions and remedial measures, and legal
expenses, which could have an adverse impact on our business,
financial condition, results of operations and liquidity. Likewise,
any investigation of any potential violations of the FCPA, other
anti-corruption laws or trade control laws by U.S. or other
authorities could also have an adverse impact on our reputation,
our business, results of operations and financial
condition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail
to comply with environmental, health and safety laws and
regulations, we could become subject to fines or penalties or incur
costs that could have a material adverse effect on the success of
our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are subject to
numerous environmental, health and safety laws and regulations,
including those governing laboratory procedures and the handling,
use, storage, treatment and disposal of hazardous materials and
wastes. Our</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
52<a name="PB_52_102658_7748" id="PB_52_102658_7748"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='52',FILE='C:\JMS\105590\18-8686-1\task8878263\8686-1-gg.htm',USER='105590',CD='May  2 05:03 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">operations currently,
and may in the future, involve the use of hazardous and flammable
materials, including chemicals and medical and biological
materials, and produce hazardous waste products. Even if we
contract with third parties for the disposal of these materials and
wastes, we cannot eliminate the risk of contamination or injury
from these materials. In the event of contamination or injury
resulting from our use of hazardous materials or disposal of
hazardous wastes, we could be held liable for any resulting
damages, and any liability could exceed our resources.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Although we
maintain workers’ compensation insurance to cover us for costs and
expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide
adequate coverage against potential liabilities. We also maintain a
general liability program for some of the risks, but our insurance
program includes limited environmental damage coverage, which has
an annual aggregate coverage limit of $2.0 million. Although we
maintain an umbrella policy with an annual aggregate coverage limit
of $10.0 million, which may provide some environmental coverage, we
do not maintain a separate policy covering environmental
damages.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition, we
may incur substantial costs to comply with current or future
environmental, health and safety laws and regulations. These
current or future laws and regulations may impair our research,
development or production efforts. Failure to comply with these
laws and regulations also may result in substantial fines,
penalties or other sanctions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our
employees may engage in misconduct or other improper activities,
including non-compliance with regulatory standards and
requirements, which could cause significant liability for us and
harm our reputation.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are exposed to
the risk of employee fraud or other misconduct, including
intentional failures to comply with FDA regulations or similar
regulations of comparable non-U.S. regulatory authorities, provide
accurate information to the FDA or comparable non-U.S. regulatory
authorities, comply with manufacturing standards we have
established, comply with federal and state healthcare fraud and
abuse laws and regulations and similar laws and regulations
established and enforced by comparable non-U.S. regulatory
authorities, report financial information or data accurately or
disclose unauthorized activities to us. In particular, sales,
marketing and business arrangements in the healthcare industry are
subject to extensive laws and regulations intended to prevent
fraud, kickbacks, self-dealing and other abusive practices. These
laws and regulations may restrict or prohibit a wide range of
pricing, discounting, marketing and promotion, sales commission,
customer incentive programs and other business
arrangements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Employee
misconduct could also involve the improper use of information
obtained during clinical trials, which could result in regulatory
sanctions and serious harm to our reputation. It is not always
possible to identify and deter employee misconduct, and the
precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in
protecting us from governmental investigations or other actions or
lawsuits stemming from a failure to be in compliance with such
laws, standards or regulations. If any such actions are instituted
against us, and we are not successful in defending ourselves or
asserting our rights, those actions could have a significant impact
on our business and results of operations, including the imposition
of significant fines or other sanctions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We rely
significantly on information technology and any failure,
inadequacy, interruption or security lapse of that technology,
including any cyber security incidents, could harm our ability to
operate our business effectively.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Despite the
implementation of security measures, our internal computer systems
and those of third parties with which we contract are vulnerable to
damage from cyber-attacks, computer viruses, unauthorized access,
natural disasters, terrorism, war and telecommunication and
electrical failures. System failures, accidents or security
breaches could cause interruptions in our operations, and could
result in a material disruption of our drug development programs
and commercialization activities and business operations, in
addition to possibly requiring substantial expenditures of
resources to remedy. The loss of clinical trial data could result
in delays in our regulatory approval efforts and significantly
increase our costs to recover or reproduce the data. To the extent
that any disruption or security breach were to result in a loss of,
or damage to, our data or applications, or inappropriate disclosure
of confidential or proprietary information, we could incur
liability and our product research, development and
commercialization efforts could be delayed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We are
subject to various laws protecting the confidentiality of certain
patient health information, and our failure to comply could result
in penalties and reputational damage.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Certain countries in which we operate have, or
are developing, laws protecting the confidentiality of certain
patient health information.</font> European Union, or EU, member
states and other jurisdictions have adopted data protection laws
and regulations, which impose significant compliance
obligations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
53<a name="PB_53_102720_141" id="PB_53_102720_141"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='53',FILE='C:\JMS\105590\18-8686-1\task8878263\8686-1-gg.htm',USER='105590',CD='May  2 05:03 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">For example, the
EU Data Protection Directive, as implemented into national laws by
the EU member states, imposes strict obligations and restrictions
on the ability to collect, analyze and transfer personal data,
including health data from clinical trials and adverse event
reporting. Data protection authorities from different EU member
states may interpret the EU Data Protection Directive and national
laws differently, which adds to the complexity of processing
personal data in the EU, and guidance on implementation and
compliance practices are often updated or otherwise revised. The EU
Data Protection Directive prohibits the transfer of personal data
to countries outside of the EU member states that are not
considered by the European Commission to provide an adequate level
of data protection, and transfers of personal data to such
countries can only be made in certain circumstances—for example,
where the transfer is required by law or the data subject (i.e. the
individual to whom the personal data relates) has given his or her
consent to the transfer. Nevertheless, any failure to comply with
the rules&nbsp;arising from the EU Data Protection Directive and
related national laws of EU member states, as well as privacy laws
in other countries in which we operate, could lead to government
enforcement actions and significant sanctions or penalties against
us, adversely impact our results of operations and subject us to
negative publicity.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The EU Data
Protection Regulation, which will replace the current EU Data
Protection Directive, was adopted in 2016 and will become
enforceable on May&nbsp;25, 2018. The EU Data Protection Regulation
will introduce new data protection requirements in the EU and
substantial fines for breaches of the data protection rules, may
increase our responsibility and liability in relation to personal
data that we process and may require us to put in place additional
mechanisms to ensure compliance with the new EU data protection
rules.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks
Related to Employee Matters and Managing Growth</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our future
success depends on our ability to retain our chief executive
officer and other key executives and to attract, retain and
motivate qualified personnel.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are highly
dependent on Dr.&nbsp;Colin Broom, our Chief Executive Officer, and
the other principal members of our management and scientific teams.
Although we have formal employment agreements with each of our
executive officers, these agreements do not prevent our executives
from terminating their employment with us at any time. We do not
maintain ‘‘key person’’ insurance on any of our executive officers.
The unplanned loss of the services of any of these persons might
impede the achievement of our research, development and
commercialization objectives.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman"><font style="font-size:10.0pt;">Recruiting
and retaining qualified scientific, clinical, manufacturing and
sales and marketing personnel, including in the United States and
Ireland where we plan to expand our physical presence, will also be
critical to our success. We may not be able to attract and retain
these personnel on acceptable terms given the competition among
numerous pharmaceutical and biotechnology companies for similar
personnel. We also experience competition for the hiring of
scientific and clinical personnel from universities and research
institutions. In addition, we rely on consultants and advisors,
including scientific and clinical advisors, to assist us in
formulating our research and development and commercialization
strategy. Our consultants and advisors may be employed by employers
other than us and may have commitments under consulting or advisory
contracts with other entities that may limit their availability to
us. If we cannot recruit and retain qualified personnel,</font> we
may be unable to successfully develop our product candidates,
conduct our clinical trials and commercialize our product
candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We expect to
expand our development, regulatory and, subject to obtaining
marketing approval of lefamulin, sales and marketing capabilities,
and as a result, we may encounter difficulties in managing our
growth, which could disrupt our operations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We expect to
experience significant growth in the number of our employees and
the scope of our operations, particularly in the areas of drug
development, regulatory affairs technical operations, supply chain,
medical affairs and, subject to obtaining marketing approval of
lefamulin, sales and marketing. To manage our anticipated future
growth, we must continue to implement and improve our managerial,
operational and financial systems, expand our facilities and
continue to recruit and train additional qualified personnel. Due
to our limited financial resources and the limited experience of
our management team in managing a company with such anticipated
growth, we may not be able to effectively manage the expansion of
our operations or recruit and train additional qualified personnel.
The physical expansion of our operations may lead to significant
costs and may divert our management and business development
resources. Any inability to manage growth could delay the execution
of our business plans or disrupt our operations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
54<a name="PB_54_102751_7608" id="PB_54_102751_7608"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='54',FILE='C:\JMS\105590\18-8686-1\task8878263\8686-1-gg.htm',USER='105590',CD='May  2 05:03 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><b><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Risks Related to Ownership of
Our Ordinary Shares</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">An active
trading market for our ordinary shares may not be
sustained</font></i></b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Following the
Redomiciliation Transaction, our ordinary shares began trading on
the Nasdaq Global Market on June&nbsp;26, 2017. Given the limited
trading history of our ordinary shares, there is a risk that an
active trading market for our ordinary shares will not be
sustained, which could put downward pressure on the market price of
our ordinary shares and thereby affect the ability of our security
holders to sell their shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">The price of
our ordinary shares may be volatile and fluctuate
substantially.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The trading price
of our ordinary shares has been and is likely to continue to be
volatile. The stock market in general and the market for smaller
biopharmaceutical companies in particular have experienced
significant volatility that has often been unrelated to the
operating performance of particular companies. The market price for
our ordinary shares may be influenced by many factors,
including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the success of competitive products or technologies;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
results of clinical trials of our product candidates or those of
our competitors;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
regulatory delays and greater government regulation of potential
products due to adverse events;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
regulatory or legal developments in the United States, the European
Union and other countries;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
developments or disputes concerning patent applications, issued
patents or other proprietary rights;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the recruitment or departure of key scientific or management
personnel;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the level of expenses related to any of our product candidates or
clinical development programs;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the results of our efforts to discover, develop, acquire or
in-license additional product candidates or products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
one of our manufacturers or suppliers could have an event which
causes an unforeseen disruption of the manufacture or supply of our
product candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
actual or anticipated changes in estimates as to financial results,
development timelines or recommendations by securities
analysts;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
variations in our financial results or those of companies that are
perceived to be similar to us;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
changes in the structure of healthcare payment systems;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
market conditions in the pharmaceutical and biotechnology
sectors;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
general economic, industry and market conditions; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the other factors described in this ‘‘Risk Factors’’ section.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In the past,
following periods of volatility in the market price of a company’s
securities, securities class-action litigation has often been
instituted against that company. We also may face securities
class-action litigation if we cannot obtain regulatory approvals
for or if we otherwise fail to commercialize lefamulin or any of
our other product candidates or if our securities experience
volatility for any reason. Such litigation, if instituted against
us, could cause us to incur substantial costs to defend such claims
and divert management’s attention and resources.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our
executive officers, directors and principal shareholders, if they
choose to act together, have the ability to control most matters
submitted to shareholders for approval.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our executive
officers and directors, combined with our shareholders, and their
respective affiliates who owned more than 5% of our outstanding
ordinary shares as of March&nbsp;31, 2018 in the aggregate,
beneficially owned approximately 52.8% of our share capital. As a
result, if these shareholders were to choose to act together, they
would be able to control most matters submitted to our shareholders
for approval, as well as our management and affairs. For example,
these persons, if they choose to act together, would have
significant influence over the election of directors and approval
of any merger, consolidation or sale of all or substantially all of
our assets.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
55<a name="PB_55_102842_8146" id="PB_55_102842_8146"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='55',FILE='C:\JMS\105590\18-8686-1\task8878263\8686-1-gg.htm',USER='105590',CD='May  2 05:03 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our ordinary
shares do not trade on any exchange outside of the United
States.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our ordinary
shares are listed only in the United States on The Nasdaq Global
Market, and we have no plans to list our ordinary shares in any
other jurisdiction. As a result, a holder of ordinary shares
outside of the United States may not be able to effect transactions
in our ordinary shares as readily as the holder may if our ordinary
shares were listed on an exchange in that holder’s home
jurisdiction.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">The sale of
a substantial number of ordinary shares may cause the market price
of our ordinary shares to decline.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Sales of a
substantial number of our ordinary shares, or the perception in the
market that these sales could occur, could reduce the market price
of our ordinary shares. We had 40,233,867 ordinary shares
outstanding as of March&nbsp;31, 2018. To the extent any of these
shares are sold into the market, particularly in substantial
quantities, the market price of our ordinary shares could
decline.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Future issuances of ordinary shares pursuant to
our equity incentive plans could also result in a reduction in the
market price of our ordinary shares.</font> We have filed
registration statements on Form&nbsp;S-8 registering all of the
ordinary shares that we may issue under our equity compensation
plans. These shares can be freely sold in the public market upon
issuance and once vested, subject to volume, notice and manner of
sale limitations applicable to affiliates. The majority of ordinary
shares that may be issued under our equity compensation plans
remain subject to vesting in tranches over a four-year period. As
of March 31, 2018, an aggregate of 1,337,202 options to purchase
our ordinary shares had vested and become exercisable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">In
addition, in March&nbsp;2018, we entered into a Controlled Equity
Offering</font><font size="1" style=
"font-size:6.5pt;position:relative;top:-3.0pt;">SM</font>&nbsp;Sales
Agreement, or the ATM Agreement, with Cantor Fitzgerald&nbsp;&amp;
Co., or Cantor, pursuant to which, from time to time, we may offer
and sell our ordinary shares having an aggregate offering price of
up to $50 million through Cantor. As of March&nbsp;31, 2018, we
issued and sold an aggregate of 3,517,511 ordinary shares under the
ATM agreement. From March&nbsp;31, 2018 to the date of this filing,
we issued and sold an aggregate of 3,590,568 ordinary shares under
the ATM agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">If a large number
of our ordinary shares are sold in the public market after they
become eligible for sale, the sales could reduce the trading price
of our ordinary shares and impede our ability to raise future
capital.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We are an ‘
‘emerging growth company’’, and the reduced disclosure requirements
applicable to emerging growth companies may make our ordinary
shares less attractive to investors.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are an ‘
‘emerging growth company,’’ as that term is used in the Jumpstart
Our Business Startups Act of 2012, or the JOBS Act, and may remain
an emerging growth company until December&nbsp;31, 2020 or such
earlier time that we are no longer an emerging growth company. For
so long as we remain an emerging growth company, we are permitted
and may take advantage of specified reduced reporting and other
burdens that are otherwise applicable generally to public
companies. These provisions include:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
an exemption from compliance with the auditor attestation
requirement of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002,
or the Sarbanes-Oxley Act, on the design and effectiveness of our
internal controls over financial reporting;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
an exemption from compliance with any requirement that the Public
Company Accounting Oversight Board may adopt regarding mandatory
audit firm rotation or a supplement to the auditor’s report
providing additional information about the audit and the financial
statements;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
reduced disclosure about the company’s executive compensation
arrangements; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
exemptions from the requirements to obtain a non-binding advisory
vote on executive compensation or a shareholder approval of any
golden parachute arrangements.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
56<a name="PB_56_103230_1456" id="PB_56_103230_1456"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='56',FILE='C:\JMS\C902550\18-8686-1\task8887158\8686-1-gi.htm',USER='C902550',CD='May  7 17:15 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We may choose to
take advantage of some, but not all, of the available exemptions.
We may take advantage of these provisions until December&nbsp;31,
2020 or such earlier time that we are no longer an emerging growth
company. We would cease to be an emerging growth company upon the
earlier to occur of: the last day of the fiscal year in which we
have more than $1 billion (as may be inflation-adjusted by the SEC
from time-to-time) in annual revenues; the date we qualify as a ‘
‘large accelerated filer,’’ with more than $700 million in market
value of our share capital held by non-affiliates; or the issuance
by us of more than $1 billion of non-convertible debt over a
three-year period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We may choose to
take advantage of some, but not all, of the available benefits
under the JOBS Act. We cannot predict whether investors will find
our ordinary shares less attractive if we rely on such exemptions.
If some investors find our ordinary shares less attractive as a
result, there may be a less active trading market for our ordinary
shares and the market price of our ordinary shares may be more
volatile.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition, the
JOBS Act also provides that an emerging growth company can take
advantage of an extended transition period for complying with new
or revised accounting standards. This allows an emerging growth
company to delay the adoption of certain accounting standards until
those standards would otherwise apply to private companies. We have
irrevocably elected not to avail ourselves of this exemption and,
therefore, we will adopt new or revised accounting standards on the
relevant dates on which adoption of such standards is required for
other public companies that are not emerging growth
companies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We have
broad discretion in the use of our funds and may not use them
effectively.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We have broad
discretion in the application of our available funds and could
spend the funds in ways that do not improve our results of
operations or enhance the value of our ordinary shares. Our failure
to apply these funds effectively could result in financial losses
that could have a material adverse effect on our business, cause
the price of our ordinary shares to decline and delay the
development of our product candidates. Pending their use, we may
invest funds in a manner that does not produce income or that loses
value.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We incur
increased costs as a result of operating as a public company, and
our management is required to devote substantial time to new
compliance initiatives and corporate governance
practices.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">As a public
company we incur, and particularly after we are no longer an
emerging growth company, we will incur significant legal,
accounting and other expenses that we did not incur as a private
company. In addition, the Sarbanes-Oxley Act, the Dodd-Frank Wall
Street Reform and Consumer Protection Act, the listing requirements
of The Nasdaq Global Market and other applicable securities
rules&nbsp;and regulations impose various requirements on public
companies, including establishment and maintenance of effective
disclosure and financial controls and corporate governance
practices. Our management and other personnel need to devote a
substantial amount of time to these compliance initiatives.
Moreover, these rules&nbsp;and regulations have increased our legal
and financial compliance costs and make some activities more
time-consuming and costly. For example, these rules&nbsp;and
regulations have made it more expensive for us to obtain director
and officer liability insurance, and if such insurance becomes
prohibitively expensive, this could make it more difficult for us
to attract and retain qualified members of our board.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">For as long as we
remain an emerging growth company, we may take advantage of certain
exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies as
described elsewhere in this ‘‘Risk Factors’’ section. We may remain
an emerging growth company until December&nbsp;31, 2020, although
if the market value of our share capital that is held by
non-affiliates exceeds $700 million as of any June&nbsp;30 before
that time or if we have annual gross revenues of $1 billion or more
in any fiscal year (as may be inflation adjusted by the SEC from
time-to-time), we would cease to be an emerging growth company as
of December&nbsp;31 of the applicable year. We also would cease to
be an emerging growth company if we issue more than $1 billion of
non-convertible debt over a three-year period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail
to maintain an effective system of internal control over financial
reporting, we may not be able to accurately report our financial
results or prevent fraud. As a result, security holders could lose
confidence in our financial and other public reporting, which would
harm our business and the trading price of our ordinary
shares.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Effective internal
control over financial reporting is necessary for us to provide
reliable financial reports and, together with adequate disclosure
controls and procedures, is designed to prevent fraud. Any failure
to implement required new or improved controls, or difficulties
encountered in their implementation could cause us to fail to meet
our reporting obligations. In addition, any testing by us, as and
when required, conducted in connection with Section&nbsp;404 of the
Sarbanes-Oxley Act, or Section&nbsp;404, or any subsequent testing
by our independent registered public accounting</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
57<a name="PB_57_103244_7091" id="PB_57_103244_7091"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='57',FILE='C:\JMS\C902550\18-8686-1\task8887158\8686-1-gi.htm',USER='C902550',CD='May  7 17:15 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">firm, as and when
required, may reveal deficiencies in our internal control over
financial reporting that are deemed to be material weaknesses or
that may require prospective or retroactive changes to our
financial statements or identify other areas for further attention
or improvement. Inferior internal controls could also cause
investors to lose confidence in our reported financial information,
which could have a negative effect on the trading price of our
ordinary shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Pursuant to
Section&nbsp;404, we will be required to furnish a report by our
management on our internal control over financial reporting.
However, as an emerging growth company, we will not be required to
include an attestation report on internal control over financial
reporting issued by our independent registered public accounting
firm until we are no longer an emerging growth company. To achieve
compliance with Section&nbsp;404 within the prescribed period, we
are engaged in a process to document and evaluate our internal
control over financial reporting, which is both costly and
challenging. In this regard, we will need to continue to dedicate
internal resources, potentially engage outside consultants and
adopt a detailed work plan to assess and document the adequacy of
internal control over financial reporting, continue steps to
improve control processes as appropriate, validate through testing
that controls are functioning as documented and implement a
continuous reporting and improvement process for internal control
over financial reporting. Despite our efforts, there is a risk that
we will not be able to conclude within the prescribed timeframe
that our internal control over financial reporting is effective as
required by Section&nbsp;404. This could result in an adverse
reaction in the financial markets due to a loss of confidence in
the reliability of our financial statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">United
States investors may have difficulty enforcing judgments against
us, our directors and executive officers.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are
incorporated under the laws of Ireland, and our registered offices
and a substantial portion of our assets are located outside of the
United States. In addition, one of our directors is a resident of a
jurisdiction other than the United States. As a result, it may not
be possible to effect service of process on such person or us in
the United States or to enforce judgments obtained in courts in the
United States against such person or us based on civil liability
provisions of the securities laws of the United States.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">There is no treaty
between Ireland and the United States providing for the reciprocal
enforcement of foreign judgments.&nbsp;&nbsp;The following
requirements must be met before the foreign judgment will be deemed
to be enforceable in Ireland:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the judgment must be for a definite sum;</p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the judgment must be final and conclusive; and</p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
the judgment must be provided by a court of competent
jurisdiction.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">An Irish court
will also exercise its right to refuse judgment if the foreign
judgment (1)&nbsp;was obtained by fraud; (2)&nbsp;violates Irish
public policy; (3)&nbsp;is in breach of natural justice; or
(4)&nbsp;is irreconcilable with an earlier
judgment.&nbsp;&nbsp;Further, an Irish court may stay proceedings
if concurrent proceedings are being brought
elsewhere.&nbsp;&nbsp;Judgments of U.S. courts of liabilities
predicated upon U.S. federal securities laws may not be enforced by
Irish courts if deemed to be contrary to public policy in
Ireland.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><b><i><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We do not
expect to pay dividends in the foreseeable
future.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have not paid any dividends on our ordinary shares since our
incorporation. Even if future operations lead to significant levels
of distributable profits, we currently intend that earnings, if
any, will be reinvested in our business and that dividends will not
be paid until we have an established revenue stream to support
continuing dividends.</font> If we propose to pay dividends in the
future, we must do so in accordance with Irish law, which provides
that distributions including dividend payments, share repurchases
and redemptions be funded from “distributable reserves.”&nbsp;
Payment of future dividends to security holders will be at the
discretion of our board, after taking into account various factors
including our business prospects, cash requirements, financial
performance, debt covenant limitations and new product
development.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We are
exposed to risks related to currency exchange
rates</font></i></b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">A significant
portion of our expenses are denominated in currencies other than
the U.S. dollar. Because our financial statements are presented in
U.S. dollars, changes in currency exchange rates have had and could
have a significant effect on our operating results. Exchange rate
fluctuations between foreign currencies and the U.S. dollar create
risk in several ways, including the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
weakening of the U.S. dollar may increase the U.S. dollar cost of
overseas research and development expenses;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
strengthening of the U.S. dollar may decrease the value of our
revenues denominated in other currencies;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
58<a name="PB_58_103315_455" id="PB_58_103315_455"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='58',FILE='C:\JMS\C902550\18-8686-1\task8887158\8686-1-gi.htm',USER='C902550',CD='May  7 17:15 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the
exchange rates on non-U.S. dollar transactions and cash deposits
can distort our financial results; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Symbol" style=
"font-size:10.0pt;">·</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
commercial pricing and profit margins are affected by currency
fluctuations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">As a holding
company, our operating results, financial condition and ability to
pay dividends or other distributions are entirely dependent on
funding, dividends and other distributions received from our
subsidiaries, which may be subject to
restrictions.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Our ability to pay
dividends or other distributions and to pay our obligations in the
future will depend on the level of funding, dividends and other
distributions, if any, received from our subsidiaries and any new
subsidiaries we establish in the future. The ability of our
subsidiaries to make loans or distributions (directly or
indirectly) to us may be restricted as a result of several factors,
including restrictions in financing agreements and the requirements
of applicable law and regulatory and fiscal or other restrictions.
In particular, our subsidiaries and any new subsidiaries may be
subject to laws that restrict dividend payments, authorize
regulatory bodies to block or reduce the flow of funds from those
subsidiaries to us, or limit or prohibit transactions with
affiliates. Restrictions and regulatory action of this kind could
impede access to funds that we may need to make dividend payments
or to fund our own obligations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Furthermore, we
may guarantee some of the payment obligations of certain of our
subsidiaries from time to time. These guarantees may require us to
provide substantial funds or assets to our subsidiaries or their
creditors or counterparties at a time when we are in need of
liquidity to fund our own obligations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">The
ownership percentage of our shareholders may be diluted in the
future which could dilute the voting power or reduce the value our
outstanding ordinary shares.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;">
<font size="2" face="Times New Roman" style="font-size:10.0pt;">As
with any publicly traded company,</font> the ownership percentage
of our shareholders may be diluted in the future because of equity
issuances for acquisitions, capital market transactions or
otherwise, including equity awards that we intend to continue to
grant to our directors, officers and employees. From time to time,
we may issue additional options or other share awards to our
directors, officers and employees under our benefits plans.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">In addition, our
articles of association authorize us to issue, without the approval
of our shareholders, one or more classes or series of preferred
shares having such designation, powers, preferences and relative,
participating, optional and other special rights, including
preferences over our ordinary shares respecting dividends and
distributions, as our board of directors generally may determine.
The terms of one or more classes or series of preferred shares
could dilute the voting power or reduce the value of our ordinary
shares. Similarly, the repurchase or redemption rights or
liquidation preferences we could assign to holders of preferred
shares could affect the residual value of the ordinary
shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">The rights
of our shareholders may differ from the rights typically offered to
shareholders of a U.S. corporation. We are incorporated as a public
limited company under Irish law.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">The rights of our
shareholders are governed by our memorandum and articles of
association and Irish law. The rights associated with our ordinary
shares are different to the rights generally associated with shares
held in a U.S. corporation. Material differences between the rights
of shareholders of a U.S. corporation and the rights of our
shareholders include differences with respect to, among other
things, distributions, dividends, repurchases and redemptions,
dividends in shares / bonus issues, the election of directors, the
removal of directors, the fiduciary and statutory duties of
directors, conflicts of interests of directors, the indemnification
of directors and officers, limitations on director liability, the
convening of annual meetings of shareholders and special
shareholder meetings, notice provisions for meetings, the quorum
for shareholder meetings, the adjournment of shareholder meetings,
the exercise of voting rights, shareholder suits, rights of
dissenting shareholders, anti-takeover measures and provisions
relating to the ability to amend the articles of
association.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">As an Irish
public limited company, certain capital structure decisions require
shareholder approval, which may limit our flexibility to manage our
capital structure.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Under Irish law,
our board of directors may increase our authorized share capital
and issue new ordinary or preferred shares up to a maximum amount
equal to the authorized but unissued share capital, without
shareholder approval, once authorized to do so by our articles of
association or by an ordinary resolution of our
shareholders.&nbsp;&nbsp;Additionally, subject to specified
exceptions,&nbsp;Irish law grants statutory preemption rights to
existing shareholders where shares are being issued for cash
consideration but allows shareholders to disapply such
statutory</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
59<a name="PB_59_103354_4141" id="PB_59_103354_4141"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='59',FILE='C:\JMS\C902550\18-8686-1\task8887158\8686-1-gi.htm',USER='C902550',CD='May  7 17:15 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">preemption rights
either in our articles of association or by way of special
resolution. Such disapplication can either be generally applicable
or be in respect of a particular allotment of
shares.&nbsp;&nbsp;Accordingly, our articles of association
contain, as permitted by Irish company law, provisions authorizing
our board of directors to issue new shares, and to disapply
statutory preemption rights.&nbsp;&nbsp;The authorization of our
board of directors to issue shares and the disapplication of
statutory preemption rights must both be renewed by the
shareholders at least every five years, and we cannot provide any
assurance that these authorizations will always be approved, which
could limit our ability to issue equity and thereby adversely
affect the holders of our ordinary shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Irish law
differs from the laws in effect in the U.S. with respect to
defending unwanted takeover proposals and may give our board less
ability to control negotiations with hostile
offerors.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are subject to
the Irish Takeover Panel Act, 1997, Takeover Rules, 2013. Under
those Irish Takeover Rules, the board is not permitted to take any
action that might frustrate an offer for our ordinary shares once
the board has received an approach that may lead to an offer or has
reason to believe that such an offer is or may be imminent, subject
to certain exceptions. Potentially frustrating actions such as
(i)&nbsp;the issue of ordinary shares, options or convertible
securities, (ii)&nbsp;material acquisitions or disposals,
(iii)&nbsp;entering into contracts other than in the ordinary
course of business or (iv)&nbsp;any action, other than seeking
alternative offers, which may result in frustration of an offer,
are prohibited during the course of an offer or at any earlier time
during which the board has reason to believe an offer is or may be
imminent. These provisions may give the board less ability to
control negotiations with hostile offerors and protect the
interests of holders of ordinary shares than would be the case for
a corporation incorporated in a jurisdiction of the United
States.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">The
operation of the Irish Takeover Rules&nbsp;may affect the ability
of certain parties to acquire our ordinary
shares.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;">
<font size="2" face="Times New Roman"><font style=
"font-size:10.0pt;">Under the Irish Takeover Rules, if an
acquisition of ordinary shares were to increase the aggregate
holding of</font></font> the acquirer and its concert parties to
ordinary shares that represent 30% or more of the voting rights of
a company, the acquirer and, in certain circumstances, its concert
parties would be required (except with the consent of the Irish
Takeover Panel) to make an offer for the outstanding ordinary
shares at a price not less than the highest price paid for the
ordinary shares by the acquirer or its concert parties during the
previous 12 months. This requirement would also be triggered by an
acquisition of ordinary shares by a person holding (together with
its concert parties) ordinary shares that represent between 30% and
50% of the voting rights in the company if the effect of such
acquisition were to increase that person’s percentage of the voting
rights by 0.05% within a 12-month period. The Irish Takeover
Rules&nbsp;could therefore discourage an investor from acquiring
30% or more of our outstanding ordinary shares, unless such
investor was prepared to make a bid to acquire all outstanding
ordinary shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We will be
exposed to the risk of future changes in law, which could
materially adversely affect us.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">We are subject to
Irish law. As a result, we are subject to the risk of future
adverse changes in Irish law (including Irish corporate and tax
law). In addition, we and our subsidiaries are also subject to the
risk of future adverse changes in Austrian and U.S. law, as well as
changes of law in other countries in which we and our subsidiaries
operate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Future
adverse changes in law could result in our not being able to
maintain a worldwide effective corporate tax rate that is
competitive in our industry.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">While we believe
that being incorporated in Ireland should not affect our ability to
maintain a worldwide effective corporate tax rate that is
competitive in our industry, we cannot give any assurance as to
what our effective tax rate will be because of, among other things,
uncertainty regarding the tax policies of the jurisdictions where
we will operate. The tax laws of Ireland, Austria, the United
States, and other jurisdictions could change in the future, and
such changes could cause a material change in our worldwide
effective corporate tax rate. In particular, legislative action
could be taken by Ireland, Austria, the United States or other
jurisdictions which could override tax treaties upon which we
expect to rely and adversely affect our effective tax rate. As a
result, our actual effective tax rate may be materially different
from our expectation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">A transfer
of our ordinary shares, other than a transfer effected by means of
the transfer of book-entry interests in the Depository Trust
Company, may be subject to Irish stamp duty.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Transfers of our
ordinary shares effected by means of the transfer of book entry
interests in the Depository Trust Company, or “DTC”, will not be
subject to Irish stamp duty. However, if you hold our ordinary
shares directly rather than beneficially through DTC, any transfer
of your shares could be subject to Irish stamp duty (currently at
the rate of</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
60<a name="PB_60_103455_8627" id="PB_60_103455_8627"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='60',FILE='C:\JMS\C902550\18-8686-1\task8887158\8686-1-gi.htm',USER='C902550',CD='May  7 17:15 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">1% of the higher of the
price paid or the market value of the shares acquired). Payment of
Irish stamp duty is generally a legal obligation of the transferee.
The potential for stamp duty could adversely affect the price of
our ordinary shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">Our ordinary
shares received by means of a gift or inheritance could be subject
to Irish capital acquisitions tax.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Irish capital
acquisitions tax, or “CAT” could apply to a gift or inheritance of
our ordinary shares irrespective of the place of residence,
ordinary residence or domicile of the parties. This is because our
ordinary shares will be regarded as property situated in Ireland.
The person who receives the gift or inheritance has primary
liability for CAT. Gifts and inheritances passing between spouses
are exempt from CAT. Children have a tax-free threshold of €310,000
in respect of taxable gifts or inheritances received from their
parents.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;">
<b><i><font size="2" face="Times New Roman" style=
"font-size:10.0pt;font-style:italic;font-weight:bold;">We may be
classified as a passive foreign investment company for our tax year
ending December&nbsp;31, 2018, which may result in adverse U.S.
federal income tax consequence to U.S. holders.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Based on our
estimated gross income and average value of our gross assets and
the nature of our business, we do not believe that we were a ‘
‘passive foreign investment company,’’ or PFIC, for U.S. federal
income tax purposes for our tax years ended December&nbsp;31, 2015,
2016 or 2017. A corporation organized outside the United States
generally will be classified as a PFIC for U.S. federal income tax
purposes (1)&nbsp;in any taxable year in which at least 75% of its
gross income is passive income or on average at least 50% of the
gross value of its assets is attributable to assets that produce
passive income or are held for the production of passive income and
(2)&nbsp;as to a given holder who was a holder in such year and
regardless of such corporation’s income or asset composition, in
any subsequent taxable year, unless certain elections are made by
that holder that can discontinue that classification as to that
holder, at the risk of imposing substantial tax costs to that
holder. Passive income for this purpose generally includes
dividends, interest, royalties, rents and gains from commodities
and securities transactions. Our status in any taxable year will
depend on our assets and activities in each year, and because this
is a factual determination made annually after the end of each
taxable year, there can be no assurance that we will not be
considered a PFIC for the current taxable year or any future
taxable year. The market value of our assets may be determined in
large part by reference to the market price of our ordinary shares,
which may fluctuate considerably given that market prices of
biotechnology companies have been especially volatile. If we were
to be treated as a PFIC for the tax year ending December&nbsp;31,
2018, or any other future taxable year during which a U.S. holder
held our ordinary shares, however, certain adverse U.S. federal
income tax consequences could apply to the U.S. holder. We
currently intend to make available the information necessary to
permit a U.S. holder to make a valid QEF election, which may
mitigate some of the adverse U.S. federal income tax consequences
that could apply to a U.S. holder of ordinary shares. However, we
may choose not to provide such information at a future
date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM
2.&nbsp; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS</font></b><a name=
"ITEM2_UNREGISTEREDSALESOFEQUITYS_103515" id=
"ITEM2_UNREGISTEREDSALESOFEQUITYS_103515"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recent
Sales of Unregistered Securities</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We did not
sell any of our equity securities or any options, warrants, or
rights to purchase our equity securities during the three months
ended March&nbsp;31, 2018 that were not registered under the
Securities Act of 1933, as amended, or the Securities
Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">Purchase of Equity
Securities</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We did not
purchase any of our registered equity securities during the period
covered by this Quarterly Report on Form&nbsp;10-Q.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">Use of
Proceeds from Registered Securities</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:25.3pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">We effected
the initial public offering of our ADSs, each representing one
tenth (1/10) of a common share, through a Registration Statement on
Form&nbsp;F-1 (File No.&nbsp;333-205073) that was declared
effective by the Securities and Exchange Commission on
September&nbsp;17, 2015. On September&nbsp;23, 2015, we completed
the sale of 9,000,000 ADSs, representing 900,000 of our common
shares, at a public offering price of&nbsp;$10.25&nbsp;per ADS,
before underwriting discounts. In addition, we granted the
underwriters a 30-day option to purchase up to 1,350,000 additional
ADSs to cover over allotments, if any. On September&nbsp;30, 2015,
we completed the additional sale of 1,350,000 ADSs under this
option at a price to the public of $10.25 per ADS, resulting in
aggregate net proceeds to us of approximately $92.4&nbsp;million
after deducting underwriting discounts and commissions of $7.4
million and offering expenses of $6.3 million. Leerink Partner LLC,
RBC Capital Markets, LLC, Needham&nbsp;&amp; Company, LLC and
Wedbush PacGrow Inc. were the underwriters for our initial public
offering.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">As of
March&nbsp;31, 2018, we have used all of the approximately $92.4
million of net proceeds from the offering in our operating
activities in a manner consistent with the planned use of proceeds
described in the prospectus for our initial public offering. We
have not used any of the net proceeds from the offering to make
payments, directly or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
61<a name="PB_61_103523_7906" id="PB_61_103523_7906"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='61',FILE='C:\JMS\C902550\18-8686-1\task8887158\8686-1-gi.htm',USER='C902550',CD='May  7 17:15 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">indirectly, to any
director or officer of ours or any of their associates, to any
person owning 10% or more of any class of our equity securities, or
to any affiliate of ours.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM
3.&nbsp; DEFAULTS UPON SENIOR SECURITIES</font></b><a name=
"ITEM3_DEFAULTSUPONSENIORSECURITI_103851" id=
"ITEM3_DEFAULTSUPONSENIORSECURITI_103851"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Not
applicable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM
4.&nbsp; MINE SAFETY DISCLOSURES</font></b><a name=
"ITEM4_MINESAFETYDISCLOSURES_103853" id=
"ITEM4_MINESAFETYDISCLOSURES_103853"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style="font-size:10.0pt;">Not
applicable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM
5.&nbsp; OTHER INFORMATION</font></b><a name=
"ITEM5_OTHERINFORMATION_103855" id=
"ITEM5_OTHERINFORMATION_103855"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face=
"Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM
6.&nbsp; EXHIBITS</font></b><a name="ITEM6_EXHIBITS_103857" id=
"ITEM6_EXHIBITS_103857"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="6%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="39%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="39%" colspan="7" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.04%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Incorporated&nbsp;by&nbsp;Reference</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="8%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
</tr>
<tr>
<td width="6%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Exhibit<br />
Number</font></b></p>
</td>
<td width="3%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="39%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.62%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Exhibit</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="8%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Form</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="9%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.52%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">File&nbsp;Number</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="8%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Date&nbsp;of<br />
Filing</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="8%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Exhibit<br />
Number</font></b></p>
</td>
<td width="1%" valign="bottom" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
</td>
<td width="8%" valign="bottom" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face=
"Times New Roman" style=
"font-size:8.0pt;font-weight:bold;">Filed<br />
Herewith</font></b></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">10.1</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><a href=
"http://www.sec.gov/Archives/edgar/data/1641640/000110465918018350/a18-8436_1ex1d1.htm">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Controlled Equity Offering Sales Agreement
dated March&nbsp;16, 2018, by and between the registrant and cantor
Fitzgerald&nbsp;&amp; Co.</font></a></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">8-K</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">001-37558</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;text-align:justify;"><font size=
"2" face="Times New Roman" style=
"font-size:10.0pt;">3/16/2018</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">1.1</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">10.2*</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><a href=
"a18-8686_1ex10d2.htm#Exhibit10_2_105659" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">License Agreement, dated March&nbsp;26, 2018,
by and among Nabriva Therapeutics Ireland DAC, Sinovant
Sciences,&nbsp;Ltd., Nabriva Therapeutics GmbH and Roivant
Sciences,&nbsp;Ltd.</font></a></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">X</font></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">31.1</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><a href=
"a18-8686_1ex31d1.htm#EXHIBIT31_1_121539" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Certification of principal executive officer
pursuant to Rule&nbsp;13a-14(a)&nbsp;or 15d-14(a)&nbsp;of the
Securities Exchange Act of 1934, as adopted pursuant to
Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</font></a></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">X</font></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">31.2</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><a href=
"a18-8686_1ex31d2.htm#EXHIBIT31_2_122018" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Certification of principal financial officer
pursuant to Rule&nbsp;13a-14(a)&nbsp;or 15d-14(a)&nbsp;of the
Securities Exchange Act of 1934, as adopted pursuant to
Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</font></a></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">X</font></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">32.1</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><a href=
"a18-8686_1ex32d1.htm#EXHIBIT32_1_122141" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Certification of principal executive officer
pursuant to 18 U.S.C. §1350, as adopted pursuant to
Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</font></a></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">X</font></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">32.2</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><a href=
"a18-8686_1ex32d2.htm#Exhibit32_2_122303" title=
"Click to goto "><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">Certification of principal financial officer
pursuant to 18 U.S.C. §1350, as adopted pursuant to
Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</font></a></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">X</font></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="6%" valign="top" style=
"padding:0in 0in 0in 0in;width:6.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">101</font></p>
</td>
<td width="3%" valign="top" style=
"padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="39%" valign="top" style=
"padding:0in 0in 0in 0in;width:39.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">The following materials
from the Company’s Quarterly Report on Form10-Q for the quarter
ended March&nbsp;31, 2018, formatted in XBRL (eXtensible Business
Reporting Language): (i)&nbsp;Consolidated Balance Sheets as of
December&nbsp;31, 2017 and March&nbsp;31, 2018,
(ii)&nbsp;Consolidated Statements of Operations for the three
months ended March&nbsp;31, 2017 and 2018, (iii)&nbsp;Consolidated
Statements of Cash Flows for the three months ended March&nbsp;31,
2017 and 2018 and (v)&nbsp;Notes to Unaudited Consolidated
Financial Statements.</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="9%" valign="top" style=
"padding:0in 0in 0in 0in;width:9.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="1%" valign="top" style=
"padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="8%" valign="top" style=
"padding:0in 0in 0in 0in;width:8.34%;">
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">X</font></p>
</td>
</tr>
</table>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
62<a name="PB_62_104429_561" id="PB_62_104429_561"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='62',FILE='C:\JMS\C902526\18-8686-1\task8887117\8686-1-gk.htm',USER='C902526',CD='May  7 16:50 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p style="margin:0in 0in .0001pt;"><a name="PB_1_104412_7056" id=
"PB_1_104412_7056"></a><font size="2" face="Times New Roman" style=
"font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;">
<hr size="1" width="25%" noshade="noshade" align="left" style=
"color:black;" /></div>
<p style=
"font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;">
<font size="2" face="Times New Roman" style=
"font-size:10.0pt;">*</font><font size="1" style=
"font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
Confidential treatment has been requested as to certain portions,
which portions have been omitted and separately filed with the
Securities and Exchange Commission.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
63<a name="PB_63_104435_5796" id="PB_63_104435_5796"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='63',FILE='C:\JMS\C902526\18-8686-1\task8887117\8686-1-gk.htm',USER='C902526',CD='May  7 16:50 2018' --><br clear="all"
style="page-break-before:always;" />
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><a href="#TableOfContents"
title="Click to go to Table of Contents"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Table of
Contents</font></a></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face=
"Times New Roman" style=
"font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b><a name=
"SIGNATURES_104918" id="SIGNATURES_104918"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.55in;"><font size="2"
face="Times New Roman" style="font-size:10.0pt;">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="50%" colspan="2" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">NABRIVA THERAPEUTICS
plc</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;Date: May&nbsp;8,
2018</font></p>
</td>
<td width="4%" valign="top" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="45%" valign="top" style=
"padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="4%" valign="top" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">By:</font></p>
</td>
<td width="45%" valign="top" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">/s/ Colin
Broom</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="4%" valign="top" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="45%" valign="top" style=
"padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Colin Broom</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="4%" valign="top" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="45%" valign="top" style=
"padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Chief Executive
Officer<br />
(Principal Executive Officer)</font></p>
</td>
</tr>
</table>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%"
style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;Date: May&nbsp;8,
2018</font></p>
</td>
<td width="4%" valign="top" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">By:</font></p>
</td>
<td width="45%" valign="top" style=
"border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">/s/ Gary
Sender</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="4%" valign="top" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="45%" valign="top" style=
"padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Gary Sender</font></p>
</td>
</tr>
<tr>
<td width="50%" valign="top" style=
"padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="4%" valign="top" style=
"padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</td>
<td width="45%" valign="top" style=
"padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">Chief Financial
Officer<br />
(Principal Financial and Accounting Officer)</font></p>
</td>
</tr>
</table>
<p align="center" style=
"margin:0in 0in .0001pt;text-align:center;"><font size="2" face=
"Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style=
"font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">
64<a name="PB_64_104910_8001" id="PB_64_104910_8001"></a></p>
<div style="margin:0in 0in .0001pt;">
<hr size="3" width="100%" noshade="noshade" align="left" style=
"color:#010101;" /></div>
</div>
<!-- SEQ.=1,FOLIO='64',FILE='C:\JMS\C902519\18-8686-1\task8876815\8686-1-jc.htm',USER='C902519',CD='May  1 15:51 2018' -->
</body>
</html>

